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Strong immune responses to melanoma predict improved survival and better 
responses to immunotherapies. However the host-tumour interactions are not yet fully 
elucidated, especially for early stage tumours and increasing understanding of this 
interaction was the aim of this thesis. The analyses were carried out using 703 primary 
melanoma transcriptomes generated from the Leeds Melanoma Cohort (LMC), 
detailed clinico-histopathological, and additional genomic data. Bioinformatics was 
applied to infer the immune environment within the tumours.  
Using a modified “Immunome Compendium” developed by Angelova et al. [1], 
consensus clustering was applied to identify three immune subgroups: low, 
intermediate and high, associated with survival. Differentially expressed genes 
between the immune subgroups in the LMC were identified and analysed in the 
context of networks and pathways using Reactome FIViz. The oncogene MYC was 
identified as a nodal gene for the Low and NFKB1 for the High Immune Subgroup. The 
expression of both genes showed significant association with protein scores from 
immunohistochemistry and with copy number alterations. The genes from NF-kB and 
IFN-g pathways were more frequently deleted and MYC was amplified in the Low 
Immune Subgroup. These observations were considered as immune evasion 
mechanisms in primary melanoma. 
Furthermore, it was observed that MYC expression was negatively correlated with 
many antigen processing and presentation genes (HLA-B , HLA-C, B2M, TAP1 and 
ERAP1) in the LMC and patient-derived melanoma cell lines and with HLA-B at a protein 
level in the LMC. My hypothesis was that MYC drives immunosuppression at least in 
part by reducing antigen presentation by the histocompatibility complex.   
Finally, it was demonstrated that smoking was detrimental for melanoma specific 
survival overall, with the strongest effect for patients with tumours classified in the 
High Immune Subgroup suggesting a specific effect on tumour progression and it is a 
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Chapter 1   
Introduction 
1.1 Aims of this thesis 
• To apply appropriate bioinformatic methods of immune microenvironment 
characterisation to gene expression data from formalin-fixed paraffin embedded 
(FFPE) primary cutaneous melanomas from individuals in a large population-
based cohort. 
• To identify prognostic subgroups based on the bioinformatically identified 
immune infiltration profiles. 
• To identify and describe molecular and environmental immunosuppressive 
factors in primary cutaneous melanoma. 
 
1.2 Aims of this chapter 
The main aim of this chapter was to give an overview of the current knowledge that is 
essential for this thesis: 
• To describe relevant knowledge about cutaneous melanoma. 
• To document known predictors of melanoma specific survival (MSS). 
• To describe the most commonly disrupted molecular pathways in melanoma and 
the available related targeted therapies. 
• To introduce what is published with respect to host immunity-tumour 
interactions and some therapies that might modulate these interactions. 
• To give an overview of the basic immune responses.  
• To describe the methods of characterising immune cells within the tumour 
microenvironment.  
 
1.3 Cutaneous melanoma 
Human skin (cutis) consists of three layers: the epidermis, dermis and subcutis. The 
basal layer of the epidermis (stratum basale) contains melanocytes, which are melanin 
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producing cells. In the skin, melanocytic benign proliferations, which are usually self-
limiting are known as melanocytic naevi or “moles”. Persistent proliferation occurs in 
some people and then the naevi become unusually large (>5mm in diameter), which 
are known as dysplastic or atypical naevi. Even though proliferation is more persistent 
in these naevi, it usually eventually stops. When the proliferations become 
uncontrolled, a proportion of naevi may develop into cutaneous melanoma, however 
this malignant neoplasm may equally arise from skin which is considered as normal. 
Understanding the drivers of proliferation is very important in melanoma and other 
cancers in order to be able to control them therapeutically. In this thesis, I report the 
use of tumour transcriptomics to understand this process and how the host tries to 
control the tumour by deploying immunological responses. For brevity, the term 
“melanoma” will be used to mean cutaneous melanoma throughout this thesis. 
Reported sunburn and sunbathing are established risk factors [2] and this led to the 
development of the intermittent exposure hypothesis [3]. It is hypothesised that the 
continued observed increase in melanoma incidence results from the increased 
exposure to intense sun, especially on holidays. In the UK the current trends towards 
tanned skin colour and accessible sunny holidays for people whose skin type (pale) is 
not photo-adapted might explain the rise in melanoma incidence. In the UK, the 
incidence of melanoma has been increasing since 1990 (it has more than doubled - 
128%) [4]. 
1.4 Melanoma prognosis 
1.4.1 Disease staging using the American Joint Cancer Committee on Cancer 
system (AJCC)  
Clinico-histopathological features which predict survival for melanoma are used by 
clinicians and pathologists to assess the patient prognosis. The formal staging system 
of melanoma used in the UK is that developed by the American Joint Cancer Committee 
on Cancer (AJCC). I have used the 7th edition [5][6] as this was the current version when 
the data for my study were collected. The AJCC system categorises melanoma into four 
main stages and here I use a broad summary. In truth, the classification is rather more 
detailed than indicated below:   
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• Stage I: early primary tumours thinner than 1mm (Breslow thickness, see below) 
• Stage II: primary tumours which are thicker but without evidence of spread to the 
lymph nodes;  
• Stage III: evidence of melanoma spreading to the regional lymph nodes and 
palpable lumps; 
• Stage IV: more aggressive disease spreading to distant organs (viscera, lung, 
brain, etc.). 
Within stage I and II melanoma, the staging is determined initially by the pathologists 
who record the Breslow thickness which is the depth of the melanoma from the 
superficial (granular) layer of the epidermis to the deepest part of the tumour. Breslow 
thickness is measured under the light microscope using a millimetre scale and the 
thicker the depth the worse patient’s prognosis [5][6].  
Stages I and II are further refined by presence/absence of tumour ulceration (also 
assessed using microscopic examination). Ulceration is the absence of an intact 
epidermis covering the melanoma [7][8]. Patients presenting with an ulcerated 
melanoma have a shorter survival than those with a non-ulcerated tumour [9]. For 
stage I, an additional measure to categorise melanoma is mitotic rate. It is the mitotic 
count (number of actively dividing cells) per tumour area of 1 mm2, which is manually 
counted by pathologists using the light microscope. A mitotic rate greater than 1/mm2 
in stage I tumours is associated with decreased patient survival and has been used in 
the 7th Edition of AJCC staging. However it has been recently shown that a high mitotic 
rate indicates poor prognosis and aggressive disease even in thicker tumours (>1mm, 
n=1524) [10]. For this reason, in this thesis, the mitotic rate was analysed 
independently of AJCC staging for the whole study cohort.  
The measurement of Breslow thickness, the detection of ulceration, and the presence 
of metastases is used to categorise the tumours into the so-called TNM classifiers 
(Tumour size, Lymph Node affected, distal Metastases) [5]. Individuals whose tumours 
are thicker than 1mm are usually then offered a staging procedure known as sentinel 
node biopsy. In this procedure dye and a radioactive tracer are used to locate the 
lymph node into which lymph from the tumour drains. The dye collects in the sentinel 
node: the first lymph node into which lymph drains. This node is removed and if that 
and or other nodes are found to contain melanoma cells then the patient is said to 
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have stage III melanoma. Patients may develop nodal tumour masses, which can be felt 
and this is also stage III disease but stage IIIb or IIIc. 
Within the late stages, the number of metastases and the organs affected (stage IV) as 
well as the number of lymph nodes involved (stage III and IV) predict melanoma 
survival [5][6]. Metastases to non-pulmonary visceral sites predict the poorest 
prognosis, such as the liver and brain. There are other clinico-pathological factors 
which also independently predict prognosis but are not included in AJCC staging, such 
as lymphovascular invasion, primary tumour site, patient sex and age, as well as the 
lymphocytes infiltrating the tumour. They are briefly described below. 
1.4.2 Lymphovascular invasion  
Lymphovascular invasion is a term that describes the histological detection of invasion 
within the lumen of vascular and lymphatic vessels by melanoma cells, within or around 
the tumour. It is known to be associated with an increased likelihood of metastasis to 
the sentinel lymph nodes [11][12]. A recent study reported that lymphovascular 
invasion (assessed histologically) independently  predicts poor survival [11].  
1.4.3 Primary tumour site 
Non-ocular melanoma occurs in different anatomic locations: on the head and neck, 
trunk (most common), limbs, genitals, rectum and mucosal sites. Primary tumours 
located at the trunk, head and neck are known to be associated with a poorer prognosis 
than the ones on the extremities [13]. Other studies showed that tumours located on 
acral sites (fingers, palms, soles, and nail beds) have poor prognosis [14][15], which 
could be due at least in part to late diagnosis [16]. Similarly melanoma detected in 
genital and rectal areas were reported to have lower survival rates [17][18]. Overall, 
unsurprisingly, the tumours occurring on sites where they are easy to detect and 
surgically remove are associated with the best prognosis, however there might be 
biological differences among tumours in different body sites. It is generally accepted 
that tumours exposed to sun have higher rates of C>T mutations caused by UV 
radiation than sun-protected tumours [19]. These mutations may induce the 
generation of neo-antigens (described later in this chapter), which might potentially 
attract immune cells to kill the lesion and result in better survival for patients having 
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tumours in sun-exposed sites. 
1.4.4 Sex 
Sex is an independent predictor of melanoma death [20][21]. Female patients have a 
lower risk of melanoma death than males consistently when analysed within pre- and 
postmenopausal ages categories across the  stages III and IV [20]. The basis of this risk 
difference is not yet fully understood.  
1.4.5 Age 
Age of melanoma patients is an important predictor of survival. Increasing age is an 
independent predictor of melanoma death [22], which is currently hypothesised to 
relate to impaired host responses to the tumour [22][23] and/or changing collagen 
matrix [24] impacting on the tumour invasive front. It has also been observed that older 
patients at diagnosis are more likely to be men than women [22][25], which makes the 
effects of age and sex difficult to disentangle. In multivariable analyses, both factors 
appear to have independent effects on survival. 
1.4.6 Tumour infiltrating lymphocytes (TILs) 
More than a century ago, immune cells occurring within melanoma were thought to 
be causative for skin neoplasia due to a process of inflammation [26]. The idea was 
challenged at the International Congress of Skin Cancer conference in Sydney in 1972 
suggesting instead the anti-melanoma function of lymphocytes [27]. The tumour 
infiltrating lymphocytes (TILs) term was introduced in 1969 by Wallace Clark and 
denoted the histologically detected presence of lymphocytes within and around 
primary melanomas, postulated to be taking part in a host response to the cancer [28]. 
Clark et al. [28] recognised that there were different patterns of lymphocytes within 
the tumours and classified TILs as absent, non-brisk and brisk (Figure 1.1).  
Brisk TILs have been shown to predict an improved outcome (overall and disease free 
survival) in some studies [29][30], but others have failed to prove an independent 
survival advantage [31][32]. The immune response might vary over time during 
melanoma progression, and that fact could explain why the survival benefit of TILs is 
not observed consistently across studies. Another plausible explanation of this 
inconsistency is the heterogeneous nature of the immune infiltrates within and around 
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tumours. There is furthermore, a large degree of inter-observer variation: the scoring 
can be pathologist-dependent, which has so far limited its utility [33][34][35]. 
Nonetheless, a recent study based on a large sample size (n=1865) did confirm that 
patients with higher counts of brisk TILs have very good prognosis [36]. Even if inter-
observer variation can be controlled there may be biological differences which could 
not be captured using standard histopathology: TILs scoring does not indicate exactly 
which type of lymphocytes invade the tumour. Some might be immuno-suppressive, 
while others might be more anti-tumorigenic. 
 
 
Figure 1.1: Clark's classification of tumour infiltrating lymphocytes 
(A) Representation of brisk TILs, which are present within the tumour or 
infiltrating the entire base of the tumour. (B) Representation of non-brisk TILs, 
which are observed in one or more foci of tumour. (C) TILs absent within the 
tumour, where no lymphocytes have infiltrated melanoma (even though they 
could be seen around it). 
 
The Melanoma Institute of Australia (MIA) has proposed a modified version of the 
Clark’s classification, introducing new grades ranging from 0 to 3 [36]: 
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• Grade 0: TILs absent  
• Grade 1: a mild/moderate focal or a mild multifocal TIL infiltrate 
• Grade 2: a marked focal, either a moderate/marked multifocal, or a mild 
dispersed TIL infiltrate 
• Grade 3: a moderate/marked dispersed TIL infiltrate. 
Like Clark’s classification, this grading positively correlates with melanoma specific 
survival [36]. In this thesis, only the Clark’s classification was used assessed by 
unselected clinical dermatopathologists and single observer Dr Sally O’Shea as 
separate variables to test their cross-validation. Throughout later analyses I will point 
out whose classifications were used.  
1.5 Key oncogenic pathways, genetic mutations  
Melanoma progression is associated with activation of pathways that regulate tumour 
growth and proliferation, which I will discuss in this section.  
1.5.1 Mitogen activated protein kinase (MAPK) signalling pathway 
MAPK signalling is a regulator of cell cycle, differentiation, migration, proliferation and 
apoptosis [37]. In healthy cells, this pathway is triggered either by receptor tyrosine 
kinases (RTKs) binding to their accompanying ligands, or integrin adhesion molecules 
on the cellular matrix or the cell membrane leading to further activation of RAS (small 
GTPase) by changing its state from GDP (guanosine diphosphate) to GTP (guanosine 
triphosphate) [37][38]. Activated RAS activates RAF (serine/threonine kinase), 
activating MEK1 and MEK2, then ERK1 and ERK2, resulting in their translocation to the 
nucleus and regulation of several transcription factors (Figure 1.2) [37][38]. The first 
most common driver mutation in melanoma is BRAF, which results in uncontrolled 
activation of the MAPK pathway. The BRAF point mutation V600 is a substitution of 
valine by another amino acid. BRAF mutations occur in ~50 % of cutaneous 
melanoma[39] (with the most common substitution of E (glutamic acid) occurring in 
~90% of these mutations and K (lysine) occurring in the remainder 10%).  
Targeted inhibitors or BRAF +/- MEK inhibitors are used to inhibit the MAPK pathway. 
Recent clinical trial results indicated that combinatory treatment delays therapy 
resistance and improves progression free and overall survival [40]. NRAS is the second 
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most commonly driver mutated gene in melanoma, also activating the MAPK pathway, 
with a frequency of 20-25% [41]. The point mutations occur in codons G12, G13 and 
Q61. However there is no treatment available in clinical practice to date that targets 
NRAS as yet [42].  
1.5.2 Phosphatidylinositide 3 Kinases (PI3K) signalling pathway 
Activation of the PI3K pathway is also involved in melanoma proliferation, cell growth 
and survival [43]. PI3K is activated by G-protein-coupled and tyrosine kinase receptors. 
Activated PI3K produces phosphatidylinositols, which bind to AKT, restraining it at the 
cell membrane. AKT restrained in the cell membrane can be phosphorylated/activated 
[44][45], resulting in the mediation of phosphorylation of downstream proteins (e.g. 
mTOR), which regulate cell cycle, proliferation and survival (Figure 1.2). Oncogenic RAS 
is known to regulate the PI3K pathway, leading to uncontrolled activation of this 
pathway and activating cancer associated genes. In normal cells, PTEN inhibits this 
pathway, by interrupting the reaction of AKT with phosphatidylinositols. In melanoma, 
40-60% of tumours have deletions or mutations in PTEN [46] and they are more 
frequent in BRAF mutated tumours [46]. It was reported that approximately ~20% of 
melanomas have PTEN inhibited/deleted together with BRAF mutations [47][46] and 
that both of these aberrations cooperate in metastatic induction [47]. PI3K and AKT 
inhibitors have been developed, however they are not commonly used in the clinic. 
Another gene that is functionally important in melanoma progression is NF1, which, 
like PTEN, is also involved in the negative regulation of RAS. Mutations of NF1 occur in 





Figure 1.2: Simplified overview of the MAPK and PI3K pathways 
 
1.5.3 Genetic mutations 
A study designed for large scale mutation detection identified some more mutated 
genes in cutaneous melanoma: TP53, CDKN2A, MAP2K1, PPP6C, RAC1, SNX31, TACC1, 
and STK19 [48], however with low frequency. This study included 15 primary tumours, 
30 metastatic samples, and 76 short-term cultures derived from metastatic tumour 
tissue from 95 melanomas of cutaneous, 5 of acral, 2 of mucosal, 1 of uveal, and 18 of 
unknown primary origin. 
Additionally a study conducted three years later using 67 primary and 265 metastatic 
samples confirmed some of these mutations: TP53, CDKN2A, MAP2K1, PPP6C, and 
RAC1, and identified some new mutations relatively frequent in melanoma: ARID2, 
IDH1, DDX3X, RB1 [46].  
Moreover, melanoma was shown to be a cancer type with the highest prevalence of 
somatic mutations in a study comparing mutational load across various cancer types 





















was characterised by C>T mutations known to be caused by ultraviolet light and this 
signature was particularly high in melanoma [49]. 
Apart from the mutations some frequent copy number changes in specific genes were 
identified in melanoma. For example, commonly amplified gene was MYC [50] and 
deleted were CDKN2A [46][48]and PTEN [50][46][48].  
1.6 The immune response 
Generally, the immune system is described as having two main components: innate 
and adaptive. The innate immune responses are mediated by germline encoded 
receptors and these responses are rapid reactions to pathogens (sometimes described 
as spontaneous), playing a role in both the immediate broad defence against 
challenges and in subsequently activating secondary more specific or adaptive immune 
responses. Pathogens are first recognised, by innate/phagocytic cells using pattern 
recognition receptors (PRRs), then they are ingested and killed. There are two main 
types of PRRs: Toll-like (extracellular pathogen detectors) and NOD-like (intracellular 
pathogen detectors). They recognise foreign DNA and RNA and this recognition triggers 
the production of IFN-a and -b (Toll-like receptors) and NF-kB (NOD-like receptors). 
Another similar process of foreign nucleic acid recognition is stimulator of interferon 
genes (STING) situated on the endoplasmic reticulum and when it is active it leads to 
transcription of interferon genes [51]. This signalling was shown to have significant 
impact on cancer immunity [52]. The major immune cells in innate immunity are:  
• macrophages 
• neutrophils 
• dendritic cells 
• mast cells 
• eosinophils 
• basophils 
• natural killer cells. 
The adaptive immune responses are mediated by somatically rearranging antigen 
receptors (which is a continuous random process). The adaptive responses are less 
rapid (as specific B and T cell clones must be triggered by other immune cells and 
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proliferate to provide effective coverage) but more specific than the innate response 
and its main function is the development of highly specific effector cells and memory 
responses, from two main types of lymphocytes: T and B cells. Both these cells have 
several subtypes, which have distinctive functions. For T cells these are: 
• effector 




• natural killer T cell (NKT, different from NK cells) 
• gamma-delta; 
and for B cells:  
• plasma cells  
• memory B cells 
• regulatory B cells. 
T cells mature in the thymus, hence their name, and they can be either CD4+ or/and 
CD8+ (which means they express CD4 or/and CD8 glycoprotein on their surface). All 
subsets of T cells express CD3 and T cell receptors (TCR), forming a TCR complex. This 
complex interacts with HLA class I (CD8 T cells) and II (CD4 T cells). B cells however, 
mature in the bone marrow and express the B cell receptor (BCR). The BCR is a 
transmembrane receptor complex, comprised of the antigen binding component (an 
immunoglobulin molecule) and associated signalling chains (CD79A and B, analogous 
to the CD3 chains of the TCR). The B cell’s key function is antibody (immunoglobulin) 
secretion. The role of antibodies is in neutralising pathogens by direct binding to them. 
B cells also capture antigens using immunoglobulin and present it to T cells via HLA 
class II; a T cell with specificity for the processed antigen captured by the antibodies 
then provides helper function (co-stimulation and cytokines release) that allows the B 
cell to differentiate into an antibody secreting plasma cell. 
All immune cells are derived from the pluripotent hematopoietic stem cells from the 
bone marrow, which have undergone differentiation mainly due to gene expression 
changes in different tissue types (haematopoiesis), shown in Figure 1.3. The first step 
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of differentiation is into common lymphoid and common myeloid progenitor cells. The 
first one matures into T cells, B cells and natural killer cells, the latter one however 
matures into all the other immune cells. Overall in healthy individuals the 
differentiation is fluid, but at the same time well controlled [53]. The classification of 
immune cells is mainly based on the expression of surface molecules, which are 
characterised by the use of standardized cluster of differentiation (CD) nomenclature 
[54], but functional tests are often used to differentiate particular subtypes. However, 
the understanding of subgroup phenotypes and functions continues to evolve. 
 
Figure 1.3: Haematopoiesis, process of differentiation of immune and blood cells [53] 
 
Immune response is a complex process in which many different subtypes of immune 
cells take part. It is possible that in a fight against cancer all of those immune cells may 
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be involved simultaneously or at different stages, therefore understanding this process 
is needed but is very challenging [55][56].  
1.6.1 Host immune response to melanoma 
The immune system is a defence mechanism that primarily protects an individual 
against pathogens but it has become increasingly apparent that it also plays a crucial 
role in the defence against cancer. The first scientist who conceived the idea of the 
immune system potentially controlling cancer proliferation was Paul Ehrlich in 1908 
[57]. However, it was only a half century later in 1957 that the formal hypothesis of 
“cancer immunosurveillance” was proposed by Sir Frank Macfarlane Burnet and Lewis 
Thomas [58].  
For melanoma, the first evidence that the immune response, mainly the TILs might play 
a role in melanoma was the discovery by Clark et al. in 1969 [28]. TILs were later on 
proven to be associated with an improved melanoma specific survival (as described 
before). Melanoma has been said to be the most immunogenic cancer over the past 
decades, based largely upon the observations made by clinical researchers. One of the 
earlier and most striking observations was the spontaneous regression (disappearance) 
of melanoma lesions in certain patients [59]. It is a very rare process speculated to be 
caused by a rapid cytotoxic (tumour killing) specific immune response [60], or by 
stimulation of the immune cells by the melanoma cells present in the lymph nodes [61].  
Other studies reported that some melanoma patients develop vitiligo 
(hypopigmentation), an autoimmune process that destroys melanocytes (acquired 
pigment loss), and that these patients have a better prognosis [62]. It was suggested 
that this higher rate of survival could be explained by higher CD8+ T cell responses to 
melanoma cells in those patients possibly due to recognition of same antigens 
produced by both melanocytes and melanoma [63][64].  
The prominent role of the immune response controlling melanoma was also shown 
while studying patients who received organ transplants who are typically given 
immunosuppressive drugs to avoid the graft rejection. The studies were designed to 
test the hypothesis that transplant recipients were at higher risk of developing skin 
cancer/melanoma. It had become clear that organ recipients indeed were at higher risk 
of developing this type of cancer due to lack of systemic immune surveillance [65]. 
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There were some transplantation cases where the organ of the donor contained 
melanoma cells (unknowingly to the surgeons) and because of the immunosuppressive 
drugs the recipients received during and after transplantation, they developed 
melanoma metastasis to distant organs [65][66]. These observations imply both that 
melanoma cells can exist in healthy organs for many years yet retain the ability to 
proliferate, and that in healthy individuals’ immune responses to melanoma may keep 
tumours in check. 
Overall, melanoma tumours in order to be recognised and attacked by the immune 
system need to provide a supportive niche for the immune cells to infiltrate melanoma 
and activate their effective functions. These functions are mainly induced by tumour 
antigens. Tumour antigens can be classified into: 
• Cancer- germline antigens – expressed by cancer cells and adult reproductive 
tissues (e.g. melanoma associated antigens (MAGE family)) 
• Differentiation – expressed by cancer cells and limited range of normal tissues 
(e.g. produced by melanocytes and melanoma cells to which T cell tolerance is 
incomplete, such as MART-1, melan-A or Tyrosinase) 
• Overexpressed – expressed in cancer cells and normal tissues, but significantly 
overexpressed in tumour cells  
• Viral – expressed by cancer cells as a result of viral infection 
• Neoantigens – expressed in cancer cells and absent from the normal tissues 
peptides considered to be a result of degraded abnormal proteins, which can 
be products of genomic mutations [67][68][69].  
Tumour antigens are processed and presented to the immune system via MHC class I 
molecules. Simplistically, the abnormal endogenous proteins are ubiquitinated and 
fragmented into peptides by the proteasome. Next, these peptides are transported 
from cytosol to endoplasmic reticulum by ATP Binding Cassette Subfamily B Member 
Transporter (TAP) and trimmed by Endoplasmic Reticulum Aminopeptidase (ERAAP). 
Finally these peptides are bound and presented to the immune cells by Major 
Histocompatibility Complex class I (Human Leukocyte Antigen (HLA) class I: HLA-A, HLA-





Figure 1.4: Schematic representation of antigen processing and presentation via MHC 
class I molecules [53] 
(1) Partially folded MHC class I a chains bind to calnexin till b2-micorglobulin 
binds. (2) When MHC class I a:b2m complex is released from calnexin, then binds 
to a complex of chaperone proteins (calreticulin, ERp57) and then to TAP via 
tapasin. (3) Cytosolic proteins and defective ribosomal products (DRiPs) are 
degraded to peptides by the proteasome and delivered to the ER by TAP. (4) A 
peptide binds to MHC class I molecule and finishes its folding. Next, the MHC class 
I molecule is released from the TAP complex and exported to the cell membrane 
[53].  
 
As mentioned earlier melanoma is considered to be a cancer type with the highest 
prevalence of the somatic mutations [49], which is considered to potentially lead to 
higher numbers of neoantigens, hence being more immunogenic. 
Melanoma can also be recognised by innate responses, mainly by Natural Killer (NK) 
cells [70] and Dendritic cells (DC) [71], for which neoantigen presentation is not 
essential. NK cells have a cytotoxic function: killing infected cells and tumour cells. NK 
























inhibitory receptors to detect changes in expression levels of host cell surface 
molecules. Activated NK cells kill target cells using granzymes and perforins, which 
induce apoptosis of those target cells and produce TNF, GM-CSF and IFN-gamma to 
modulate innate and adaptive immunity [53]. DCs, however, process and present 
antigens (via HLA class I and II) to T cells. They are sometimes described as professional 
antigen presenting cells (APCs). There are two broad classes of dendritic cells: 
conventional (myeloid) and plasmacytoid (which are much less abundant), which 
produce high levels of IFN-g and IFN-a [72][73].  
 Regulation of host immune response 
Although it is evident that melanomas can provoke anti-tumour responses and can be 
eliminated by that process, at some point some of the tumour cells clearly acquire the 
ability to evade the immune reaction, which results in tumours that grow faster with 
increased ability for invasion and metastasis [74]. For example, the downregulation of 
components of antigen processing and presentation and IFN-g signalling [55] 
contribute to immune evasion, as well as upregulation of b-catenin signalling, which 
inhibits the expression of chemokine (CCL4) that attract the infiltration of CD103+ DCs 
into the tumour [75][76].  
Another type of immune evasion mechanism reported is the up-regulation of 
checkpoint molecules like PD-L1, PD1 and IDO or chemokines by tumour or immune 
cells that activate and attract regulatory immune cells. However the upregulation of 
checkpoint molecules was recently shown to be associated with higher immune 
infiltrates which have a good prognostic value [77]; the expression of checkpoint 
molecules within tumour microenvironment may simply reflect a homeostatic 
response to activation of T cells functioning as a feedback loop. Furthermore, Myeloid 
Derived Suppressor Cells (MDSCs) can have the ability to supress the immune response 
against melanoma. MDSCs originate from the myeloid linage (stem cells from the bone 
marrow). These are a heterogeneous group of cells, which have an ability to suppress 
T cells in pathological conditions, including in cancer overall and melanoma in 
particular [78][79][80]. Similar overall function to MDSCs have Regulatory T cells 
(Tregs). Tregs are CD4 positive expressing the forkhead box P3 (FOXP3) protein which 
is a transcription factor.  As their name implies, they take part in the regulation of 
immune responses. They express checkpoint molecule Cytotoxic T-lymphocyte-
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associated protein 4 (CTLA-4) (see “Immunotherapies” below). In some cancer types, 
Tregs have been reported to be associated with a poor survival while in other cancers 
it is the opposite [81]. 
Moreover, other components of tumour microenvironment (TME), such as stromal 
cells, cancer-associated fibroblasts (CAFs), vascular components, and adipose cells, and 
their complex interactions might also regulate the effectiveness of immune responses 
against melanoma [82]. All of the them can release different types of cytokines 
affecting of the anti-tumour immune responses as well as tumour progression [82]. For 
example in melanoma lymphatic vessels were shown to have an immuno-suppressive 
role as well as a role in inducing the anti-tumour local inflammation/immune response 
[83][84]. Another study reported that the changes in collagen matrix (related to age) 
were associated with impaired host immune responses to the tumour [24]. Last but 
not least, in melanoma CAFs were reported to contribute to decrease of melanoma 
susceptibility to be killed by NK cells [85], and in general in cancer, they are recognised 
for induction of excessive inflammation within the tumour [86]. 
Finally, the tumour-host interactions might be also affected by genetics, age of the 
patient, microbiome, viral infections, exposure to sunlight, and immune-modifying 
drugs [87]. For example, less sunlight, viral infection and younger age are associated 
with higher immune responses [87]. Moreover, smoking and Vitamin D are known to 
affect systemic immune responses [88][89], but their role in tumour-host interaction is 
not yet understood in melanoma. During my thesis I had access to reported patient’s 
smoking habits and vitamin D blood levels, hence I have explored only these two and 
described in details in Chapter 6.  
1.6.2 Immunotherapies 
Over time, the accumulation of data indicating that immune responses are important 
in melanoma has led to the development of therapies that can boost immunity. Despite 
a slow start in this field, the current lines of immunotherapies are effective in a 
significant proportion of melanoma patients.  
The most promising therapeutic option for stage IV melanoma (advanced metastatic 
stage) are immunotherapies, most commonly checkpoint blockade. Immune 
checkpoint receptors (which are targeted by immunotherapies) negatively regulate T 
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cell activation, and function to limit potential self-induced damage to the host. CTLA-4 
is mainly expressed on activated T-cells and Treg and is closely related to the CD80/86 
ligand, as well as costimulatory molecule CD28. Both CD28 and CTLA-4 compete for 
binding to CD80/CD86 [90][91]. When the receptor is bound to CD80/86, a signal is 
produced to switch off the activated T-cell alternatively - CTLA4 on Treg blocks CD28 
binding to CD80/86 [90][91]. Programmed death ligand 1 (PD-L1), is another 
checkpoint molecule which may be expressed by antigen presenting cells or tumour 
cells. It binds to programmed death 1 receptor (PD-1), which is expressed on 
macrophages, B cells and activated T cells, NK cells, NKT, cells and subsets of DC cells 
[91], causing T cell inactivation. The CTLA-4 inhibitor Ipilimumab (Yervoy) was approved 
by the FDA for metastatic melanoma treatment in 2011 [92], followed by 
Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which block PD-L1 [93][94]. 
The unprecedented therapeutic benefits reported from combined checkpoint blockade 
(anti-PD-1 and anti-CTLA4) have shown the potential to exploit the current body of 
knowledge on the immune response to cancer, but still only around 58% of treated 
patients survive 3 years [95]. Note that these combinations are still in clinical trials and 
have so far only been followed-up for a short period of time.  
Checkpoint blockade is associated with significant toxicity (immune related adverse 
events such as inflammation of multiple organs), which causes significant morbidity 
even treatment related deaths. The toxicity issues are even more problematic where 
checkpoint blockade is used in the adjuvant setting. Most recently a study showed that 
neoadjuvant (first step treatment before the main therapy) setting for 
immunotherapies might be more promising for melanoma patients, however still the 
toxicity rates are very high and more studies are needed to overcome this problem, for 
example by dose reduction [96][97].  
Another type of hopeful immunotherapy is adoptive cell therapy (ACT). This type of 
therapy was introduced in 1998 by Steve Rosenberg, which was based on isolating TILs 
from the tumour, culturing and propagating the cells ex vivo, and finally injecting them 
back to the melanoma patients [98]. Subsequently, similar technique was introduced 
by isolating peripheral immune cells and engineering them with chimeric antigen 
receptors (CARs). The idea behind this treatment is to engineer the patient’s immune 
cells and make them more sensitive to cancer cell recognition. T cells are extracted 
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from the tumour, cultured in vitro, engineered by introducing chimeric antigen 
receptor (CAR) into their genome and transferred back to the patient’s body [99][100]. 
CAR is a treatment combination of antibodies, TCR and co-stimulatory molecules. 
Specifically, CAR is composed of extracellular portion, which usually are antigen binding 
domains derived from variable domains of antibodies, and which are designed to 
recognise specific tumour antigens. The intracellular signalling module of the CAR is 
derived from T cell signalling proteins, mainly CD3z (CD3 molecule and z-chain) and 
additional costimulatory domains from receptors such as CD28, CD134 (OX40), and 
CD137 [101]. When CAR is activated by tumour-associated antigen, it has the ability to 
activate different pathways at the simultaneously, for example T cell effector and 
costimulator functions [99][100], which results in over-activation of T cells. As for 
combined checkpoint inhibitors [102], around 50% of melanoma patients currently 
benefit from adoptive T cell transfer therapy [103][104].  
It is important to study immune responses in melanoma because it is needed to 
understand the failure of immune surveillance and resistance to immunotherapies. The 
increased understanding will help in designing more effective and potentially less toxic 
therapies. There is a possibility that environmental or lifestyle factors might modify the 
host-tumour interactions [87], henceforth studying them might lead to important 
findings that could be added to the patient care.  
1.6.3 Established methods to characterise immune cell subtypes within 
tumour  
1.6.3.1 Histopathological quantification of immune cell infiltration 
Excised melanoma samples are normally prepared for examination by fixation in 
formalin and embedding in paraffin wax (FFPE), although for large samples portions of 
the tumour can be stored fresh-frozen (cryopreservation) for research purposes. FFPE 
is the preferred method in pathology laboratories because the tissue block can be 
stored for a long time and be reanalysed if needed for further diagnoses. On the other 
hand, cryopreservation is preferable for many research processes since the genetic and 
protein material is not degraded by formaldehyde and higher temperature storage, 
which is the main disadvantage of FFPE method. From both FFPE or cryopreserved 
tissue, sections of the tissue are cut, stained (predominantly with Hematoxylin and 
20 
 
Eosin (H&E) for histopathological characterisation) and examined using light 
microscopy. The extent of the TILs can be assessed by eye; this is a routine part of 
diagnostic histopathological examination of melanoma within the clinical setting as 
described earlier in this chapter.  
However, to distinguish many of the individual cellular subpopulations within the 
infiltrate, immunohistochemistry (IHC) is required. This method of staining relies on 
the use of antibodies that specifically bind to an epitope (part of an antigen recognised 
by an antibody) expressed by immune cells. The nomenclature of immune cell subtypes 
has been developed on the basis of proteins expressed on their cell surface in blood. 
This method of measuring immune subtypes within the tumour is labour intensive and 
challenging if more than a handful of antigens are to be tested simultaneously. For 
simultaneous multi-antigen detection, multiplex immunochemistry is required, usually 
with usage of fluorochrome rather than standard chromogenic reactions [105]. 
Although this method is commonly used it carries some technical limitations, such as 
signal overlap between fluorophores [105]. To overcome this problem Garry Nolan and 
colleagues at Stanford University developed a more advanced method: Multiplex ion 
beam imaging (MIBI), where up to 100 antigens can be detected on FFPE tissues 
utilising metal isotopes reporters [106] which can be washed off the surface allowing 
consecutive probes to be used. This method is not yet widely used however because it 
is too expensive and requires specialized training for performance and analysis of the 
results. In summary, all types of IHC require a reasonable amount of tumour tissue and 
are time consuming especially when assessing numerous immune cell populations in a 
large number of samples. 
Flow cytometry (or FACS, for Fluorescence-activated cell sorting) of disaggregated 
tissues offers an alternative antibody-based method to measure the numbers and 
proportions of immune cells in tissues. However, in this case the tissue has to be fresh 
– cells need to be alive in order to obtain specific antigen-antibody binding [107]. This 
is rarely available for melanoma primaries at least, due to the very small size of the 
tumours. The concerns are around freezing tissues and effectively destroying their 
architecture precluding accurate staging of the tumour. Furthermore, flow cytometry 
is based on the detection of surface markers (Cluster of Differentiation, CDs) of the 
immune cell types, few of which are exclusive to individual cell populations, such that 
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multiple antibodies are required to differentiate between immune cells. Another key 
difficulty associated with FACS is tissue preparation, mainly its step of disaggregation, 
which might lead to destruction of surface antigens especially when the cells stick to 
each other which is often the case in carcinomas. Moreover, isolation of the cells from 
their original environment might induce different gene expression and protein patterns 
during this process. 
 Bioinformatic methods of immune cells scoring within tumours 
Genomic and transcriptomic tumour profiling has become commonplace, as 
microarrays and sequencing techniques improved and costs fell leading to increased 
accessibility. Fresh or cryopreserved tumours are sampled, nucleic acids extracted and 
isolated and then assayed to generate detailed profiles. DNA or cDNA from RNA 
(depending on the research aim) can be used to generate different types of genetic 
profiles: genome sequences, copy number changes, promoter methylation and whole 
genome transcriptomes, or any combinations of the above. However, in order to have 
all genetic profiles per sample a reasonable amount of genetic material is required. 
Genetic profiling assays were needed with a high enough sensitivity to allow accurate 
signal detection when a very small amount of genetic material is available, and 
preferably effective in formalin fixed tissue.  
The transcriptomic data utilised in this thesis were generated with arrays developed 
specifically to allow analysis of degraded RNA which occurs in formalin fixed blocks. 
This technological advance has allowed the research group to generate a uniquely large 
collection of tumour derived transcriptomes from FFPE primaries (as described in the 
Methods section).
In my thesis one of the tested hypothesis was that the bioinformatic analysis of 
tumour-derived gene expression profiles would allow inference of the abundance of a 
large number of immune cells subsets infiltrating the tumours using these cells specific 
markers.  
I explored a number of bioinformatic approaches that have recently been published: 
CIBERSORT, the Immunome compendium reported by Bindea et al. [108], subsequently 
updated by Angelova et al. [1]. There are other methods in literature which infer 
immune cell subtypes [109][110][111][112], however they were not considered in this 
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thesis because they either cover a smaller spectrum of cell subtypes [109][111] or only 
RNA sequencing data may be applied to them [110], or they appeared relatively late 
during my PhD (November 2017) [112]. 
1.6.3.2.1 CIBERSORT – “LM22” 
Newman et al. designed and validated a leukocyte gene signature matrix (immune 
sorting template) termed LM22 [113]. In their study, 547 genes were used to 
distinguish 22 human hematopoietic cell phenotypes:  
The design of the approach was based on isolating immune cell types from the blood 
and generating whole genome transcriptomes for each purified cell type on 
microarrays (HGU133A) (Figure 1.5). After learning the particulars of each cell subtype 
in a machine learning approach (linear support vector regression), CIBERSORT (Cell 
type Identification By Estimating Relative Subsets Of RNA Transcripts) can generate an 
estimate of the relative proportions of these cells in any tissue using their 
transcriptomic data. Newman et al. developed an algorithm to address the problem of 
mixture deconvolution (where a signal, in this instance a measure of gene expression 
was a result of a signal derived from the tissue and something else which might be 
thought of as noise). The deconvolution algorithm was intended to produce a purer 
signal and where the deconvolution fails then the implication is that the data quality 
cannot be relied upon. The “P value of deconvolution” gives the CIBERSORT user a 
measure of whether the sample was well deconvolved or not. It is an empirical p-value 




Figure 1.5: Overall representation of CIBERSORT design and application to leukocyte 
deconvolution (adopted from Gentles et al. [113]) 
 
The gene expression data used as input into CIBERSORT can be derived from any tissue 
type. However, the algorithm was developed using RNA-seq data from fresh tissue and 
from a personal communication with the authors, it is unclear whether it could be 
applied to array data generated from FFPE tissue. As a way of evaluating this method, 
I applied CIBERSORT to the array data in the LMC study since it is one of the most well-
developed tool with a dedicated online-accessible software and it is the only one (or 
one of a few) to provide a metric (p-value) indicating success or failure to infer immune 
cell presence. 
1.6.3.2.2 Bindea et al. – the “Immunome” 
Bindea et al. (2013) [108] used six publicly available gene expression datasets (from 
Gene Expression Omnibus and Array Express databases) derived from purified immune 
cell subsets to establish a reference - the Immunome compendium. In their study, the 
gene expression profiles from immune cells, the normal mucosa and colon cancer cell 
lines, blood and lymph vessels were tested using pairwise correlation to identify a 
unique signature of each of them. For example, if the genes expressed by blood 
vessels/normal mucosa correlated with some of the immune genes, then these 
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genes characterising 24 cell types and the control tissues (colon cancer cell lines, 
normal mucosae, blood and lymph vessels). 
Each cell subtype has its genes assigned, but some of the genes can be expressed by 
multiple cell subtypes. Bindea and colleagues validated the method using multiple 
techniques and experimental approaches (including DNA microarrays (Affymetrix), 
quantitative polymerase chain reaction (qPCR), FACS, immunohistochemistry, and 
mouse models) and strong correlations were found with all these approaches. The 
inferred presence of cytotoxic, T cell, B cell and other cell subsets in the colon cancer 
tissue was strongly associated with improved patient survival [108]. We have applied 
this method to the FFPE melanomas of the LMC and found similar results [76]. 
However, since its first publication, the Immunome compendium was extended to 
more cell subtypes and was based upon more genes from extensive searches of a much 
larger number of sources [1]. In this thesis, I used this updated version (see below) and 
made some further developments (see Methods section) inspired from the earlier work 
conducted in our group based on the Bindea et al.’s signature [76].  
1.6.3.2.3 Updated Immunome by Angelova et al. 
The new Immunome by Angelova et al. [1] identifying uniquely expressed genes by 
immune cell subtypes, was an extension of Bindea et al.’s strategy [108], with however 
some different starting assumptions. Principally, the newer approach comprises 36 
publicly available datasets from Gene Expression Omnibus and Array Express from 
purified immune cell from blood in various diseases. It was a significant increase in data 
sets used compared to Bindea et al. study, which used only 6 sources. All datasets 
utilised by Bindea et al.’s Immunome were also included in Angelova et al.’s. Among 
the genes described to be unique per immune cell score by both methods, only 112 
genes are common to the 2 methods (Figure 1.6). Presumably, the absence of a large 
number of genes of the initial Immunome compendium (Bindea et al.’s) in the updated 
version (Angelova et al.’s) means that by those genes were no longer considered cell-
specific using more extensive data sources.  
The immune cell types proposed by each described method are shown in the Table 1.1: 









Table 1.1: Immune cell types proposed by all the three methods and their existence 
in each of them 
Immune cell type CIBERSORT Bindea Angelova 
activated B cells   x 
activated CD4   x 
activated CD8   x 
activated dendritic cells x x  
activated mast cells x   
B cell  x  
B cells memory x  x 
B cells naïve x   
central memory CD4   x 
central memory CD8   x 
cytotoxic cells  x  
dendritic cells  x x 
effector memory CD4   x 
effector memory CD8   x 
Eosinophils x x x 
immature B cells   x 
immature dendritic cells  x x 
M0 macrophages x   
M1 macrophages x   
M2 macrophages x   
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Immune cell type CIBERSORT Bindea Angelova 
Macrophages  x x 
mast cells  x x 
memory dendritic cells   x 
Monocytes x  x 
myeloid derived suppressor cells   x 
natural killer cells CD56bright  x x 
natural killer cells CD56dim  x x 
natural killer cells  x x 
natural killer T   x 
Neutrophils x x x 
NK cells activated x   
NK cells resting x   
plasma cells x   
plasmacytoid dendritic cells  x x 
resting dendritic cells x   
resting mast cells x   
T cells x  x 
T cells CD4 memory activated x   
T cells CD4 memory resting x   
T cells CD4 naïve x   
T cells CD8 x x x 
T cells follicular helper x x x 
T cells gamma delta x x x 
T central memory cells  x  
T effector memory cells  x  
T helper 1  x x 
T helper 17 cells  x x 
T helper 2  x x 
T helper cells  x  
T regulatory cells x x x 
 
 
CIBERSORT and Angelova et al.’s Immunome provide valuable and promising 
methodology to characterise immune cells within the tumours. All the methods deliver 
some distinct and common immune cell types to be characterised. As shown in the 
Table 1.1 all of the methods proposed very specific immune cell types, which might be 
actually difficult to define their functional differences. Nevertheless, I explored utility 
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of two of them applying them to primary melanoma FFPE-derived gene expressions. 






Materials and Methods 
This chapter summaries the Leeds Melanoma Cohort from which the data used in my 
work was generated. Moreover, additional datasets, and standard statistical tests used 
in majority of the chapters of the thesis are described. The more advanced statistical 
and bioinformatic methods applied to only one chapter will be described in full details 
in the relevant chapter. 
2.1 The Leeds Melanoma Cohort (LMC) 
A cohort of 2184 primary cutaneous melanoma patients was recruited in the period 
2000 to 2012 (67% recruitment rate) [114] by Julia Newton-Bishop and research staff. 
The participants were predominantly recruited from a geographically defined area 
(Yorkshire up to the river Tyne) with some additional recruitment from specialist 
centres in order to recruit a larger number of people with rare tumours e.g. acral 
tumours, and people having sentinel node biopsies.  
Lifestyle data, co-morbidities and drug exposures including supplements were 
collected from participants by questionnaire. Clinical data were extracted from medical 
records and in order to derive melanoma specific survival (MSS), follow up was 
conducted using the national cancer registry, medical records in primary, and 
secondary care and by annual questionnaires completed by consenting participants. 
The median follow-up for the cohort at the time of the analysis of the data presented 
in this thesis was 7.5 years. The LMC was reviewed by the North East – York Research 
ethics committee (Jarrow, Tyne and Wear, UK) and received ethical approval - MREC 
1/3/57 and PIAG 3-09(d)/2003. The histological features of the tumours were reported 
by clinical dermatopathologists. Dr Sally O’Shea from our research group (former 
clinical PhD student) also carried out a single observer review of as many of the slides 
from tumours used to generate the transcriptomes as were available. Dr O’Shea 
derived a number of measures of the tumour and its environment which were found 




2.1.1 Sampling of the FFPE primary tumour blocks 
Sampling of the FFPE primary tumour blocks was performed predominantly by Dr 
Jonathan Laye. 5µm primary tumour sections were cut using a microtome and 
mounted onto Superfrost™ glass slides (Solmedia, Romford, UK). The sections were 
dried overnight and then hot-plated for a minimum of 20min at 70°C and subsequently 
following a standard protocol Haematoxylin and Eosin (H&E) staining was performed.  
All the resulting H&E-stained sections of primary tumours were reviewed using light 
microscopy by Prof. Julia Newton-Bishop and Dr Jonathan Laye. Using a fine-tipped 
marker pen, the area of the slide corresponding to the invasive tumour was marked for 
sampling, consistently ensuring that the region selected had the least stromal content 
and the least infiltrating lymphocytes. The intent was to ensure comparability between 
tumours. Necrotic areas were avoided. The marked slide was then used to orientate 
the tumour block so that it could be sampled using a 0.6mm diameter microarray 
needle (Beecher Instruments Inc, USA) taking a core horizontally. Depending upon the 
size of the primary tumour, sampling was performed to yield up to 2 tissue cores. 
Although the 2184 participants were ascertained from the population rather than from 
hospital (and therefore potentially biased) series, the protocol demanded that blocks 
should not be destroyed by sampling less the patient need their sample for clinical 
testing later. Hence we did not sample approximately half the blocks. Unfortunately, 
two batches of arrays were lost attributed to technical difficulties related to 
unexpected loss of reagent function over time. The requirement to avoid block 
destruction for living participants did mean that there was some bias to sampling of 
thicker tumours. The mean thickness for those sampled was 3.0mm compared with 
2.2mm for the whole cohort. 
The DNA and mRNA were isolated from the cores by Dr Jonathan Laye and Dr Ross 
Jewell, preceded with tissue deparaffinisation and digestion. DNA was extracted using 
Qiagen AllPrep® DNA/RNA FFPE kit and Qiagen QiAamp® FFPE tissue kit. RNA was 
isolated using High Pure paraffin RNA kit (Roche Diagnostics Ltd, Burges Hill, UK). All 
the nucleic acid extraction procedures were performed as recommended in 
manufacturers’ protocols. The extracted DNA was used for generation of Copy Number 
Variation data and mutational (NRAS, BRAF) data, while mRNA was used for the 




2.1.2 Measurement of the gene expression 
The mRNA was extracted from 820 tumour cores (703 unique patients and 117 
duplicates). Gene expression was assayed by an external service provider ServiceXS 
(Leiden, Netherlands) using the Whole-Genome DASL (cDNA-mediated Annealing, 
Selection, extension and Ligation) HT12v4 assay (Illumina®) in 3 batches. This array was 
generated for use on formalin fixed tissue in that the probes were short: about 50 bases 
in length in order to enable profiling of partially degraded RNA, which resulted due to 
FFPE archival methods. The generated raw expression data were normalised by Dr 
Jérémie Nsengimana. Firstly, the data were background-corrected and quantile-
normalised in R using the package Lumi [115]. Singular value decomposition (SVD) was 
applied in package Swamp [116] in R in order to evaluate the association between the 
top principal components and technical variables: batch, chip, age of FFPE block, and 
RNA concentration. The variables that were found to be associated with these top 
components were adjusted out, and SVD was applied again with and without data 
permutation to evaluate the remaining “biological” variability in the data. In order to 
detect outliers normalized full intensity plots were examined. Among sample 
duplicates, in the final data set the sample with the highest number of detected genes 
was retained. Generally, the median and interquartile range of genes that were 
detected per sample were 14,784 (P<0.05, range 14,153– 15,304), which was 
consistent with other studies, which used DASL arrays in melanoma 
[117][118][119][120]. Some of the DASL probes were designed to hit: 
• all splice isoforms of a gene 
• or specific splice isoform of a gene, for which multiple isoforms are known to exist 
• or one known single splice isoform  
• or multiple isoforms -  more than one and fewer than all of the splice isoforms of 
a gene, 
however, the majority of probes were the ones targeting all splice isoforms. For some 
of the genes more than one probe was designed and for most of my analyses I 
examined all the probes, then chose the probes with the highest proportion detected 
(throughout the samples at the P<0.05), and eventually annotated them to the gene 




(Angelova et al.) to the LMC transcriptome I filtered out the probes that were designed 
to hit only one specific isoform of a gene. I did not apply this filtration to another 
immune cell scoring method - CIBERSORT because this idea emerged long after I 
decided to drop the latter method.  
The LMC gene expression data are accessible from the European Genome-phenome 
Archive (EGA) - accession number: EGAS00001002922. These data were the principal 
data used in this thesis.  
2.1.3 Mutation data  
 NRAS and BRAF mutations from pyrosequencing 
The DNA was used to carry out the NRAS and BRAF mutation screening using 
pyrosequencing [121] by Dr Philip Chambers, Genomics facility, Leeds. The 
pyrosequencing primers were designed to detect BRAF codon 600, NRAS codon 61, and 
NRAS codons 12 &13. These analyses were performed prior to my arrival in Leeds. 
During my PhD we collaborated with the David Adams’ laboratory at the Wellcome 
Sanger Institute to mutation screen a large number of genes see below. 
 Gene panel mutation screen from next generation sequencing (NGS) 
The mutation data were generated at the Wellcome Sanger Institute in Cambridge 
using DNA extracted from the tumours in Leeds. The data were pre-processed by Sofia 
Chen (Marie Skłodowska-Curie PhD student), supervised by David Adams. Briefly, from 
the LMC 521 samples were sequenced on Illumina HiSeq4000. Mutation data were only 
available from 319 of the 703 tumours from which transcriptomic data were generated 
(Figure 2.1) as the 0.6mm cores derived DNA had been exhausted in the process of 
making libraries for copy number data generation in Leeds. 
To detect mutations Sofia used targeted capture custom design, with Agilent 
SureSelectXT baits diluted 1/24 
(https://www.agilent.com/cs/library/catalogs/public/5991-7099EN.PDF).   
The human reference genome assembly GRCh37d5 was used for mapping the reads. 
This step performed using BWA mem and the duplicates were marked using Picard 




v.1.11.2 and the variant annotation was accomplished by using VAGrENT. In order to 
annotate functional consequences of the indels Pindel v.2.2.2 in together with VEP was 
used to. Variants with the low quality were excluded.  
Moreover, variants which had both minor allele frequency (MAF) <0.10 and a coverage 
<30x within the tumour sample were filtered out. The mutational load was provided as 
three variables: mutation count per megabase, exonic mutation per megabase, and 
nonsynonymous mutation per megabase. For my analyses, which were mainly related 
to immune responses I used the mutation count per megabase, which could be 
considered as the most representative of neoantigen load (explained in Chapter 1). The 
mutational load per megabase per sample was obtained by dividing the number of 
mutations per patient by 5.2 (the sequenced regions were 5.2 megabases long). This 
variable, was categorized into tertiles, because these were predictive for melanoma 
specific survival, as initially showed by Sofia Chen’s analyses (private communication). 
2.1.4 Somatic copy number alteration (CNA) data 
Dr Anastasia Filia (former PhD student) generated the whole-genome DNA libraries for 
the Next Generation Sequencing (NGS) using the NEBNext® UltraTM DNA Library Prep 
kit for Illumina® (indexed primers) (New England BioLabs, UK) in Leeds. NGS was run 
on Illumina GAII or HiSeq sequencer. The CNA data from NGS reads were generated by 
Dr Anastasia Filia and Dr Alastair Droop as described in Filia et al. (under revision, 
Scientific Reports, October 2018), however in my thesis the method of the CNA data 
analysis was slightly altered as compared to the previous one and it was carried out by 
my colleague Marie Skłodowska-Curie PhD Student, Joey Mark Santiago Diaz CNA data 
were generated from 303 FFPE tumours, including 276 for which the transcriptomic 
data were also available (Figure 2.1). From the sequenced tumour DNA samples, the 







Figure 2.1: Venn diagrams representing the numbers of the samples available for 
transcriptomic and CNA or mutational data 
2.1.5 Immunohistochemistry 
Immunohistochemical staining was performed by Dr Jonathan Laye and myself using 
IntelliPath FLX detection reagents (MenaPath, A. Menarini Diagnostics, UK) according 
to manufacturer’s protocol.  
The tissue blocks for immunohistochemistry were chosen based on the availability of 
gene expression data from the tumour and the identification of blocks that could be 
resampled or were no longer needed for clinical purposes due to the patients’ death 
due to any cause. This was therefore a small sample biased in terms of thickness and 
associated mortality given the proportion of samples used from patients who had died 
of melanoma. The samples were the only ones available however and as a reasonable 
proportion of people had died of causes other than melanoma were judged acceptable. 
5µm tissue sections were cut and mounted on Superfrost Plus™ slides (Solmedia, 
Romford, UK), dried overnight and hot plated for 1hr at 70°C. The slides were immersed 




a pressure cooker to perform antigen retrieval by heat: the tissue sections were heated 
to 125°C sustained for 2min followed by cooling to 90°C which was then maintained 
for a further 10 seconds. The slides were then washed in warm MenaPath Wash Buffer 
to remove antigen retrieval solution and any remaining wax, and then in distilled water. 
The area of the tumours was circumscribed using a wax pen and the slides returned to 
MenaPath Wash Buffer. Each tissue section was treated with 100µl MenaPath 
Peroxidase Blocking agent for 20min to quench endogenous peroxidase activity within 
the tissue. After briefly rinsing in MenaPath Wash Buffer, the tissue sections were 
treated with 100µl MenaPath Background Blocking Agent with Casein for 20min to limit 
non-specific antibody binding. After further rinsing in MenaPath Wash Buffer, each 
tissue section was incubated with 100µl primary antibody, diluted in Zymed antibody 
diluent (Thermo Fisher Scientific, UK) in accordance with previously optimised 
conditions, and incubated at room temperature for 1h. The slides were then rinsed 3 
times for 3min each in MenaPath Wash Buffer before the addition of 100µl MenaPath 
HRP-polymer to each tissue section and incubated for 30min at room temperature. The 
slides were again washed 3 times for 3min in MenaPath Wash Buffer and then treated 
with MenaPath Purple Chromogen for 10min. Slides were rinsed for 1min in tap water 
and then underwent counterstaining for 30sec in Mayer’s Haematoxylin, followed by 
1min rinse in running tap water. The tissue sections were ‘blued in Scott’s tap water 
for 2 min, rinsed again in running tap water for 1 min and underwent dehydration in in 
a series of 100% ethanol washes (4 washes of 3 min each) and ‘cleared’ in xylene (3 
washes of 3 min each). Coverslips (Solmedia, Romford, UK) were applied onto the 
tissue sections using DPX mounting medium (Solmedia, Romford, UK). 
A purple chromogen was chosen instead of brown in order to avoid confusion with 
melanin. However, we did feel ultimately that the disadvantage of this colour of 
chromogen is that occasionally if the staining is not strong enough it might be difficult 
to assess the positive nuclear staining which would be purple from unstained blue 
ones. 
2.2 Data not originating from LMC 
In addition to various histological and molecular data included in the LMC, in this thesis 




were used: The Cancer Genome Atlas (TCGA) metastatic melanoma [46], established 
melanoma cell line cultured in house and patient derived cell lines cultured at the 
University of Zürich. 
2.2.1 The Cancer Genome Atlas - TCGA 
I downloaded the gene expression (measured by RNAseq) and survival data from The 
Cancer Genome Atlas (TCGA) metastatic melanoma, produced using fresh frozen 
tissues. (http://www.cbioportal.org/data_sets.jsp, downloaded in 2016). I have chosen 
to analyse only the metastatic tumours, due to problematic survival data for primary 
tumour. Basically Dr Jérémie Nsengimana observed that these tumours had much 
worse prognosis than the metastatic ones, which was counterintuitive. In general, this 
study used tumours that were highly selected/biased, at very advanced stages and with 
limited clinical metadata. 
Nevertheless, I used in total 339 metastatic samples, representing 80% of the total 
TCGA dataset at that time. The participants in this study were patients from different 
locations, hence it was not data from a population-based cohort like LMC. The overall 
survival (OS) was used in survival analyses performed in this dataset as there was no 
record of the cause of death. The follow up was as follows: Median=353 days, Min=12 
days, Max=3798 days. 
2.2.2 Established melanoma cell lines 
Melanoma cell lines SkMEL28 (ATCC) and MeWo (courtesy of Professor Alan Melcher, 
formerly at Leeds, storing samples in the Leeds CRUK cell line bank) were cultured in 
our lab and their gene expression produced and pre-processed by Dr Anastasia Filia 
(former PhD student) and Dr Alastair Droop. I used these data to identify genes in the 
Angelova et al.’s Immunome which are expressed by melanoma cells and could 
therefore not be considered specific to immune cells. The total RNA was extracted 
following the Qiagen RNA mini kit (QIAGEN). The measurement of the gene expression 
was performed using the Affymetrix GeneChip® Human Genome U133 plus 2.0 Array 
by the service provider at the Patterson Institute, University of Manchester. The data 




Multi-chip analysis (RMA) [122] and affyPLM [123] packages in R available in 
Bioconductor (https://www.bioconductor.org). 
2.2.3 Patient derived melanoma cell lines from Zurich University 
These data were produced and analysed by a colleague Marie-Curie PhD student 
Sabrina Hogan based at the University of Zürich, under the supervision of Prof. Mitchell 
P. Levesque. 
Primary melanoma cells were isolated from clinical samples at the University of Zurich 
as described previously [124]. Melanoma cell cultures were obtained from remaining 
tumour material of patient biopsies after sampling for histological review, using the 
selective adherence method [124]. The protocol used to design these patient-derived 
cultures was adapted to discourage fibroblast cell growth and was reported to be 
successful in 70% of samples submitted to the live cell biobank. 
Total RNA from melanoma cell cultures (N=103) was extracted using the Qiagen RNA 
mini kit (QIAGEN) according to the manufacturer’s protocol. RNA capture was 
performed with the TruSeq RNA Library Prep Kit v2 (Illumina) and the library was 
sequenced on a HiSeq4000. RNA counts were quantified from single-end reads using 
STAR aligner [125].  
2.3 Statistical methods 
All the statistical methods were performed in STATA (SE) v14.1. Some of the 
manipulations of the data (e.g. transposition) were implemented in R v3.3.2 and 
RStudio v1.0.136.  
2.3.1 Variables used in statistical analyses of the LMC samples 
 Categorical variables 
• AJCC stage was used as described in the Introduction and was recorded in 3 
levels: stage I, II, and III, N=695 
• Ulceration was recorded as a binary variable: “yes” vs “no”, N=703 
• TILs as described in the Introduction: absent, brisk and non-brisk, measured by 
clinical histopathologists (N=553). The single observer Dr Sally O’Shea, (N=601) 




introduction (Figure 1). Both of these measures were used separately as a cross-
validation between the measures from the clinic and single observer. Dr O’Shea 
also generated the measures of lymphocytes infiltrate around the cored region, 
however for smaller number of samples, hence I excluded them in my analyses 
• Site of melanoma was used as either binary (“Limbs” vs “Rest”) or with 4 levels: 
“Limbs” (N=299), “Head and neck” (N=80), “Trunk” (N=233) and “Other” (N=90), 
in total N=702. “Other” represent rare, non-sun exposed tumours such as: 
o ear, nose, thorax (N=5) 
o acral (N=19) 
o anal (N=5) 
o cervix (N=1) 
o foot (N=18) 
o hand (N=5) 
o nodal with no known primary (N=3) 
o penis (N=3) 
o perineal (N=1) 
o subungual (N=14)  
o vaginal (N=3)    
o vulval (N=13)    
• Sex was used as a binary variable (females, males), N=703 
• Smoking was analysed as categorical variable as “ever” (N=324) vs “never” 
smokers (N=334); Total N=658 and “smokers” (N=543) vs “still smokers” (N=85) 
• Vascular invasion assessed by the presence of melanoma cells within blood 
vessels recorded as “yes” vs “no”, by clinical histopathologists reporting clinical 
samples N=627 
• NRAS/BRAF Mutation data: NRAS mutant vs BRAF mutant vs “double wild type”, 
N=575 





 Continuous variables 
• Breslow thickness was measured as described in the Introduction: 
median=2.3mm, min=0.33mm, max=20mm, N=692 
• Mitotic rate was quantified as mitotic count within tumour per mm2: median=3, 
min=0, max=83, N=596 
• Age at diagnosis – age of the patient was recorded at diagnosis of primary 
melanoma: median=58.3, min=18.29, max=81.25, N=703 
• Duration of smoking was recorded as a number of years smoked by participants: 
median=0, min=0, max=60.9, N=654. More than half of the patients had never 
smoked (see previous section) 
• Vitamin D levels (nmol/L) in the blood were measured in the NHS biochemistry 
laboratory in Leeds, in a sample taken at recruitment (add average time from 
diagnosis to recruitment). Concentrations of 25-hydroxyvitamin D2 and D3 
(nmol/L) were measured in 100 µL of cryopreserved serum by liquid 
chromatography tandem mass spectrometry. The levels were adjusted for 
season, by rescaling every patient’s record to winter: median=39.5nmol/L, 
min=0nmol/L, max=191.2nmol/L, N=549. This adjustment was based upon the 
observation that levels are on average 20nmol/L higher in summer months than 
at the end of winter 
• Melanoma specific survival (MSS) was used in survival analyses in LMC: 
median=6.3years, min=0.45years, max=14.3years, N=703 
2.3.2 Statistical tests  
Parametric and non-parametric tests were used depending on the distribution of a 
tested variable. 
I used the Student t-test (parametric test) or Mann Whitney U (non-parametric test) 
for comparison of two groups. For more than two groups comparisons, I used the 
Analysis of variance ANOVA (parametric test) or the Kruskal-Wallis (non-parametric) 





I ran correlation analyses using the Pearson (parametric test) or Spearman’s rank 
correlation (non-parametric) coefficients. For multiple testing, I utilised Bonferroni 
correction and Benjamini-Hochberg tests, depending on the required stringency and 
the research area common practice. 
 Survival analyses 
Survival analyses were carried out using Cox’s proportional hazards regression 
(univariable and multivariable). Survival data were visualised using the Kaplan Meier 
approach. 
The survival data consist of one observation per case with the data being either of the 
form: (i) case dies at time ! since diagnosis (termed "failure") or (ii) case still alive at 
time (!) after diagnosis (censored observation).  
In the analyses presented here, the failure event will be defined in each analysis but 
will usually reflect "death from melanoma". Cases who have died from causes at time 
! after diagnosis other than melanoma are censored at that time. 
The Cox proportional hazards model assumes that the probability density (probability 
per unit time) for "dying" at time	! (given that an individual survived until !) is equal to 
a hazard function, ℎ(!), times a function of predictor variables. For convenience, the 
effect of the predictor variables is modelled as exp()*+* + )-+- + ⋯ + )/+/) where 
(+*, +-,… +/) are predictor variables and ()*, )-, …)/) are the weights associated with 
the corresponding predictor variable which are typically estimated during analysis by 
maximum likelihood; the estimates of )*, )- etc. are log "hazard ratios" (HRs). The 
insight provided by Sir David Cox was that using the likelihood formulation and this 
precise model, the likelihood is independent of the unknown baseline hazard ℎ2(!). HR 
estimated to be greater than 1 implies decreased survival (increased hazard) while HR 
< 1 implies improved survival. The significance of the Cox proportional hazards was 
estimated by the appropriate likelihood ratio tests with the statistical significance 





In silico characterisation of tumour immune microenvironment 
3.1 Aims  
• To evaluate, develop, and apply bioinformatic approaches to characterisation of 
immune cell subtypes infiltrating primary melanomas. 
• To cluster primary melanoma transcriptomes based upon inferred immune cell 
scores. 
• To identify immunologically distinct and prognostic primary melanoma 
subgroups. 
In this chapter, I applied two of the three bioinformatic methods of immune cell 
quantification in silico described in the Introduction to the LMC transcriptomic dataset: 
CIBERSORT [113] and Angelova et al.’s Immunome [1]. As explained earlier, the 
Angelova et al.’s Immunome is an extension of the system described by Bindea et al. 
[108] and used by Dr Jérémie Nsengimana in our research group previously [76]. The 
scores generated based on Bindea et al.’s Immunome were used for some selected 
comparisons in this thesis. 
3.2 Methods 
3.2.1 Application of the CIBERSORT method to the LMC transcriptome 
CIBERSORT - a computer algorithm of gene expression deconvolution to infer immune 
cell infiltrates [113] was developed using Affymetrix data and has not yet been 
evaluated in other settings. The first aim of this chapter was to apply it to FFPE tumour 
array-based transcriptomes (DASL HT12.4). The algorithm can be used interactively 
online or as a downloadable R package. As described in Chapter 1, it is based on linear 
support vector regression (SVR) machine learning to deconvolve the cell mixture in 
gene expression with data resampling to derive an empirical p-value showing the 
success or failure of the algorithm when applied to each sample. As a default, 
CIBERSORT uses as reference the LM22, a transcriptomic signature of 22 purified 




with the sum of those proportions adding up to 1. The method failure may occur for 
example if there are no immune cell infiltrates at all in the tumour.  
The principal equation that CIBERSORT algorithm utilises is: 
3 = 5	6	7,	where: 
3 = mRNA mixture (measured gene expression in the tumour) 
5	= vector of the unknown (relative) fractions of each cell type in the tumour 
7 = GEP (gene expression profile) matrix of the 22 pure cells on the 547 reference 
genes, the “LM22” signature.  
Note that CIBERSORT allows the user to define their own signature of cells to 
investigate (which can be fewer or more than 22 and may include non-immune cells). 
It is assumed that the size of matrix 7 is much smaller than the size of matrix 3	(i.e. 
many more genes measured overall than the number of genes characterising the cells 
of the signature). 
I applied the online version of this method (http://cibersort.stanford.edu/) to the LMC 
dataset, with the default LM22 signature. The deconvolution p-value was produced 
using Monte Carlo sampling, with 1000 permutations as recommended. For each 
tumour analysed, the tested null hypothesis was that there were no immune infiltrates 
of the LM22 signature (see LM22 signature components in the Introduction, Table 1). 
The algorithm calculates the Pearson correlation between the input gene expression 
matrix (3) and its expectation under the null hypothesis using the inferred cell 
proportions (5	6	7). A significant p-value means that the inferred cell proportions are 
unlikely to be random observations, while a non-significant p-value means that the 
inferred proportions may well represent noise.  
After preliminary checks, I found that the LM22 reference signature had data on a 
different scale to our dataset, due to different approaches to pre-processing and 
transformation. For LM22 the maximum value was 42,851.29 and the minimum 
461.191. The LMC data were on log2 scale with a maximum of 17. Although a simple 
power transformation of the LMC dataset would have made the two scales 
comparable, they would not have been entirely similar (the new maximum value would 




To have completely similar scales prior to running CIBERSORT, I collaborated with Dr 
Victor Boudara (Mathematics department, University of Leeds), who devised the 
formula described below and I applied it to the LMC dataset. In essence, I applied two 
data transformations: 
a) The first was to transform one interval (LMC data scale) [y1 ; y2] into a second interval 


























After obtaining both constants a and k any value, y, contained in the LMC dataset 
interval [y1 ; y2] can be transformed into, y’, contained in the LM22 signature interval 
[x1 ; x2], by using: 
4) 
:′ = 9:;. 
b) The second data transformation was scaling both the LMC gene expressions and the 
LM22 gene expressions, using standard normal transformation, setting the mean to 0 




3.2.2 Application of Angelova et al.’s Immunome 
The Bindea et al.’s Immunome [108] and its later version by Angelova et al.  [1] were 
developed by using purified immune cells and different tissue types as controls, 
including colorectal cancer cells, because the authors are colon cancer researchers. 
Before applying this approach to melanoma FFPE samples, I performed gene and cell 
filtration to adapt the compendium to the melanoma context. The reason for doing this 
was to ensure as much as was possible that the measured immune cell signals 
originated effectively from the immune cells, not from melanoma cells or 
melanocytes[76]. I applied three filters to the Angelova et al.’ Immunome. 
Firstly, I removed the genes that were expressed among the top 25% across the whole 
genome in a melanocyte cell line (GSE4570) and in our cultured melanoma cell lines, 
MEWO and SK-MEL28 (cells cultured and RNA extracted by Dr Anastasia Filia, former 
PhD student in the lab). SK-MEL28 gene expression was measured in 8 replicates while 
those from MEWO were generated in 7 replicates. The replicates were averaged within 
each dataset and genes were ranked based on this average expression. We considered 
genes that ranked among the top 25% most expressed in each dataset as evidence of 
their substantial expression by melanoma cells with therefore little support that they 
are immune cell specific. Our hypothesis here is that we do not expect immune cells in 
melanoma cell lines. These genes were then removed from the Angelova et al.’s 
Immunome.  
Secondly, I calculated the proportion of genes removed by this filtering step per 
immune cell type and eliminated the whole cell type altogether if less than 10% of its 
genes remained. The exception to this was only if I could find concordant evidence 
from published literature that the reduced number of genes was indeed characteristic 
of the immune cells in question.  
Thirdly, for the remaining immune cells I tested reciprocal correlations between genes 
assigned to each cell type, as the Immunome compendium approach was based on 
genes co-ordinately expressed within a particular cell subtype, i.e. a positive 
correlation between those genes was expected. I reasoned that, for each immune cell 
subtype, gene expression correlations that were observed in the blood might differ 




the majority of others, then the evidence of their specificity to that cell type is 
weakened and they should be removed. In the majority of cell scores, most of genes 
were co-expressed as expected but in a few cases there were negative correlations and 
I removed those genes negatively correlating with the majority. The negative or very 
weak correlations could also be a reflection of technical issues with probes, which 
failed the detection of the particular genes, particularly in mRNA degraded by the 
tissue fixation in formalin. This problem could be partially addressed by testing these 
correlations using a dataset generated from fresh frozen tissue with less degraded 
mRNA, such as TCGA. The correlation plots between all genes within each immune cell 
type were constructed in R using “corrplot” package [126][127]. This analysis was 
conducted in both the LMC and the TCGA dataset (for the replication). 
After applying all above described filters, I devised a score for each immune cell type, 
calculated as the mean of expression values of all genes attributed to that cell, after z-
score normalization of the log2 transformed gene expression data as described before 
[76]. The scripts to create the immune cell scores were written in Bash (Unix shell) with 
the help from Dr Victor Boudara and then applied in STATA. The same set of genes per 
immune cell type was applied to LMC and TCGA. 
3.2.3 Consensus clustering of LMC tumours based on the immune cell scores 
Clustering is a grouping/subdivision of the data (objects) based on their similarities and 
it can be performed on genes- or samples basis. It assigns the most similar objects to 
the same group and the most dissimilar ones to distinct groups. Cluster analysis helps 
to find functional structures within large datasets on a comprehensive level, therefore 
it became almost a standard method for simultaneously analysing expressions of 
multiple genes in large experiments [128]. The genomics research field has expanded 
regarding the development of various classes/algorithms of clustering. For example, 
one very commonly clustering type is hierarchical clustering, which produces a 
dendrogram (graphical representation) of similarities between samples and/or genes 
for example with respect to gene expression values [129]. The dendrogram can be cut 
an any level to set the final number of clusters after a visual inspection.  
The other widely used algorithm is K-means, which is based on partitioning the data 




K-means usually outperforms hierarchical clustering in finding the optimal number of 
clusters [131][132][133]. The most frequently used similarity measures are Euclidean 
or Pearson correlation distances and both perform reasonably well for clustering 
methods [131][132]. 
Although clustering provides good solutions to subdivide the data, it faces some 
difficulties in the identification of non-overlapping groups/clusters and their final 
number. In fact, visual inspection of dendrograms in HC and predetermining the 
number of clusters in K-Means can be very subjective. It also encounters the problem 
of overfitting, when the sample size is relatively small in comparison to the number of 
analysed genes. To overcome this problem, consensus clustering was introduced, 
which is a resampling based method of identifying sample classes in microarray data 
[134]. Subsets of data are resampled multiple times (for example N=1000) from the 
original dataset and a user-selected clustering algorithm is applied to each subset, 
assuming a growing number of clusters from 2 to a user-defined maximum K. At each 
analysis iteration, each sample is placed in one of the clusters and a consensus score is 
produced, reflecting the sample belonging to each cluster. In an ideal situation a 
sample belongs to one and only one cluster. All analysis iterations should effectively 
classify that sample in its cluster, i.e. no iteration should classify it in other clusters. In 
other words, the sample is put in its cluster with 100% consensus and in other clusters 
with 0% consensus. In reality however, samples will have varying levels of consensus 
scores in each cluster, but after consensus clustering each sample is finally assigned to 
its most likely cluster (one with the highest consensus score). A consensus score is the 
proportion of iterations classifying a sample in a particular cluster and it is stored in a 
H+H matrix, where H is the total number of clusters. 
 A number of metrics are generated in consensus clustering to aid the decision on the 
optimal number of clusters: the consensus heatmap, the consensus cumulative density 
function (CDF) and the delta graph of the area under the CDF [134]. The consensus 
heatmap is a results of clustering of the consensus matrix values using hierarchical 
clustering and the dendrogram is cut at the chosen k threshold. The heatmaps are 
symmetrical and their “cleanliness” at each k indicates the stability; the blue colour 
designates high consensus whereas white no consensus (samples are always classified 




for which consensus score is less than or equal to +	(0 ≤ + ≤ 1) for each k. The optimal 
number of clusters is the CDF curve for k with the highest proportion of “0” and “1”. 
The delta graph of the area under the curve is the change in the area under the CDF 
when the number of clusters increases. Using this graph the optimal number of clusters 
is when the change of the area under the CDF is the smallest when the number of k 
increases. 
I have used the same parameters for consensus clustering (listed below), as proposed 
previously in consensus cluster analysis [134] within ConsensusClusterPlus [135] 
package in R to generate tumour subgroups. I decided to proceed with the same 
parameters, because, it was shown that they result in obtaining the most stable 
clusters using the gene expression data.  I chose K-means as an algorithm for clustering 
with max K=12, Euclidean distance metric, 5000 repetitions, 80% genes and tumour 
resampling. Consensus heatmap, CDF and delta CDF plots were used to define the 
optimal number of clusters.  
After sample classification, I tested the association between the obtained clusters and 
melanoma specific survival using Cox regression and likelihood ratio tests. The immune 
cell scores were plotted on a heatmap alongside the identified clusters to visualise their 
association (“pheatmap” package in R). 
 Comparison of newly obtained immune signature with existing melanoma 
signatures 
We previously used consensus clustering in our group to identify 6 consensus 
immunome clusters (CICs) in the 703 LMC tumours based on selected immune genes 
[76]. For the current analysis, I chose to apply a dimensionality reduction to the genes 
by using them to calculate scores of 27 immune cells (see previous section) and then 
use these scores in consensus clustering to identify immunologically different tumour 
subtypes. I hypothesised that dimensionality reduction prior to clustering would 
delineate larger and more prognostic subgroups, allowing for enough power for 
downstream analyses aimed at biological characterisation. This hypothesis was driven 
by the observation that among the 6 CICs we reported previously [76], 5 had similar 
profiles of survival (good prognosis, but distinct histological features) and only one was 




for AJCC stage the two low immune CICs had a poor outcome. I tested the agreement 
between the 6 CICs and the new subgroups using Cramer’s V statistic. 
Back in 2015, consensus hierarchical clustering of 1,500 gene expressions with the 
highest variance was used by The Cancer Genome Atlas (TCGA) research network to 
classify 329 melanoma samples. Data were generated using RNA-seq from fresh frozen 
tissue, mostly from metastatic lesions. Three molecular classes were identified: “MITF 
low”, “keratin”, and “immune”, with the most favourable survival for the “immune” 
and least for “keratin” [46]. In this thesis, I will call these classes “TCGA classes”. Dr 
Nsengimana applied the nearest centroid method [136][137] to classify our 703 
primary melanomas into these TCGA classes. I assessed the intersection between these 
TCGA classes and my newly identified clusters using the Cramer’s V statistic.  
3.2.4 Replication of obtained clusters on independent dataset (TCGA) 
In order to assure that the consensus clustering results generated from the LMC were 
not over-fitted, they needed replication on an independent dataset. For this purpose, 
I utilised the TCGA metastatic melanomas, restricting the analysis to the metastatic 
samples (N=339 samples, 80% of the total dataset). These data were downloaded from 
the cBioPortal website (http://www.cbioportal.org). The reason to exclude TCGA 
primaries is because we have discovered in our group (Dr Nsengimana) that their 
survival data records were inaccurate (primary disease was associated with better 
outcome than metastasis). They could therefore bias the survival analysis of clusters.  
To replicate clustering analysis in TCGA, I applied the nearest centroid method [137] in 
R. Firstly, I obtained the centroid vectors by averaging scores of each immune cell 
subtype within each cluster from LMC. Secondly, I scored each immune cell subtype 
for each TCGA sample in the same manner as I had done in the LMC. Thirdly, I 
calculated the Spearman correlation coefficient between each TCGA sample with each 
immune cluster centroid. Finally, the sample was assigned to the immune cluster with 
which it had the highest correlation. Subsequently, I tested the difference in overall 




3.2.5 Clinico-histopathological characterisation of the obtained clusters 
I analysed the biological and clinical validity of the clusters by comparing various 
clinico-histopathological variables recorded in our cohort (LMC). I tested the 
differences among the clusters using the chi-square test for categorical variables and 
the Kruskal-Wallis test for continuous variables. The following variables were tested: 
• Age at diagnosis (continuous, years) 
• Site of melanoma (%) (Limbs, Head, Trunk vs Rare, explained in Chapter 2) 
• Sex (% males) 
• BRAF-mutated (%) 
• NRAS-mutated (%) 
• Ulceration status (%) 
• Breslow thickness (continuous, mm) 
• Mitotic rate (continuous, count/mm2) 
• AJCC stage (%) (I vs II vs III) 
• TILs (%) (Brisk, Non-brisk, unclassified, no TILs), defined by dermato-pathologists 
and single observer from the research group, Dr S O’Shea 
• Smoking (% ever smoked) 
• Season-adjusted serum vitamin D at recruitment (continuous, nmol/L) 
• Mutational load (3 groups %). 
3.3 Results 
3.3.1 Application of CIBERSORT to LMC transcriptomes 
Without scale transformation (i.e. using the log2 transformed gene expression in the 
LMC and raw data in the LM22) CIBERSORT was able to successfully deconvolve only 
32% of the samples (226 out of 699) at p£0.005; 37% (259 out of 699) at p£0.05; and 
41% (290 out of 699) at p£0.1. At the time of CIBERSORT exploration only 699 tumour 
data were available. The p-value threshold of 0.005 is the software recommended 
default [138] but I noted that relaxing this threshold did not increase substantially the 
number of deconvolved samples, therefore I remained at the recommend threshold.  
To understand why CIBERSORT produced those results, I assessed the immunological 




deconvolved. All the LMC samples have been previously classified in 6 consensus 
immunome clusters (CICs) based on the Bindea et al.’s Immunome [108][76]. The 6 
CICs were in strong agreement with TILs reported by the pathologist: the high and 
intermediate immune clusters (CIC 2, CIC 3 and CIC 5) had highest number of tumours 
with evidence of brisk TILs while the low immune cluster (CIC 4, CIC 1 and CIC 6) 
contained the highest number of tumours with “absent” TILs [76]. Upon applying 
CIBERSORT, the vast majority of successfully deconvolved tumours were in the high 
immune cluster (CIC 2) and to some extent in the intermediate immune clusters (CIC 3 
and CIC 5) (Table 3.1). The majority of poorly deconvolved samples were in the low 
immune clusters (CIC 4, CIC 1 and CIC 6). The contrast was striking between high 
immune CIC2 (136/145 well deconvolved) and all low immune CICs (only 5/70 
deconvolved in CIC1, 3/171 in CIC 4, 5/100 in CIC6) (Table 3.1). 
 
Table 3.1: Matching patients with CIBERSORT deconvolution status at p£0.005 to the 
six “Consensus Immunome Clusters” without scale transformation 
 
Consensus Immunome clusters [76] 
CIC 1 CIC 2 CIC 3 CIC 4 CIC 5 CIC 6 
Number of deconvolved 
samples at P<0.005 
5 136 42 3 28 5 
Number of non-
deconvolved samples 
65 9 41 168 77 95 
 
These results suggested that CIBERSORT can accurately estimate the proportions of 
immune cell subpopulations when there is a relatively high level of infiltration in the 
tumour and is unreliable where there are only a few or no immune cells present in the 
tumour.  
The result from the first scale transformation (equation 4) produced a slight 
improvement in the total number of deconvolved samples increasing the number only 
modestly, by 38 samples at deconvolution threshold p£0.005 and 48 samples at 
deconvolution threshold p£0.05. The second data transformation (standard normal) 
resulted in 30 more samples deconvolved at p£0.005, 149 additional samples were 




3.3.2 Application of Angelova et al.’s Immunome  
Before applying this method, I applied QC filters to select the genes most 
representative of cell subtypes (Figure 3.1). The first gene filter removed 354 genes 
(genes highly expressed in melanoma cell lines), leaving 458 genes in the list of genes 
present on the Illumina HT12.4 DASL array used in this study, representing 30 distinct 
immune cell types (Subset 1, Figure 3.1). The second filter (removal of cell types where 
the first filtration eliminated >90% of the genes) resulted in the elimination of effector 
memory CD4+ T cell, activated CD8+ T cell and activated CD4+ T cell scores (Subset 2, 
Figure 3.1, Appendix A.1.1). The plasmacytoid dendritic cell score (pDCs) however was 
retained despite having only 1 specific gene (IL3RA), because this gene was also unique 
in representing the pDCs in the previous version of the Immunome compendium [108] 
and is well-known to be highly expressed in pDCs [139][140]. The gene reciprocal 
correlations per immune cell were not always positive in the LMC (Figure 3.2, Appendix 
A.1.2) and eventually the gene filtration based on negatively correlating genes in LMC 
resulted in a final number of 376 genes representing 27 immune cell subsets (Subset 






Figure 3.1: QC pipeline for devising the list of genes indicative of specific immune cells 
infiltrating melanoma 
 
In the TCGA dataset, the reciprocal correlation matrices demonstrated fewer negative 
correlations for the majority of the immune cells (Figure 3.2, Appendix A.1.2). To 
further compare correlation matrices in LMC and TCGA datasets using Angelova et al. 
[1]  and Bindea et al.’s [108] Immunome lists, I chose a few cells that are often 
described in literature by a single strong marker, such as FOXP3 for Tregs [141] and 
GATA3 for Th2 [142] but assigned several “specific” genes in the Angelova et al.’s 
Immunome. Figure 3.2 illustrates the correlation between tumour expressions of Treg 
genes by the Angelova et al.’s Immunome in LMC and TCGA. Bindea et al.’s Immunome 
used only FOXP3 to represent Tregs. Figure 3 represents the correlation of the genes 





As it can be seen from Figure 3.2, FOXP3, a widely accepted marker of Tregs, negatively 
correlated with majority of other Treg genes in the LMC, but not in TCGA. This might 
be an example of the failure of the probe detecting this gene on DASL array. Therefore, 
prior to the calculation of the Treg score I removed FOXP3, and other genes showing a 
negative correlation the majority (MADCAM1, and RYR1). In general, there was a 
reasonable number of positively correlating genes in the LMC, and in most cases these 
correlations were much stronger in TCGA.  
 
Figure 3.2: An example of correlation matrices of genes for regulatory T cells in the 
LMC and TCGA datasets  
 
For the Th2 comparison, similar observations were made regarding the quality of the 
data (Figure 3.3). Overall, the correlations were stronger in the TCGA dataset, for both 
Angelova et al. and Bindea et al.’s Immunomes. When comparing the genes for scores 
generated based on Angelova et al. versus Bindea et al.’s Immunome in LMC and TCGA, 
it could be observed that GATA3 the marker for the Th2 cell type was negatively 
correlated with majority of the genes in the Bindea et al.’s Immunome both in LMC and 
TCGA, however it was not the case in the Angelova et al.’s Immunome. I removed the 
following genes by the correlation filtration from the Th2 gene specific list: RMBS3, 





































































































































































































































































































































































































































































































































































































Figure 3.3: An example of correlation matrices of genes for Th2 cells in the LMC and 
TCGA imputed by Angelova et al. and Bindea et al.’s Immunomes  
 
After these QC steps, I generated a single score for each immune cell subtype by 
combining tumour expression values for the remaining genes (see Methods). Then I 
tested the association between each immune cell score with melanoma specific 
survival (MSS) (univariable analysis) and the results revealed that in the great majority 
the immune cell scores (17 out of 27 in the LMC) were associated with improved 
survival after Bonferroni correction for multiple testing (P<0.002) and these 


























































































































































































































































































































































































































































































































































































Table 3.2: Melanoma Specific Survival (MSS) for each cell type in the LMC and overall 
survival (OS) in TCGA, using univariable Cox proportional hazard model 
Significant associations in the LMC after multiple-testing correction by Bonferroni 
method are shown in bold. 
 LMC (primaries) TCGA (metastases) 
Cell type HR P 95% CI low 
95% CI 





Activated B cells 0.60 1.18x10-5 0.48 0.75 0.63 2.79x10-6 0.52 0.76 
Central memory CD4 0.54 7.31x10-6 0.41 0.71 0.52 5.46x10-5 0.84 1.27 
Central memory CD8 0.72 9.58x10-3 0.56 0.92 0.55 4.33x10-7 0.89 1.44 
Cytotoxic cells 0.72 3.35x10-4 0.60 0.86 0.65 1.91x10-6 0.38 0.72 
DC 0.51 4.27x10-6 0.39 0.68 0.53 1.81x10-6 0.44 0.70 
Effector memory 
CD8 
0.63 2.97x10-4 0.49 0.81 0.54 1.49x10
-8 0.54 0.78 
Eosinophil 1.39 2.13x10-2 1.05 1.84 0.72 5.97x10-2 0.41 0.69 
iDC 0.88 2.87x10-1 0.68 1.12 0.56 1.85x10-6 0.26 0.76 
Immature B cells 0.66 7.16x10-4 0.51 0.84 0.61 1.12x10-5 0.79 1.09 
Macrophages 0.71 1.20x10-2 0.54 0.93 0.68 2.24x10-3 0.51 1.01 
Mast cells 0.51 3.90x10-5 0.37 0.70 0.56 3.50x10-3 0.49 0.76 
MDSC 0.64 9.27x10-5 0.51 0.80 0.62 1.58x10-5 0.44 0.67 
Memory B cells 1.03 8.11x10-1 0.81 1.31 0.65 2.06x10-3 0.50 0.77 
Monocytes 0.94 5.74x10-1 0.75 1.17 0.65 7.30x10-5 0.54 0.87 
Neutrophils 0.68 4.18x10-3 0.52 0.88 0.49 4.83x10-7 0.44 0.69 
NK 0.68 2.39x10-4 0.55 0.83 0.64 4.16x10-5 0.38 0.83 
NK56 bright 0.71 8.60x10-4 0.58 0.87 0.55 4.08x10-7 0.49 0.85 
NK56 dim 0.78 3.39x10-2 0.62 0.98 1.66 1.14x10-3 0.53 0.81 
NKT 0.67 2.43x10-4 0.54 0.83 0.48 3.04x10-6 0.52 0.80 
pDC 0.91 2.09x10-1 0.79 1.05 0.77 1.13x10-3 0.45 0.69 
T cells 0.55 4.58x10-6 0.42 0.71 0.55 2.36x10-7 1.22 2.26 
TFH 0.69 4.00x10-4 0.56 0.85 0.65 3.78x10-6 0.35 0.65 
TGD 0.68 1.19x10-3 0.54 0.86 0.64 3.66x10-6 0.38 0.65 
Th1 0.57 4.55x10-6 0.45 0.73 0.58 1.35x10-7 0.44 0.69 
Th17 0.82 2.45x10-1 0.58 1.15 0.44 2.87x10-3 0.54 0.78 
Th2 0.51 6.17x10-8 0.40 0.65 0.56 6.08x10-8 0.53 0.78 





3.3.3 Consensus clustering of LMC tumours based on the immune cell scores 
 Final number of clusters 
Consensus cluster analysis of the 703 LMC tumours was conducted using the 27 
immune cell scores. Examination of consensus heatmaps, CDF and delta CDF area plot 
(Figure 3.4) allowed me to decide the optimal number of clusters. The change in delta 
CDF area (Figure 3.4E) suggested 4 or 5 clusters because after that the curve flatlined. 
Further, using the patterns of the consensus heatmaps, the consensus CDF plot, and 
the average cluster consensus plot, 3 clusters appeared as the most stable (Figure 3.4).  
Having each sample assigned to one of the three clusters, for visualisation purposes, 
one-off hierarchical cluster analysis of cell scores (but not the samples) was conducted 
and a heatmap was plotted. The three clusters showed distinct immune phenotypes 
across the vast majority of cells: one cluster of tumours (N=156) showed evidence of 
coordinated infiltration of 22 of the 27 immune cells while, at other end, another 
cluster (N=272) showed the weakest signals for these 22 cells. Between these 2 
extremes there was a cluster of tumours (N=275) displaying the 22 immune cells at 
intermediate level (Figure 3.5). The 3 clusters were called respectively High, Low and 





Figure 3.4: Representation of Consensus Clustering Results 
(A) Sample dendrogram and heatmap with the number of clusters; The heatmaps 
are symmetrical and indicate the stability (“Cleanliness” of the heatmaps), the 
blue colour indicates high consensus (i.e. samples occurring in the same cluster 
with high incidence in the 5000 repetitions) whereas white indicates no 
consensus (samples are always classified in different clusters). (A) k=2; (B) k=3; 
(C) k=4. (D) Cumulative density functions (CDF) of independent runs with k=2 to 
12 in 5000 data resampling. The most stable number of clusters is the one with 
the highest number of “0” and “1” on the x axis. The red and orange curves 
showed these features. (E) Relative change in area under the CDF with increasing 
k. (F) Average cluster consensus plot for k=2 to 12 clusters. 
















Figure 3.5: Heatmap representing immune cell scores across the three identified 
immune subgroups 
The tumour samples (columns) were fixed according to the consensus clustering 
output while the immune scores were hierarchically clustered (rows). 
 
 MSS for the obtained clusters 
The three immune subgroups were associated with MSS: a significantly lower hazard 
of melanoma death was observed for patients assigned to the High compared to Low 
(Hazard Ratio (HR)=0.5, P=0.001, 95% CI 0.3-0.7); and Intermediate Immune Subgroups 







Figure 3.6: Kaplan Meier plot (MSS) for the three immune subgroups 
The p-value was obtained from the overall Cox proportional hazard regression. 
 
 Comparison of the three immune subgroups with existing molecular 
melanoma signatures 
As already mentioned, our group published previously 6 Consensus Immunome 
Clusters (CICs) in this melanoma cohort [76]. The 3 three Immune Subgroups derived 
here showed a very significant overlap with those 6 CICs (Figure 3.7), with a Cramer’s 
V of 0.72, P=6.61x10-151. The High Immune Subgroup was comprised predominantly of 
three Consensus Immunome Clusters: CIC 2 (High Immune) – 73.1%, CIC 3 
(Intermediate Immune/Keratin Poor) – 16.7% and CIC 5 (Intermediate Immune/Keratin 
High) – 9.6%. The Low Immune Subgroup was predominantly comprised of: CIC 4 (Low 
Immune/Beta-catenin High) – 58.1%, CIC 6 (Low Immune/Keratin Rich) – 31.3% and CIC 
1 (Low Immune/Beta-catenin Low) – 9.2%. These results were therefore consistent. 
However, the Intermediate Immune Subgroup was composed of tumours from all 6 
CICs with a less clear pattern although the most represented groups were CIC 5 and CIC 
3 both of which were already described as having intermediate levels of immune 





















Figure 3.7: Intersection of the three Immune Subgroups and previously published 
Consensus Immunome Clusters by Nsengimana et al. in LMC [76] 
 
 
Figure 3.8: Kaplan Meier plot for the 6CIC generated by Nsengimana et al. in LMC [76] 
When the 6 CICs were adjusted AJCC stage, both CIC 4 and 6 had equally poor 
survival. For legend, see Figure 3.7. 
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The 3 immune subgroups were also compared to another set of 3 melanoma molecular 
subtypes published by the TCGA called “immune”, “keratin-rich” and “MITF low” 
classes.  
Here too, a good overall concordance was found with Cramer’s V=0.47, P=2.5x10-54, 
albeit weaker than the concordance with the 6 CICs. Specifically, the High Immune 
Subgroup was comprised predominantly of TCGA “immune” class (85.7%), the 
Intermediate Immune Subgroup contained 33.7% of “immune”, 46% of “keratin” and 
20.4% of “MITF low” tumours while Low Immune Subgroup was mainly a mixture of 
“keratin” (53.8%) and “MITF low” (41.1%). In terms of association with melanoma-
specific survival in the LMC dataset, there is a significant difference between “MITF 
low” and “immune” subgroups (HR=1.97, P=0.001, 95% CI 1.3-2.9), while the “keratin” 
and “immune” groups have similar survival profiles (HR=0.98, P=1.97, 95% CI 0.7-1.44). 
(Table 3.3, Figure 3.10, Figure 3.10). Additionally, I tested whether the “keratin” group 
in the LMC could manifest higher expression of keratinocyte specific genes, due to 
sampling of keratinocytes (cells from the outermost layer of the skin) along with 
tumour cells from the thin tumours. I tested the expression of a gene called filaggrin 
(FLG), that is known to be expressed in keratinocytes [143] across the TCGA classes in 
the LMC samples. The results showed that the FLG expression was significantly higher 
in the “keratin” group (P=3.3x10-65), (Figure 3.11). I have also tested the Breslow 
thickness among these group, and it showed to be the lowest in the “keratin” group 





Figure 3.9: Intersection of the three Immune Subgroups and the TCGA subtypes 
applied to the LMC (N=560) 
 
Table 3.3: Survival analysis of the TCGA classes applied to LMC (N=560) 
 HR P 95% Conf. Interval 
Immune - - - - 
Keratin 0.98 0.9 0.66 1.44 
MTF low 1.97 0.001 1.34 2.90 













Figure 3.10: Kaplan Meier plot for the TCGA classes applied to LMC (N=560) 
 





































Figure 3.12: Breslow thickness across the TCGA classes in LMC 
 
3.3.4 Validation of the 3 Immune Subgroups in TCGA melanoma metastases 
After classifying TCGA metastatic tumours in the 3 Immune Subgroups using the 
nearest centroid method, a heatmap was drawn in a similar way as in the LMC (Figure 
3.13). Similar overall patterns of immune cell scores were found (Figure 3.13) and the 
association with survival analysis showed a strong agreement with earlier results from 
the LMC: High Immune exhibited a reduced death hazard with compared to Low 
Immune Subgroup (HR=0.3, P=1.0x10-7, 95% CI 0.2-0.5) or to the Intermediate Immune 





















Figure 3.13: Heatmap of immune cell scores across the replicated three Immune 
Subgroups in TCGA 
 
 
Figure 3.14: Kaplan Meier plot for OS differences between the three replicated 






















3.3.5 Clinico-histopathological analysis of the Immune Subgroups 
In the LMC data, Breslow thickness, mitotic rate and the proportion of tumours without 
TILs (from both clinical dermatopathologists and a single observer in our research 
group) were significantly lower in the High Immune Subgroup compared to other 
groups (Table 3.4). As expected, the most significant difference was in TILs, with 
tumours classified in High Immune group more frequently displaying brisk TILs (P=4x10-
8). The Low Immune Subgroup had the lowest proportion of tumours with a BRAF 
mutation and the highest proportion with NRAS mutation, although these results were 
borderline significant. Site of melanoma was significantly different among Immune 
Subgroups, tumours arising on the rare sites (non-sun exposed) being more frequent 
in the Low Immune Subgroup. AJCC stage, sex, age at diagnosis, site, smoking and 
serum vitamin D at diagnosis (season-adjusted) were not significantly different 
between the three Immune Subgroups (Table 3.4). 
Table 3.4: Associations of clinico-histopathological characteristics with the three 
immune subgroups in the LMC 




Immune P-value (N) 
Number of participants (703) 272 275 156   
Melanoma death (%) 36.0 28.7 18.8 0.001 (666) 
Age at diagnosis (median, 
years) 
58.3 55.7 59.9 0.6 (703) 
Site of melanoma    0.02 (702) 
       Limbs (%) 38.6 45.6 44.2  
       Head (%) 11.0 10.9 12.8  
       Trunk (%) 31.6 33.9 34.6  
       Rare (i.e. sun protected) (%) 18.8 9.5 8.3  
Sex (% males) 43.0 44.7 50.0 0.4 (703) 
BRAF-mutated (%)  40.5 50.4 51.2 0.06 (582) 
NRAS-mutated (%)  29.8 24.4 16.8 0.03 (574) 
Ulcerated (%) 36.0 33.5 28.9 0.32 (703) 
Breslow thickness (median, 
mm) 
2.4 2.3 2.0 0.004 (692) 
Mitotic rate (median, 
count/mm2) 








Immune P-value (N) 
AJCC stage (%) 
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TILs (%) (clinic 
dermatopathologists) 
     Brisk 
     Non-brisk 
     Unclassified 


















TILs (%) – (single observer, S 
O’S) 
     Brisk 
     Non-brisk 















Smoking (% ever smoked) 47.2 51.6 48.7 0.6 (658) 
Season-adjusted serum vitamin 
D at recruitment (winter 
median, nmol/L ) 
40.1 41.2 36.1 0.2 (549) 
Mutational load 
     Low 
     Intermediate 
















• Immune cell scores were characterised based on Angelova et al.’s Immunome. 
• The tumour samples were clustered based on immune cell scores and three 
immune subgroups were obtained having distinct survival.  
• The three immune subgroups were replicated in the independent metastatic 
melanoma dataset (TCGA). 
• The three subgroups defined by inferring immune cell infiltration had 
correspondingly different histologically detected TILs, the Low Immune tumours 
having fewer TILs. 
• The reported environmental factors of interest e.g. smoking and vitamin D levels, 





3.5.1 Immune cell scores 
In general, meaningful characterisation of immune cells infiltrating tumours from 
potentially noisy and heterogeneous FFPE tumour gene expression data is challenging. 
The aim is important however, as understanding host-tumour interaction might inform 
lifestyle advice for newly diagnosed melanoma patients and understanding of primary 
and acquired resistance to checkpoint therapies. The concept is that bioinformatic 
analysis of transcriptomic data will allow deconvolution of complicated relationships 
between tumour and stromal cells in situ i.e. without the need to disaggregate tissues. 
Moreover, that this would be possible for large numbers of tumours ascertained from 
populations and therefore more typical of the generality of tumours rather than 
selected large tumours big enough to sample and disaggregate. 
As mentioned in the introduction, there are several methods for inferring immune cell 
score, available. In my thesis I have explored CIBERSORT and developed a method 
based on Angelova et al.’s Immunome. I did not test all of the approaches either 
because they were reported to cover a relatively small spectrum of cell subtypes [109] 
or because they required RNA sequencing data (as indicated in the R package code the 
provided by the authors) [110], or they were published relatively late during my PhD 
(November 2017) [112]. 
Generally, these methods do not allow distinction to be made between strong signals 
related to a large number of cells or fewer cells but with higher gene expression per 
cell. Moreover, the gene-cell specificity may be context-dependent, i.e. genes could be 
expressed by more than one cell type (immune or non-immune) depending on the 
tissue or local microenvironment. 
Nonetheless, I have explored some of them in my thesis. I first evaluated the utility of 
an existing cell scoring method (CIBERSORT), which uses as reference gene signatures 
of flow cytometry sorted circulating immune cells (LM22). This method has some 
valuable features that other methods do not have. One of them is that it is available as 
a software easily accessible, it is user friendly, and no bioinformatic knowledge is 
needed in order to run the algorithm. Another one is that it provides the empirical p-




deconvolution for each sample. Moreover, the LM22 signature is comprehensive and 
contains some immune cell subsets with subtle differences which might have a 
relevance to melanoma. For example M0, M1, and M2 macrophages are held to be 
distinct in this signature and macrophage polarity has been shown to play a role in 
cancer prognosis [144].  
However, when applied to the LMC dataset, CIBERSORT showed to have some 
limitations. In fact, the algorithm inferred successfully immune cell proportions in a 
minority of tumours. 
Varying the p-value threshold did not make a significant difference. Similar results were 
also found after applying different data transformation strategies. However, and 
interestingly, the tumour samples where CIBERSORT failed to estimate immune cell 
proportions were more likely to be recorded as having no TILs and were classified and 
Consensus Immunome Clusters 1, 6 and 4 which all have been associated with lack of 
immune infiltration [76]. It can be concluded therefore that failure of CIBERSORT to 
find immune cell proportions with a significant p-value is not an artefact but a true 
reflection of very low levels of immune infiltration. I nevertheless consider this as a 
limitation of the method because it is unclear how to use the cell proportions estimated 
with low level of confidence (P>threshold). In its set up, the total of all 22 immune cell 
proportions is 100%, meaning that if there are no immune cell at all in the tumour, 
proportions of all 22 are still estimated but there is no indication on what they actually 
represent. The use of a relative rather than absolute quantitation may be more 
appropriate to compare the extent of different immune cells within a tumour rather 
than comparing tumours.  
Since CIBERSORT was unconvincing, I adopted and modified another method of 
immune cell scoring. The Immunome proposed by Angelova et al. [1] was explored in-
depth in this chapter and the scoring approach I developed using this list was the basis 
for further analyses in my thesis (next chapters). Advantages of the Angelova et al.’s 
Immunome are that it covers a large number of immune cells (31), and can be adapted 
to a specific cancer under study by performing additional (quality control) QC. It allows 
user-defined immune cell scoring on an absolute rather than a relative scale. However, 
this approach has an additional caveat apart from the ones mentioned above. Using 




Angelova et al. were expressed at significant levels by melanoma cells or melanocytes. 
It is this observation that prompted the decision to conduct some QC steps (gene 
filtration) before developing the immune scoring method. After this filtering, further 
explorations showed that some of the genes deemed to be specific to certain purified 
immune cell subtypes according to Angelova et al. [1] actually displayed a negative 
correlation with each other in the tumours, implying either the presence of technical 
issues or that these genes might be less useful markers of those cell subsets in 
melanoma than they would be in the peripheral the blood.  In favour of the potential 
bias from technical variation we observed that gene expression correlations within 
immune cell type were less likely to be negative in TCGA melanoma samples, which 
were produced from fresh frozen tissue, therefore with less degraded mRNA compared 
to the LMC. One example was the Treg score. When analysing the gene correlations for 
Treg score, the well-known marker for this cell type – FOXP3 was negatively correlated 
with majority of genes assigned to this cell type in LMC, but not in TCGA. Consequently, 
I concluded that the there is a possibility that in the LMC transcriptome the probe 
designed for this gene was not efficient enough, as it also could be the case for other 
probes.  
It is important to indicate, that when it comes to Bindea et al.’s Immunome the Treg 
score (only the FOXP3 gene, for which the probe in LMC possibly could not be efficient) 
could not be confidently used.  
When I compared the Th2 score using the list of genes proposed by Bindea et al. and 
Angelova et al.’s Immunomes I showed that GATA3 (well recognised marker for Th2 
cells) was negatively correlated with the rest of the proposed genes, but it was not 
observed using Angelova et al.’s Immunome both in LMC and TCGA. 
The examination of correlation of genes assigned to Treg and Th2 scores in TCGA and 
LMC reassured me that the Angelova et al.’s Immunome is more reliable than Bindea 
et al.’s Immunome at least for characterising these two particular cell types. Because 
of this reason and the fact that the Angelova et al.’s Immunome was devised from more 
microarray data than Bindea et al.’s. I used this list, after using the devised filters for 
scoring immune cells in the LMC. Subsequently I proceeded with using these immune 




3.5.2 Clustering  
Consensus clustering is widely used method to find stable sample subgroups in high-
dimensional data. I have chosen this approach over one-off clustering because it 
generates helpful metrics to indicate the optimal number of clusters which is 
unavailable in standard clustering [134]. This approach allowed me to identify 3 stable 
immune subgroups, which were well-replicated in TCGA metastases, both in terms of 
overall cell score patterns and in their associations with survival. The concordant 
results were reassuring that the cell scoring method was reproducible in independent 
datasets.  
Replication of the 3 immune subgroups in TCGA metastatic samples suggested that the 
immune infiltration and exclusion mechanism spans the whole range of disease 
progression, i.e. both primary and metastatic tumours may have different levels of 
immune response.  
Additionally, the identified immune subgroups were consistent with the earlier 
reported 6 CICs [76]. Besides using different Immunomes (Bindea et al. vs. Angelova et 
al.), the other differences between the earlier report [76] and the current analysis are 
a more in-depth QC filtering and tumour clustering using cell scores rather than the 
expression of individuals genes. I hypothesized that dimensionality reduction by using 
the immune cell scores in tumour clustering could be more informative and less 
affected by noise. The 3 identified immune subgroups had distinctive survival profiles. 
In comparison with 6 CIC and TCGA (“immune”, “keratin” and “MITF low”) signatures, 
which did not show as distinct survival patterns for each group, the newly identified 
immune subgroups showed to have advantage over these signatures. Interestingly in 
the TCGA (not in the LMC) the “keratin” signature which predicted the poorest 
prognosis was comprised of approximately 74% primary melanomas [46]. In the LMC I 
showed that “keratin” group was comprised of samples that were thinner and 
contaminated by keratinocytes (high FLG expression) comparing to other groups. 
Patients with thin tumours are known to have favourable survival, and this could 
explain why “keratin” group (the thinnest tumours) had comparable survival to the 
“immune” group in the LMC. Taken together, this observation supports our concern 
that in TCGA primary melanomas (mostly categorised as “keratin”) have the poorest 




The immune cell scores were highly correlated and had similar patterns of distribution 
across the immune subgroups. I have moreover observed that immune cell scores, for 
which the reciprocal gene correlations per score were weak (e.g. Eosinophil, pDC, 
Memory B cells, NK dim), were less distinct among clusters (or contributed less to 
clustering) than those having high correlations, and all of them did not significantly 
predict prognosis. This observations, questioned the reliability of these particular 
immune cell scores for further analyses.  
The high correlation of the majority of immune scores with each other suggests that 
multiple immune surveillance mechanisms (together with immune checkpoint 
pathways) are co-ordinately activated to combat cancerous melanocytic lesion, as it 
has been reported previously [77][76]. However, there is also a concern that applying 
computational methods to gene expressions for cell sorting may not have enough 
power to detect subtle differences in the abundance or the functions of these cells. 
There might be epigenetic or post-translational changes that regulate the immune cell 
function that are not detectable in transcriptomes. Nevertheless, the High Immune 
Subgroup had the highest expression of almost all the immune cells and the best 
melanoma specific survival among the three immune subgroups consistently with 
current literature.  
3.5.3 Clinico-histopathological associations with obtained clusters 
Upon testing the clinico-histopathological associations among the three immune 
subgroups, AJCC stage, age at diagnosis, sex, ulceration, vitamin D or reported smoking 
did not vary across the immune clusters, meaning that these variables were 
independent of the strength of the immune response in this analysis. The three 
immune subgroups showed good overlap with TILs measurements, which gave support 
to the view that using inferred immune cell scores do represent the presence of more 
immune cells. Moreover, overall I observed clear association of the high immune 
responses negatively correlated with tumour thickness and mitotic rates. Tumour site 
was associated with immune subgroup status and this was driven by the finding that 
the majority of samples from “rare sites” (those arising on ‘sun-protected’ sites) were 
classified as low immune. It is well-documented that exposure to ultraviolet light 




melanomas in sun-protected body sites have fewer genomic mutations, and therefore 
fewer neoantigens, potentially reducing the attraction of TILs [19]. This is a credible 
explanation for the observed worse survival and higher stage at diagnosis of patients 
with these rare melanomas, as well as the probability of late diagnosis [16]. However, 
the mutational load, which we assumed that could reflect the neoantigen load, was 
not shown to be significantly different across the three immune subgroups. This 
observation was surprising, because it has already been shown that total 
mutational/neoantigen load correlated with better responses to immunotherapies for 
metastatic melanoma patients [145][146][147] and higher immune cell scores for the 
TCGA melanoma data [148]. However, Spranger et al. in the study analysing TCGA 
tumour data showed no association of mutational density with level of T cell infiltration 
in melanoma and other cancers [149]. Moreover, it is important to stress that the 
mutational load data used in these analyses was selected, meaning that the mutation 
count was based only for a panel of 555 genes (see Chapter 2), which might not 
necessarily represent the whole genome/total mutational load. Moreover, the 
mutation data were generated from thicker tumours and only for 319 samples, 
potentially introducing bias and statistical power issues. Lastly, some studies suggested 
that it is a neoantigen quality not quantity that predicts response to immune therapies 
in melanoma and other cancers [150][151] and it was shown that only ~10 of somatic 
mutations, which results in amino acid changes were predicted to bind to MHC class I 
[152]. 
NRAS-mutated tumours were more often classified into the Low Immune Subgroup and 
BRAF-mutated into Intermediate or High Immune Subgroup, although at a borderline 
significance level. This evidence could suggest that rather BRAF mutated tumour might 
be more immunogenic than NRAS mutated tumours and the literature supports this 
observation. BRAF mutated melanomas have been reported to be immunogenic 
[153][154][155] and it was reported by Nsengimana et al. (the researcher in our group),  
that survival benefit from immune cell infiltration was observed in BRAF or wild-type 
tumours while it was absent in NRAS mutated tumours in LMC [76]. Moreover, another 
study analysing 912 higher-risk primary melanomas, demonstrated that NRAS mutated 
tumours had significantly lower TILs than BRAF and WT tumours [156]. This results 




presentation complex (MHC class I) on the surface of lymphoma tumour cells [157].  
On a contrary another study showed that patients with NRAS mutated melanoma 
tended to have more favourable survival after treatment from anti PD-L1/PD1 therapy 
[158], but this study was conducted on relatively small samples size (229) and only 
metastatic melanomas. 
In summary, the above results reassured me that the tumour subgroups obtained from 
consensus clustering correspond to biologically distinct entities with potentially 
specific immune surveillance, edition and evasion mechanisms. In the next chapters 
these three immune subgroups were explored as the basis of identifying modulators 





Identification of genes and pathways associated with immune 
response to melanoma 
4.1 Aims of the chapter 
• To identify pathways that are associated with immune response to melanoma 
using the genome wide differential expression across the three immune 
subgroups uncovered in Chapter 3. 
• To identify the most nodal genes in those pathways using network analysis.  
• To validate the role of nodal genes as mediating immunosuppression in 
melanoma cell lines. 
4.2 Methods 
4.2.1 Overrepresentation analysis (ORA) 
Overrepresentation analysis is a widely utilised method of studying gene expression 
data in order to identify groups of genes expressed more highly in the analysed groups 
of subjects (i.e. with different phenotypes) [159]. This process is generally divided into 
two stages: first, testing differentially expressed genes between the two phenotypes 
using standard statistical methods; and second, biological interpretation of the 
identified genes by for example pathway enrichment analyses. The ORA can be only 
implemented if the sample size is large enough to find significantly differentially 
expressed genes between the analysed groups [159]. Since the LMC is a large data set, 
I reasoned that this method would be appropriate. 
 Testing differentially expressed genes among the three immune subgroups 
In order to identify biological pathways associated with the immune responses to 
melanoma I carried out an agnostic analysis, which tested the whole transcriptome 




I tested differential expression of 29,424 probes among the three immune subgroups 
in LMC using the Kruskal Wallis test in STATA. The significance threshold was set at 
Bonferroni-adjusted a=0.05 for multiple testing (i.e. 2x10-6). Subsequently I matched 
the probes to the gene names and I removed the 376 genes which had been used to 
create the immune cell scores. 
To visualise the expression of significantly differentially expressed genes among the 
three immune subgroups I generated a heatmap using the “pheatmap” package in R, 
with hierarchical clustering of the genes (using the Pearson correlation coefficient as 
distance metric). For differential expression analysis, I only tested the differences 
between the two extreme immune subgroups – Low vs High using the Mann-Whitney 
U test. 
 Biological interpretation of the differentially expressed genes 
I analysed separately the genes that were significantly upregulated in the Low and in 
the High Immune Subgroup (p-value threshold 2x10-6) in Reactome FiViz 5.2.0.beta 
[160] and Centiscape v.2.1 [161] plugins of Cytoscape v.3.5 [162]. Reactome FIViz 
enables analysis of pathways and protein-protein interaction (PPI) networks using just 
a list of gene names as an input or gene expression data (mainly used for correlation 
calculation among the genes). In my analyses I used the gene names that were 
upregulated either in the Low or in the High Immune Subgroup.  
Reactome FiViz has an inbuilt protein functional interaction (FI) network, which was 
predicted by machine learning approach (naïve Bayes classifier) using protein-protein 
interaction (PPI) databases such as: 
• human physical PPIs catalogued in IntAct [163], HPRD[164], and BioGrid [165]  
• human PPIs projected from fly, worm and yeast in IntAct [163] based on Ensembl 
Compara [166]  
• human gene co-expression derived from DNA microarray studies (two data sets 
[167][168])  
• shared GO (Gene Ontology) biological process annotations [169]  




• PPIs extracted from the biomedical literature by the text-mining engine 
GeneWays [171].  
The naïve Bayes classifier was trained based on the pairwise protein relationships by 
utilising curated pathways from Reactome [172] (training dataset). Subsequently, in 
order to predict functional interactions of the pairs of proteins, the trained naïve Bayes 
classifier was applied. Next, the predicted FIs were merged with the ones from curated 
pathways databases: 
• R – Reactome 
• C – CellMap 
• K – KEGG 
• N – NCI PID 
• P – Panther 
• B – BioCarta, 
where the curation in this instance means that the pathway databases were created 
by researchers who carefully verified the evidence from each source of interaction.  
The pathway enrichment analysis was based on the hypergeometric test, which tests 
if the submitted list of genes or proteins contains more genes/proteins for a given 
pathway than would be expected by chance. The significance of that test is indicated 
by a p-value and its version adjusted for multiple testing by Benjamini-Hochberg 
method [173], i.e. the False Discovery Rate (FDR) for each pathway from the curated 
databases mentioned above. 
The software generates a table with enriched pathways within a given gene set, where: 
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of 
numbers of genes contained in pathways to the total number of genes in the Reactome 
FI network; “Number of protein in GeneSet” is the number of proteins within a given 
pathway; and “Protein from network” indicates number of genes from the input gene 
list per pathway. 
To run this analysis, I firstly uploaded the gene names upregulated in the High and Low 
Immune Subgroups into RectomeFIViz and the PPI network was constructed. Next, I 
tested the pathway enrichment separately for each list, setting the FDR threshold for 




After having the PPI networks constructed based on the genes of interest from each of 
the 2 immune subgroups I looked for the most important/influential genes within the 
networks. In order to identify these genes in the networks, the “betweenness” metric 
(indicating a key role in communication between proteins) was used as a centrality 
measure in Centiscape [161]. In technical terms betweenness is the number of shortest 
paths going through a node (gene) when connecting each pair of nodes in the network. 
In biological terms the nodes with the highest betweenness centrality are likely to be 
crucial in holding together/controlling the proteins within the network [161]. I 
performed the visual adjustments (size, colour of the nodes as well as edges shapes) of 
the networks in another software package called Gephi v.0.9.1 [174]. 
4.2.2 Patient derived melanoma cell lines analysis 
After identifying key immunosuppressive gene in the Low Immune Subgroup network, 
it was necessary to verify its functional role in an independent dataset. In our data, a 
gene could be expressed by tumour cells, immune cells, both or even by other 
components of tumour microenvironment. In order to explore the gene expression 
associations with the nodal gene we therefore collaborated with Mitch Levesque’s 
group in Zürich to examine the associations with the nodal gene in patient derived 
tumour cell lines, which lack immune cells. The methodology described (Chapter 2) for 
the generation of the cell lines is reported to significantly reduce fibroblast cell 
numbers. 
The statistical analysis of the RNAseq gene expression data originating from the 103 
melanoma cell lines (described in Chapter 2) was carried out by Sabrina Hogan (Marie 
Skłodowska-Curie PhD student at the University of Zurich, Switzerland). The Spearman 
rank correlation test was used to test correlations of the nodal gene (from the network 
created based on genes upregulated in the Low Immune Subgroup) with the whole 
transcriptome in the primary melanoma cell lines. Subsequently, I analysed the 
topmost 50 positively and negatively correlating genes with the nodal gene in 






 Overrepresentation analysis (ORA) 
There were 5324 genes differentially expressed across the genome among the three 
immune subgroups, they are shown Figure 4.1. The heatmap shows a clear clustering 
of High and Low Immune Subgroups while, the Intermediate Immune Subgroup was 
essentially a mixture of these extreme subgroups (Figure 4.1). Excluding this middle 
group, the number of genes differential expressed between the two extreme groups is 
5607, with 3324 upregulated in the High and 2283 upregulated in the Low Immune 
Subgroup.  
4.3.1.1 Low Immune Subgroup 
The pathways significantly enriched in the genes upregulated in the Low Immune 
Subgroup predominantly represented proliferation and metabolic functions. The most 
enriched pathways were the tricarboxylic acid (TCA) cycle and respiratory electron 
transport (FDR=5.3x10-14), mitochondrial translation (FDR=5.3x10-14), ribosomal and 
rRNA processing, and mitosis pathways (Table 4.1, and Appendix A.2.1). The analysis 
of the PPI network of the genes enriched in the Low Immune Subgroup revealed that 
proto-oncogene MYC had the highest betweenness centrality, suggesting that it was 
the most pivotal protein in this network (betweenness=31141) (Figure 4.2). The next 
two genes with relatively high betweenness were: Polo like kinase 1 (PLK1) – 
betweenness=18634, and Protein Phosphatase 2 Scaffold Subunit Alpha (PPP2R1A) 
with betweenness of 11667. For further analyses I have chosen MYC as an 






Figure 4.1: Heatmap representing significantly diferentially expressed genes (rows) 




Table 4.1: The top ten enriched pathways in the Low Immune Subgroup 
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; “Number of protein in GeneSet” is the number of proteins within a 
given pathway; and “Protein from network” indicates number of genes from the 













Network P-value FDR 
The citric acid (TCA) cycle 
and respiratory electron 
transport (R) 





0.0085 92 58 1.1x10-16 5.3 x10
-
14 
Ribosome (K) 0.0142 154 59 1.3x10-14 4.2x10-12 
Generic Transcription 
Pathway (R) 
0.0455 494 121 9.0 x10-14 2.1x10-11 
rRNA processing (R) 0.0165 179 62 2.1 x10-13 4.1x10-11 
Parkinson's disease (K) 0.0131 142 53 7.8 x10-13 1.2x10-10 
Mitotic Prometaphase (R) 0.0091 99 43 1.0 x10-12 1.4x10-10 
Mitotic Metaphase and 
Anaphase (R) 
0.0151 164 57 1.8 x10-12 2.1x10-10 
Oxidative 
phosphorylation (K) 





Figure 4.2: PPI network of the genes upregulated in the Low Immune Subgroup 
The size of the node indicates its importance (centrality). 
 
Previously our group reported that b-catenin signalling is upregulated in 42% of LMC 
tumours overall and in 73% of one particular tumour subset with the poor immune 
responses confirming its immunosuppressive function [76]. In Chapter 3, I showed that 
the three immune subgroups and 6 CICs (associated with b-catenin signalling pathway) 
were in a strong agreement. The agnostic analysis of the genes upregulated in the Low 
Immune Subgroup showed that MYC might be the crucial gene involved in the immune 
evasion, but the gene coding for beta catenin (CTNNB1) was also involved in this 
network. This observation could indicate co-operation of MYC and CTNNB1, which was 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Therefore, I asked what was the relation of MYC and CTNNB1 in terms of association 
with the Low Immune Subgroup. I dichotomised both MYC and CTNNB1 based on 
median expression and generated combinations of these new binary variables: 
• CTNNB1/MYC low (N=230) 
• MYC dominant, i.e. CTNNB1 low/ MYC high (N=122) 
• CTNNB1 dominant, i.e. MYC low/ CTNNB1 high (N=135) 
• CTNNB1/MYC high (N=216). 
Figure 4.3 shows that tumours with both MYC and CTNNB1 high were most frequent in 
the Low Immune Subgroup (47%). This subgroup also contained 18% of tumours with 
MYC dominant and 17% of tumours with CTNNB1 dominant. The CTNNB1 dominant 
subgroup was equally distributed across the three immune subgroups (17%, 23%, 
17%), while MYC dominant was more frequent in the Low than High Immune Subgroup 
(18% vs 9%) (Table 4.2).  
  
 
Figure 4.3: Percentages of 4 groups based on MYC and CTNNB1 expression across the 
three immune subgroups 
  





1 CTNNB1/MYC low 2 MYC dominant




 Table 4.2: Distribution of frequency of the MYC/CTNNB1 groups across the three 








MYC high Total 
High Immune (N) 94 14 26 22 156 
(%) 60.26 8.97 16.67 14.1 100 
Intermediate 
Immune (N) 
85 60 63 67 275 
(%) 30.91 21.82 22.91 24.36 100 
Low Immune (N) 51 48 46 127 272 
(%) 18.75 17.65 16.91 46.69 100 
Total (N) 230 122 135 216 703 
(%) 32.72 17.35 19.2 30.73 100 
 
4.3.1.2 High Immune Subgroup 
The analysis of the genes upregulated in the High Immune Subgroup (n=2283) 
indicated that they were mostly enriched in genes active in immune pathways, as 
expected. The top enriched pathways were: Interferon alpha/beta and gamma 
signalling (FDR=2x10-14), antigen processing and presentation (FDR=2x10-14), 
chemokine signalling (FDR=2.7x10-11), and NF-kB signalling (FDR=9.8x10-11) (Figure 4.4, 
Table 4.3 and Appendix A.2.2). All these pathways are known to be activated in various 
immune cells and in general in immune microenvironment. The up-regulation of these 
pathways confirmed the up-regulation of the immune cell scores in this immune 
subgroup. 
The nodal gene in this network was a transcription factor NFKB1 (Nuclear factor NF-
kappa-B) encoding the p105/p50 subunit of NF-kB (Figure 4.4). The betweenness 
measure for NFKB1 was 19838. The second node with highest centrality measure was 
tyrosine-protein kinase - FYN (betweenness =11863) and Signal transducer and 





Table 4.3: The top 12 enriched pathways in the High Immune Subgroup.  
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; “Number of protein in GeneSet” is the number of proteins within a 
given pathway; and “Protein from network” indicates number of genes from the 

















0.0063 68 42 1.1x10-16 2.0x10-14 
Antigen processing and 
presentation(K) 
0.0071 77 39 1.1x10-16 2.0x10-14 
Influenza A(K) 0.0161 175 56 1.1x10-16 2.0x10-14 
Interferon gamma 
signaling(R) 
0.0067 73 47 1.1x10-16 2.0x10-14 
Signaling by Interleukins(R) 0.0423 460 99 1.1x10-16 2.0x10-14 
Herpes simplex infection(K) 0.017 185 57 2.2x10-16 3.3x10-14 
Cytokine-cytokine receptor 
interaction(K) 
0.0244 265 67 7.9x10-15 1.0x10-12 
Th17 cell differentiation(K) 0.0098 107 39 9.6x10-14 1.1x10-11 
Chemokine signaling 
pathway(K) 
0.0172 187 52 2.7x10-13 2.7x10-11 
NOD-like receptor 
signalling pathway(K) 
0.0156 170 49 3.7x10-13 3.3x10-11 
TNF signalling pathway(K) 0.0101 110 38 9.7x10-13 7.8x10-11 
NF-kappa B signalling 
pathway(K) 





Figure 4.4: PPI network of the genes upregulated in the High Immune Subgroup 
The size of the node indicates the gene importance (centrality).  
 
4.3.2 Patient derived melanoma cell lines analysis 
The identification of MYC as the gene with the highest centrality (betweenness) among 
the genes of the Low Immune Subgroup network and at the same time having a 
negative correlation with the High Immune genes suggested that it might play a key 
role in immune evasion/escape. However, MYC is widely expressed in different tissues 
and different cell types [143] and we have no indication of which cells is expressing it 
in our dataset. It was therefore important to test whether gene expression correlated 
with protein expression and which cells within the tumours express that protein. This 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Given that the transcriptomic data set was derived from tumour cells, however other 
cell types of tumour microenvironment (e.g. stroma) could influence the mRNA levels, 
I hypothesised that looking at the correlates of MYC expression in tumour cell lines 
could give insights about MYC’s role in immune evasion restricting the analysis to the 
pure melanoma cells. 
Therefore, I collaborated with Sabrina Hogan (a colleague Marie Skłodowska-Curie PhD 
student) based at the University of Zürich. The Zürich group generated RNAseq data 
from 103 patient derived early passage melanoma cell lines. I asked Sabrina to take an 
agnostic approach to testing the correlations between MYC expression and the whole 
transcriptome in those cell cultures. These cell lines were lacking immune cells, which 
usually die in tumour cultures, and were fibroblast deficient (as described in Chapter 
2). After the analysis, genes were ranked by their correlation coefficient with MYC. I 
was interested in the most negatively correlating genes as they could imply down-
regulatory effect of MYC. Interestingly of the 50 genes most significantly negatively 
correlated with MYC five are involved in antigen processing and presentation (Figure 
4.5): 
• Major histocompatibility complex class I, B (HLA-B):  
(R=-0.57, P=1.6x10-10) 
• Major histocompatibility complex class I, C (HLA-C): 
(R=-0.45, P=1.8x10-6) 
• Beta-2-microglobulin (B2M):  
(R=-0.45, P=2.69x10-6) 
• Transporter 1, ATP Binding Cassette Subfamily B Member (TAP1):  
(R=-0.44, P=4.45x10-6) 
• Endoplasmic Reticulum Aminopeptidase 1 (ERAP1): 
(R=-0.44, P=5.0x10-6). 
In LMC the correlation of MYC with the genes above were: 
• HLA-B (R=-0.17, P=3.7x10-6) 
• HLA-C (R=-0.15, P=7.4x10-5) 
• B2M (R=-0.17, P=8.5x10-6) 




• ERAP1 (R=-0.17, P=5.5x10-6) 
And in the TCGA metastatic samples: 
• HLA-B (R=-0.24, P=5.1x10-6) 
• HLA-C (R=-0.22, P=3.7x10-5) 
• B2M (R=-0.24, P=5.5x10-6) 
• TAP1 (R=-0.17, P=0.001) 
• ERAP1 (R=-0.14, P=0.006). 
When these 50 genes most negatively correlating with MYC in cell lines were tested for 
pathway enrichment in Reactome FIViz, the most significantly enriched pathways were 
class I MHC mediated antigen processing & presentation (FDR=1.2x10-6), and 
interferon gamma singling (FDR=1.2x10-4) (Table 4.4). On the other hand, the 50 genes 
most positively correlating with MYC were enriched in senescence-associated 
secretory phenotype (SASP) (FDR= 6.16x10-3) and the cell cycle (FDR= 6.16x10-3) (Table 
4.5). Altogether these results showed that MYC was negatively correlated with 
immunity and positively with senescence and proliferation, which were similar to the 






Figure 4.5: The 25 genes most positively and negatively correlated with MYC in melanoma cell lines data (Analysis by Sabrina Hogan)  
 
Table 4.4: Enriched pathways in the gene list negatively correlated with MYC in patient derived melanoma cell lines  
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of numbers of genes contained in pathways to total genes in the Reactome FI 
network; “Number of protein in GeneSet” is the number of proteins within a given pathway; and “Protein from network” indicates number of genes from 
the input gene list per pathway. “Nodes” are proteins from the network. 
GeneSet 
Ratio Of Protein 
In GeneSet 
Number Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Class I MHC mediated antigen processing 
& presentation(R) 0.0174 189 5 3.25E-08 1.20E-06 HLA-B, TAP1, HLA-C, SEC24D, B2M 
Antigen processing and presentation(K) 0.0071 77 4 8.67E-08 1.56E-06 HLA-B, TAP1, HLA-C, B2M 
Interferon gamma signaling(R) 0.0067 73 3 1.04E-05 1.25E-04 HLA-B, HLA-C, B2M 




































































































































































































































































































































Table 4.5: Enriched pathways in the gene list positively correlated with MYC in patient derived melanoma cell lines 
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of numbers of genes contained in pathways to total genes in the Reactome FI 
network; “Number of protein in GeneSet” is the number of proteins within a given pathway; and “Protein from network” indicates number of genes from 
the input gene list per pathway. “Nodes” are proteins from the network. 
GeneSet 
Ratio Of Protein 
In GeneSet 
Number Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Senescence-Associated Secretory Phenotype (SASP)(R) 0.0048 52 2 1.37E-04 6.16E-03 CDK2, CDC16 
APC/C-mediated degradation of cell cycle proteins(R) 0.0076 83 2 3.46E-04 6.16E-03 CDK2, CDC16 
Progesterone-mediated oocyte maturation(K) 0.009 98 2 4.82E-04 6.16E-03 CDK2, CDC16 








Whole transcriptomic differential expression analysis of the immune subgroups 
followed by enrichment and network analysis indicated that: 
• The pathways enriched in the Low Immune Subgroup were associated with 
proliferation and cell cycling. 
• The nodal gene identified in the Low Immune Subgroup, with the most central 
role in holding the network together was MYC. 
• From the presented results based on LMC, TCGA and cell lines supported by the 
literature: MYC was considered as an immune evasive candidate, functioning via 
down regulation of HLA-B or possibly more MHC class I molecules. 
• The pathways enriched in the High Immune Subgroup were associated with many 
crucial immune pathways. 
• The nodal gene identified in the High Immune Subgroup was NFKB1, a 
transcription factor known to be expressed in all cell types and for its role in 
immune reactions. 
4.5 Discussion 
The three immune subgroups generated based on imputed immune cell scores (as 
described in the previous chapter) allowed the identification of key pathways and 
genes associated with the immune response to melanoma. 
4.5.1 Methodological aspects 
With the advent of large-scale gene expression data, many tools to analyse pathway 
enrichment have emerged, such as Database for Annotation, Visualization and 
Integrated Discovery (DAVID) [175], which is no longer updated, Kyoto Encyclopedia of 
genes and Genomes (KEGG) [176], Gene Set Enrichment Analysis (GSEA) [177], and 
Reactome [178]. These tools however are limited to only one type of data analysis, 
which is generally pathway enrichment. For the analysis of the genes upregulated in 
the Low and High Immune Subgroups I intended to use a tool used to analyse pathway 




analyses give an overview of the biological characterisation of the input gene list, 
whereas network analysis enables to identify small subsets of those genes, which are 
functionally the most important. Amongst the most known bioinformatic software, 
that provide a possibly of these two types of analyse are: STRING ((https://string-
db.org)) and Reactome FIViZ [160]. However, STRING does not support an analysis of 
more than 20,000 genes, hence I used Reactome FIViz. This tool has several additional 
advantages when compared to STRING, for example (as mentioned in the background 
section) it allows direct analysis of gene expression and mutational data, although I did 
not use this function during my analysis. As an input for Reactome FIViz, I have only 
used the gene names, not gene expression, because the gene list already came from 
differential expression analyses with upregulation in one group of tumours compared 
to another, which meant that all the genes in the list were positively correlated. 
Irrespective of the software used, the biological networks predicted using curated 
databases can be affected by curation bias [179][180]. For example, more studied 
genes/protein are likely to have more identified annotations and network connections 
than those less studied. It is well known that transcription factors, whose function is to 
control other genes, are among the most well studied molecules due to their wide-
ranging impact. It was therefore not entirely surprising that genes with the highest 
centrality in both the Low Immune and High Immune Subgroups were transcription 
factors (MYC and NFKB1). Validation of these genes in an independent experiment of 
melanoma cell cultures, in particular MYC for its role in immune evasion, was necessary 
and provided convincing results. 
Additionally, in order to ensure validity of the results obtained on the gene expression 
level through the network analyses, they were compared to protein data from 
immunohistochemistry staining and to DNA copy number alteration data in the next 
chapter (Chapter 5). 
4.5.2 Biological aspects 
The genes upregulated in the Low Immune Subgroup were associated with 
proliferation and metabolic activity, suggesting that tumours in this subgroup were 
very aggressive. These agnostic genomic results are consistent with the results showed 




significantly higher in the Low Immune Subgroup, and the subgroup was associated 
with poorer survival. The most pivotal gene in the protein-protein interaction network 
in this subgroup was MYC, a widely studied proto-oncogene known to regulate the 
transcription of many genes involved in cell growth, apoptosis and metabolism by 
forming a heterodimer with its partner MAX (MYC-associated factor) and binding to E-
box (enhancer box) of target genes [181].  
In melanoma it has been previously reported, that MYC was involved in metastases and 
invasiveness [182]. However, in recent years researchers have examined MYC from a 
slightly different biological viewpoint, such as its involvement in immunosuppressive 
processes, and were able to provide some evidence for that in various cancer types 
[183][184][185], but not for melanoma. Given this evidence from literature and my 
observation of a negative correlation between MYC expression and immune pathways 
in the LMC dataset, I explored a possible immunosuppressive function of MYC in 
primary melanoma by further using cell line data from a collaboration (Sabrina Hogan, 
University of Zürich). The agnostic analysis of the cell line transcriptome revealed a 
similar trend as seen in patients of LMC dataset, i.e. that MYC was negatively associated 
with the immune function overall and the antigen processing machinery in particular. 
This was consistent with the report by Versteeg et al. [186], in which an inverse 
relationship between HLA class I and MYC expression was seen in melanoma cell lines. 
Evidence that MYC down-regulates the expression HLA-B, by directly binding to its 
proximal promoter independently of MAX has also been reported in melanoma cell 
lines [187]. These studies however were performed around 20 years ago, and up to 
nowadays this relationship of MYC and HLA-class I was not shown in human melanoma 
samples. More recently it was shown that MYC disrupts HLA class II-mediated immune 
recognition in human B cell tumours [188].  
The comparisons between MYC and CTNNB1 expression in the tumours indicated that 
both MYC and CTNNB1 could contribute to the immune evasion simultaneously as the 
Low Immune Subgroup was comprised mostly of samples with both MYC and CTNNB1 
high expression. The whole genome comparison between the MYC and CTNNB1 
dominant groups revealed that there was no clear distinction seen in relation to the 
immunosuppressive pathways between these two groups in the whole dataset, 




keratinization. These observations might suggest that the MYC dominant group was 
contaminated by the expression of genes originating from keratinocytes. Similar results 
and conclusions were shown by Dr Jérémie Nsengimana in the analyses of b-catenin 
signalling as an immune evasion mechanisms in the LMC [76]. In this study, it was found 
that only MYC was upregulated (not CTNNB1) in the CIC6, which was called immune 
low/keratin high and it was thin group of samples. To make sure that MYC overall was 
not associated with keratin contamination I tested a correlation of MYC and FLG 
(filaggrin expressed by keratinocytes) using Spearman correlation, and the results 
confirmed that there was no correlation (R=0.007, P=0.8). 
In summary the above evidences suggested that the immune evasive mechanisms 
driven by MYC and CTNNB1 were not mutually exclusive and they co-occurred in a large 
proportion of the Low Immune Subgroup tumours. It is of note that, although MYC is 
downstream of b-catenin pathway, it does not eliminate the possibly that MYC is 
controlled by different mechanisms such as MYC amplifications, which was tested and 
this is reported in Chapter 5. Additionally, literature suggested that MYC might also 
control b-catenin signalling [149].  
Overall, my observations and those from the literature manifest evidence that MYC is 
contributing to the immune evasion in primary melanoma by impairing the antigen 
presentation and processing machinery at several levels including by reducing the 
protein levels of HLA-B on the cell membrane.  
Unsurprisingly the genes upregulated in the High Immune Subgroup were assigned 
overall to the immune function. Many immune checkpoint genes were also identified 
in this subgroup, as well as Tregs and MDSCs. Taking together upregulation of 
immunosuppressive and immuno-stimulating genes/immune cell scores in the high 
Immune Subgroup suggested a coordination of the immune cell populations as a whole 
or that the interpretation of immune cell subgroup infiltration from transcriptomic 
datasets may be insensitive to some subtle variations. However, it was recently 
reported that Treg numbers and checkpoint molecules increase as a results of a 
homeostatic mechanism when CD8+ T cell numbers increase in melanoma [189][76]. 
NFKB1 was the most nodal gene within the network created based on genes 




genes such as Nuclear Factor Kappa B Subunit 2 (NFKB2), Proto-oncogene cRel (REL), 
Transcription factor p65 (RELA), Transcription factor RelB (RELB), and many more, were 
also upregulated in the High Immune Subgroup indicating activation of that pathway 
(Appendix A.2.2).  
However, the expression of an important gene (RELA) coding for a protein that forms 
a heterodimer with NF-kB p105 (NFKB1) before its translocation to the nucleus and 
activation of transcription, did not vary across the immune 3 subgroups. This might 
reflect that this protein is constitutively expressed (meaning that its expression does 
not vary) in different tissues types and their biological states.  
Nevertheless, the products of NKFB1 such as NF-kB p105 precursor, which after 
phosphorylation becomes p50, might form different combination of heterodimers and 
homodimers with the rest of the NF-kB family members. The functions of each dimer 
vary, and they either might activate the transcription of target genes or repress it [190]. 
Using only gene expression data, we were not able to investigate this process deeper.  
NF-kB singling is known for its immune regulatory functions as well as for regulation of 
apoptosis and cell survival [190]. Abnormal NF-kB singling and NFKB1 gene expression 
particularly was found to have carcinogenic functions and promote tumour progression 
by inflammation (for example via STAT3) as well as to act as tumour suppressor 
[190][191][192]. Importantly, these functions depend on which components of tumour 
microenvironment (such as immune cells, cancer associated fibroblast, or tumour cells) 
have the abnormal NF-kB singling [193]. Assuming that the signal of NF-kB pathway of 
the LMC tumours was coming from the tumour cells, (which was tested in the next 
chapter), the results from this chapter suggested that this gene and overall NF-kB 
signalling was associated with higher anti-tumour immune responses. However, this 
observation did not explain the causality of the tumour NF-kB signalling activation. It 
could be that the immune cells attracted to the tumour microenvironment produced 
signals to activate NF-kB signalling by the tumour cells. Or on a contrary tumour cells 
prior being attracted by the immune cells, had NF-kB signalling active resulting in 
secretion of chemo attractant cytokines, which facilitated recognition of the tumour 




One study examined the expression of tumour NF-kB genes in lung cancer, and 
reported that this pathway promoted T cell- mediated immune surveillance [194]. 
Moreover, another study showed that hyper-activation of NF-kB signalling within the 
tumour microenvironment contributes to reprograming of chemokine 
microenvironment to enhance recruitment of cytolytic T cells in colorectal tumours 
[195]. Gastric cancer was also shown to be caused by loss of NFKB1 particularly with 
aberrant inflammation within the tumour [196].  
The literature supported the observations reported in this chapter such as positive 
association of NF-kB signalling and NFKB1 with high immune signals within the tumour, 
however it is crucial to test where the NF-kB signalling gene expression originated from 





Evaluation of the transcriptomic results on DNA and protein 
level 
5.1 Aims 
Herein the results from the previous chapters, which were based on the gene 
expression level, were evaluated by using protein immunohistochemistry (IHC) and 
DNA copy number alteration data (CNA). These analyses were performed only in a 
subset of the tumours due to technical and ethical reasons.   
The aims were:  
• To analyse CNA data for MYC and NFKB1, pathways and other genes from the top 
enriched pathways from the previous chapter aiming to observe some 
associations between CNAs and gene expression, the three immune subgroups 
and survival.  
• To perform immunohistochemical staining for MYC, HLA-B and NFKB1 (NF-kB 
p105) and correlate the results with mRNA level of the corresponding genes 
aiming to observe the positive correlations. 
5.2 Evaluation of CNA 
5.2.1 Introduction 
CNA data used in this thesis were generated based on next generation sequencing 
(NGS) of the FFPE tumours. The methods for analysis of structural variation of the 
genome in cancer have been identified previously using NGS data [197], however 
samples from fresh tissues were generally used, not FFPE. The performance of NGS 
highly depends on the quality of the DNA extracted from the analysed tissues [198] and 
it is well known that the genetic material extracted from FFPE tissues is degraded but 
in melanoma, it is very often the only available. In addition, melanomas are generally 
very small (compared to other tumours), and the quantity of the genetic material 




further complicates the processing of genomic material as it has been shown to interact 
with polymerase in PCR manipulations, inhibiting its function [199] and affecting library 
production for sequencing.  
Our group has developed methods which enabled to produce reliable CNA data from 
FFPE samples from relatively small quantities of DNA in the range of 25-1000ng (Filia 
et al., in press). Joey Mark Santiago Diaz (a colleague Marie Skłodowska-Curie PhD 
student in the group) has developed quality control and analysis pipelines for these 
data as part of his PhD project, and these data are now available. 
5.2.2 Methods 
Using the CNA data for 276 samples, I evaluated the amplifications and deletions of the 
nodal genes (MYC and NFKB1) identified in the network analyses in Chapter 4. 
Moreover, because the NF-kB and IFN-g pathways were the most enriched pathways 
in the High Immune Subgroup, I subsequently asked if some of additional genes within 
these pathways were disrupted in the Low Immune Subgroup. For the NF-kB pathway, 
I chose these key genes involved in its signalling: 
• Nuclear Factor Kappa B Subunit 2 (NFKB2)  
• Proto-oncogene cRel (REL)  
• Transcription factor p65 (RELA)  
• Transcription factor RelB (RELB). 
Furthermore, following a discussion with Prof. Ulf Klein (an immunologist from 
University of Leeds, specialising in NF-kB signalling), I included the following genes 
associated with positive regulation of this signalling pathway: 
• Conserved Helix-Loop-Helix Ubiquitous Kinase (CHUK) [200] 
• Interleukin-1 receptor-associated kinase-like 2 (IRAK2) [201] 
• Mitogen-activated protein kinase kinase kinase 14/ NF-kB-inducing kinase 
(MAP3K14/NIK) [202] 
• Myeloid differentiation primary response protein MyD88 (MYD88) [203] 
• Mitogen-activated protein kinase kinase kinase 7 (MAP3K7/TAK1) [204] 
• Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) [205] 




Interleukin-1 receptor-associated kinase-like 1 (IRAK1)[207] and Inhibitor of nuclear 
factor kappa-B kinase subunit gamma (IKBKG)[208] were also suggested, but the CNA 
data did not cover these genes, because they were located in the “black listed” (difficult 
to be sequenced) regions of the genome. 
From the IFN-g signalling pathway I have assessed copy number changes of the key 
genes involved in this signalling: tyrosine-protein kinase (JAK1 and JAK2), signal 
transducer and activator of transcription 1-alpha/beta (STAT1), and interferon gamma 
(IFNG)[209]. In addition to these genes, I included b-catenin (CTNNB1) to test whether 
activation of b-catenin pathway is controlled by changes on DNA level. 
The CNA data were generated at a continuous scale as normalised zero-centred read 
counts of DNA sequences per window of 10kb. Negative values indicate DNA fragment 
deletion and positive value indicate DNA fragment amplification. I used the median 
value of the ratio of the sample read count to normal control read count of the 
windows (10K) covering the gene of interest as the copy number estimate. Most of the 
analysed genes spanned more than one 10K window except MYC, which covered only 
one 10K window and initial analyses for MYC were not conclusive and therefore I chose 
to analyse a region commonly amplified in cancer around MYC (23091 bases) [210] 
rather than MYC alone. 
To define amplifications and deletions, I developed an ad-hoc categorisation of 
continuous CNA data into amplification and deletion, based on visual examination of 
the CNA distribution for all genes of interest. An arbitrary cut-off, value of |0.3| (ratio 
of a read count of tumour to normal) was used. I defined deletion and amplification as 
cut-off point of windows (covering a gene region) median at below -0.3 or above 0.3 
respectively for the majority of the genes and at below -0.45 or above 0.45 for one 
gene (JAK2). These cut-offs however do not indicate whether the aberration is homo- 
or heterozygous although the assumption is that the deeper the aberration the higher 
chances for homozygous change or even polyploidy. 
It was examined whether copy number alterations of the genes of interest were 
associated with the three immune subgroups using the Fisher’s exact test. I analysed 
the expression level of corresponding genes among the aberrations using Kruskal-




the aberrations in Cox proportional hazard regression models, unadjusted and adjusted 
for AJCC stage. I further tested whether the prediction of survival for patients with MYC 
and NFKB1 aberrations was additive by including them jointly in the analysis.  
For the CNA visualisation I used the ComplexHeatmp package in R [211] to create 
“Oncoprint” graph, which enables to visualise/detect mutual exclusivity of the 
aberrations.  
As stated in Chapters 3 and 4, our group reported evidence that b-catenin signalling 
pathway is upregulated in 30% of LMC tumours overall and in 59% of the low immune 
tumours indicating its immunosuppressive function [76]. Apart from testing interaction 
of MYC and CTNNB1 on gene expression level in previous chapter, I also examined the 
overlap between b-catenin gene expression and the possible immunosuppressive 
mechanisms driven by deletions of NF-kB pathway genes and their joint effect on 
survival using Cox-proportional hazard regression. I created and tested a NF-kB CNA 
score (NFKB1, NFKB2, CHUK, MAP3K7, IRAK2, MYD88) for which at least one alteration 
was observed within a tumour. The result from this kind of analysis could indicate 
whether these pathways were independent from each other. 
5.3 Evaluation of Immunohistochemical staining 
5.3.1 Methods 
Stored unstained FFPE sections of available primary tumours from the LMC were used 
to assess the protein-level and mRNA level correlations. The terms of the ethical 
approval for this study were that it should be avoided to destruct of tumour blocks 
which might be required by the patient for further clinical testing, hence a limited 
number of samples was available for this analysis. The sections for IHC could only be 
cut from tumour blocks of deceased study participants both either from melanoma or 
non-melanoma causes. Dr Jonathan Laye and Tracey Mell sectioned the tumour blocks 
and mounted the 5µm sections on Superfrost Plus slides (Thermo Fisher Scientific, UK). 
Dr Jonathan Laye and I performed immunohistochemical staining of the slides using 
IntelliPath FLX detection reagents (MenaPath, A. Menarini Diagnostics, UK) by heat 




manufacturer’s protocol. Both procedures were described in the Materials and 
Methods section. 
The most influential genes (MYC and NFKB1) identified from the analysis of the protein-
protein interaction networks, which were created using genes upregulated in the High 
and Low Immune Subgroup (see Chapter 4) were examined. Moreover, HLA-B was also 
analysed, which was negatively correlated with MYC in the LMC, TCGA (metastatic 
samples) and in melanoma cell lines, consistently with literature [187]. The antibodies 
(Abcam, UK) used for staining were: anti-MYC (ab32072; suggested antibody 
concentration: 5 µg/ml), anti-NF-kB p105 (ab32360; suggested antibody 
concentration: 1/250 - 1/500), and anti-HLA-B (ab193415; suggested antibody 
concentration: 1/20 - 1/200).  
 Antibody optimisation 
The antibodies were optimised using the available tissues that are known to express 
the analysed proteins in high levels. The tissue type for the antibody staining was 
chosen based on the data at the Human Protein Atlas [143]. Moreover, the Human 
Protein Atlas and UniProt portal [212] provided the information of the cellular 
localisation of protein of interest. 
The optimisation of an antibody is a process by which we can test whether the antibody 
is specific to the analysed protein (detected in the predicted cellular localisation) as 
well as to assess which concentration would be the most suitable to allow scoring of 
the staining of the tissue of interest – here melanoma tumours. Mainly the staining 
should not be too strong to overcall the positive staining and also should not be too 
weak to miss the specific staining. 
The staining for the antibody optimisation was performed by Dr Jonathan Laye and 
myself using IntelliPath FLX detection reagents (MenaPath, A. Menarini Diagnostics, 
UK) according to manufacturer’s protocol.  
The anti-MYC antibody was optimised using healthy human tonsil tissue in four 
different concentrations (µg/µl): 1:50, 1:100, 1:150, and 1:200. The anti-HLA-B was 
optimised on healthy human skin tissue in concentrations (µg/µl): 1:50, 1:100, 1:150. 




biopsies in six concentrations (µg/µl): 1:100, 1:200, 1:250, 1:375, 1:500, 1:600. The 
concentration of the antibody for the subsequent tumour staining was chosen based 
on its optimal intensity to detect the signal.  
 Scoring of the stained slides 
The scoring of the tumours after staining was developed by pairs of observers (by 
myself for all of the slides and by independent assessors: Prof. Julia Newton-Bishop, Dr 
Jonathan Laye and Sathya Muralidhar (Marie Skłodowska Curie PhD student) for 
selected antibodies). All the assessors were blinded to the transcriptomic data while 
scoring.  
Anti-MYC staining was performed on 48 slides. Light microscopy at 10X magnification 
was used to evaluate the expression of MYC and HLA-B due to homogenous staining. 
Staining scores for these two proteins were recorded from the regions immediately 
surrounding the tumour core - the ‘punch hole’ (Figure 5.1). MYC was assessed by 
nuclear staining as this protein is known to function within the nucleus as it is a 
transcription factor [143][212] (Table 5.1). 
 
Figure 5.1: Example of a tumour with the two “punch holes” after the core sampling 





Table 5.1: Scoring system for MYC IHC staining 
IHC MYC Staining 
Cored region staining description Score 
Nuclear staining absent 0 
Weak to moderate nuclear staining 1 
Intense nuclear staining 2 
 
The same scoring levels were utilised to assess the staining of HLA-B, however 
restricted to membranous staining, because it is the final localisation of this protein to 
present antigens to the immune cells [143][212]. (Table 5.2). In total 30 slides were 
stained for HLA-B. 
Table 5.2: Scoring system for HLA-B IHC staining 
IHC HLA-B Staining 
Cored region staining description Score 
Membranous staining absent 0 
Weak to moderate membranous 
staining 
1 
Intense membranous staining 2 
 
In the tumours that were sampled/cored more than once the staining scores were 
generated and if these were contradictory the slides were not used for subsequent 
analyses. Anti-NF-kB p105 was evaluated in cytoplasm as it is known to be detected in 
this location in inactive form and in the nucleus, for detection of its active transcription 
factor function [143][212]. The staining of NF-kB p105 for 29 tumours was evaluated 
using 20X magnification for cytoplasm around the core and 40X magnification for nuclei 
across the whole slide. Cytoplasmic staining was graded as in Table 5.3. 
Table 5.3: Scoring system for cytoplasmic NF-kB p105 IHC staining 
IHC NF-kB p105 Staining 
Tumour area staining description Score 
Cytoplasmic staining absent 0 
Weak cytoplasmic staining 1 
Moderate cytoplasmic staining 2 





Because the nuclear activity of NF-kB signalling is transient and not all the nuclei were 
positive at the same time, the scoring was assessed as follows: if more than 5 nuclei 
were positive in the tumour I recorded the staining as “positively stained”, otherwise 
as “negatively stained” (Table 5.4).  
Table 5.4: Scoring system for nuclear NF-kB p105 IHC staining 
IHC NF-kB p105 Staining 
Tumour area staining description Score 
<5 nuclei positively stained Negative 
≥5 nuclei positively stained Positive 
 
NF-kB p105 is known to be expressed by the immune cells, hence the infiltrated 
lymphocytes were scored as well for cytoplasmic and nuclear staining, either “positive” 
or “negative” (Table 5.5).  
Table 5.5: Scoring system for TILs NF-kB p105 IHC staining 
IHC NF-kB p105 Staining 
TILs staining description Score 
Cytoplasmic/nuclear staining absent Negative 
Cytoplasmic/nuclear staining present Positive 
 
Additional quantification of MYC and HLA-B staining was performed using light 
microscopy in conjunction with Nuance software v.3.0.1.2 (PerkinElmer, Inc.). Tissue 
sections were examined under 20X magnification, and consecutive MYC and HLA-B-
stained images of the most representative part of the tumour were digitally scanned. 
Spectral analysis was performed to quantify the light signal derived from 
immunohistochemical chromagen, haematoxylin counterstain and signal co-localised 
from both chromagen and counterstain. Threshold levels were arbitrarily set to fix the 
strength of haematoxylin and chromagen signal deemed to be positive and for each 
tumour the signals were recorded as the percentage of positive pixels per scoring area.  
The chromagen percentage score was utilized to quantify HLA-B staining. Because 




localised signal derived from chromagen and counterstain to derive a MYC-nuclear 
expression score.  
 Statistical analysis 
For the statistical analyses of MYC (tumour nuclear) and HLA-B (tumour membranous) 
staining, I tested the variation of the mRNA expression of the corresponding proteins, 
across tumours scored 0 to 2 for staining using Kruskal-Wallis test as well as between 
pooled scores: negative (0) and positive (1 and 2 pooled together), using Mann-
Whitney U test in order to obtain higher statistical power. For NF-kB p105 staining I 
tested NFKB1 mRNA expression change among the cytoplasmic four scores as well as 
pooled scores: negative (0) and positive (1,2 and 3 pooled) and nuclear scores 
(negatively vs positively stained) also in order to obtain higher statistical power. I 
moreover compared the nuclear staining of the tumour and nuclear staining of the TILs 
using the Chi-squared test. For the continuous scoring (using the Nuance software) of 
HLA-B and MYC I performed Spearman’s rank correlation between mRNA and IHC 
staining excluding samples where MYC was detected in less than 1% of pixels, which I 
considered as absent.  
5.4 Results 
5.4.1 DNA copy number changes in primary melanoma in relation to immune 
response 
Since up-regulation of MYC and down-regulation of NFKB1 expression (identified as the 
nodal genes) were observed in the Low Immune Subgroup, I hypothesised that 
amplifications of MYC and deletions of NFKB1 could be more common in these 
tumours. Using CNA from a subset (N=276) of the LMC tumours firstly the histograms 
for the CNA data per each gene were examined (Figure 5.2). Usually it was observed 





Figure 5.2: Examples of histograms representing the distribution of CNA for selected 
genes 
Amplifications and deletions were generally exclusive per analysed gene. 
 
MYC amplifications were found in 29% and NFKB1 deletions in 14% of the Low Immune 
Subgroup, which was significantly higher than in the Intermediate or the High Immune 
Subgroup (P= 0.02 for MYC, P=0.0003 for NFKB1) (Table 5.6, Figure 5.3). Among the 
genes involved in the positive regulation of NF-kB signalling there were deletions in 
NFKB2 (26%), CHUK (22%), MYD88 (5%), IRAK2 (5%), MAP3K7 (17%), JAK2 (10%), and 
STAT1 (4%) in the whole dataset (Table 5.6, Figure 5.3). These copy number changes 
were not mutually exclusive (Figure 5.3) and were much more frequent in the Low 
Immune than in other subgroups (Table 5.6, Figure 5.3). The most significant 
distribution of the CNA across the three immune subgroups was observed for JAK2 
(P=2x10-8), where 25% of samples had deletions in the Low Immune Subgroup, while 
only 1.6% in the High Immune Subgroup. Another gene with strong significant 




comparable to NFKB1. 38.6% of samples with NFKB2 deletions were identified in the 
Low Immune Subgroup, while 9.4% in the High Immune (P=0.0001). 
 
Figure 5.3: Graphical representation (“Oncoprint”) of the significantly altered genes 
across the three immune subgroups  


























































































































Table 5.6: Table representing CNA changes of all the analysed genes across the 
immune subgroups 




Immune Total CNA P  
TOTAL (N) 64 116 96   
MYC      
No change (N) 57 93 68 218  
No change (%) 89.06 80.17 70.83 78.99  
Amplification (N) 7 23 28 58  
Amplification (%) 10.94 19.83 29.17 21.01 0.02 
NFKB1      
No change (N) 63 112 82 257  
No change (%) 98.44 96.55 85.42 93.12  
Amplification (N) 1 2 1 4  
Amplification (%) 1.56 1.72 1.04 1.45  
Deletion (N) 0 2 13 15  
Deletion (%) 0 1.72 13.54 5.43 0.0003 
NFKB2      
No change (N) 58 87 59 204  
No change (%) 90.62 75 61.46 73.91  
Amplification (N) 0 1 0 1  
Amplification (%) 0 0.86 0 0.36  
Deletion (N) 6 28 37 71  
Deletion (%) 9.38 24.14 38.54 25.72 0.0001 
CHUK      
No change (N) 59 93 63 215  
No change (%) 92.19 80.87 65.62 78.18  
Deletion (N) 5 22 33 60  
Deletion (%) 7.81 19.13 34.38 21.82 0.0002 
IRAK2      
No change (N) 63 109 87 259  
No change (%) 98.44 93.97 90.62 93.84  
Amplification (N) 1 0 1 2  
Amplification (%) 1.56 0 1.04 0.72  
Deletion (N) 0 7 8 15  








Immune Total CNA P  
MAP3K14      
No change (N) 63 106 86 255  
No change (%) 98.44 91.38 89.58 92.39  
Amplification (N) 1 4 3 8  
Amplification (%) 1.56 3.45 3.12 2.9  
Deletion (N) 0 6 7 13  
Deletion (%) 0 5.17 7.29 4.71 0.2 
MYD88      
No change (N) 62 108 87 257  
No change (%) 96.88 93.1 90.62 93.12  
Amplification (N) 2 2 0 4  
Amplification (%) 3.12 1.72 0 1.45  
Deletion (N) 0 6 9 15  
Deletion (%) 0 5.17 9.38 5.43 0.02 
MAP3K7      
No change (N) 61 98 64 223  
No change (%) 95.31 84.48 66.67 80.8  
Amplification (N) 0 3 3 6  
Amplification (%) 0 2.59 3.12 2.17  
Deletion (N) 3 15 29 47  
Deletion (%) 4.69 12.93 30.21 17.03 0.00005 
REL      
No change (N) 62 103 85 250  
No change (%) 96.88 88.79 88.54 90.58  
Amplification (N) 2 11 8 21  
Amplification (%) 3.12 9.48 8.33 7.61  
Deletion (N) 0 2 3 5  
Deletion (%) 0 1.72 3.12 1.81 0.3 
RELB      
No change (N) 61 108 87 256  
No change (%) 95.31 93.1 90.62 92.75  
Amplification (N) 3 8 8 19  
Amplification (%) 4.69 6.9 8.33 6.88  








Immune Total CNA P  
Deletion (%) 0 0 1.04 0.36 0.7 
RELA      
No change (N) 58 103 80 241  
No change (%) 90.62 88.79 83.33 87.32  
Amplification (N) 4 3 3 10  
Amplification (%) 6.25 2.59 3.12 3.62  
Deletion (N) 2 10 13 25  
Deletion (%) 3.12 8.62 13.54 9.06 0.1 
IKBKB      
No change (N) 63 103 73 239  
No change (%) 98.44 88.79 76.04 86.59  
Amplification (N) 1 8 13 22  
Amplification (%) 1.56 6.9 13.54 7.97  
Deletion (N) 0 5 10 15  
Deletion (%) 0 4.31 10.42 5.43 0.001 
NFKBIA      
No change (N) 55 100 79 234  
No change (%) 85.94 86.21 82.29 84.78  
Amplification (N) 6 6 6 18  
Amplification (%) 9.38 5.17 6.25 6.52  
Deletion (N) 3 10 11 24  
Deletion (%) 4.69 8.62 11.46 8.7 0.5 
JAK2      
No change (N) 63 113 71 247  
No change (%) 98.44 97.41 73.96 89.49  
Amplification (N) 0 0 1 1  
Amplification (%) 0 0 1.04 0.36  
Deletion (N) 1 3 24 28  
Deletion (%) 1.56 2.59 25 10.14 2x10-8 
STAT1      
No change (N) 56 109 91 256  
No change (%) 87.5 93.97 94.79 92.75  
Amplification (N) 6 4 0 10  








Immune Total CNA P  
Deletion (N) 2 3 5 10  
Deletion (%) 3.12 2.59 5.21 3.62 0.02 
JAK1      
No change (N) 62 106 80 248  
No change (%) 96.88 91.38 83.33 89.86  
Amplification (N) 2 5 11 18  
Amplification (%) 3.12 4.31 11.46 6.52  
Deletion (N) 0 5 5 10  
Deletion (%) 0 4.31 5.21 3.62 0.05 
IFNG      
No change (N) 60 107 83 250  
No change (%) 93.75 92.24 86.46 90.58  
Amplification (N) 1 5 4 10  
Amplification (%) 1.56 4.31 4.17 3.62  
Deletion (N) 3 4 9 16  
Deletion (%) 4.69 3.45 9.38 5.8 0.4 
CTNNB1      
No change (N) 63 102 85 250  
No change (%) 98.44 87.93 88.54 90.58  
Amplification (N) 1 6 1 8  
Amplification (%) 1.56 5.17 1.04 2.9  
Deletion (N) 0 8 10 18  
Deletion (%) 0 6.9 10.42 6.52 0.02 
 
Deletions rather than amplifications of CTNNB1 were seen in the Low Immune 
Subgroup (10.4% in Low immune and none in High immune, P=0.02) (Table 5.6), 
although the gene expression was unaffected by these deletions (P=0.2) (Table 5.7). 
For the vast majority of other genes, the copy number changes were highly correlated 
with mRNA expression of the corresponding gene (Table 5.7). For example, the results 





Table 5.7: Variation in gene expression between the groups of tumours with and 
without CNA (for the genes significantly varying across the three immune 
subgroups) 
Gene name Fold change P 
MYC 0.8 0.0006 
NFKB1 1.2 0.008 
NFKB2 1.6 1.5x10-11 
CHUK 1.2 0.004 
IRAK2 1.7 0.003 
MYD88 1.2 0.02 
MAP3K7 1.2 4.8x10-10 
STAT1 1.1 0.7 
 
Importantly, copy number changes of MYC (amplifications) and NFKB1 (deletions) were 
strongly predictive of poor prognosis overall in univariable analysis and when AJCC 
stage was adjusted (MYC amplifications: adjusted HR=1.8 (95% CI 1.8-2.6, P=0.006; 
NFKB1 deletions: adjusted HR=1.5 (95% CI 1.1-2.1, P=0.007) (Table 5.8, Table 5.9). 
Seven patients who had both amplifications of MYC and deletion of NFKB1 had an even 
worsened prognosis (adjusted HR=3.7, 95% CI 1.6-8.5, P=0.002), (Table 5.8, Table 5.9), 
suggesting an additive detrimental effect of these copy number changes. The 
unadjusted survival analyses of MYC and NFKB1 CNAs are plotted on Figure 5.4. It is of 
note, that all seven patients with alterations in both genes have died. 
Other deletions associated with melanoma specific survival were observed in NFKB2, 
CHUK, IRAK2, MYD88, MAP3K7, JAK2, STAT1 (Table 5.8), and CHUK, MYD88, IRAK2 or 





Table 5.8: Univariable melanoma specific survival anaysis of CNAs 
Gene name HR P 95% Conf. Interval 
MYC 1.79 0.004 1.20 2.66 
NFKB1 1.67 0.001 1.24 2.26 
NFKB2 1.22 0.044 1.01 1.48 
CHUK 1.32 0.007 1.08 1.61 
IRAK2 1.40 0.044 1.01 1.93 
MYD88 1.57 0.004 1.15 2.15 
MAP3K7 1.24 0.054 1.00 1.54 
JAK2 1.51 0.001 1.18 1.95 
STAT1 1.04 0.871 0.63 1.72 
 
 
Table 5.9: Melanoma specific survival anaysis of CNAs adjusting AJCC stage 
Gene name HR P 95% CI 
MYC 1.76 0.006 1.18 2.64 
NFKB1 1.52 0.007 1.12 2.05 
Amp of MYC + Del of 
NFKB1 
3.70 0.002 1.60 8.52 
NFKB2 1.16 0.136 0.95 1.42 
CHUK 1.31 0.009 1.07 1.60 
IRAK2 1.38 0.053 1.00 1.91 
MYD88 1.49 0.013 1.09 2.04 
MAP3K7 1.14 0.252 0.91 1.43 
JAK2 1.40 0.009 1.09 1.81 








Figure 5.4: Kaplan Meier plots for amplifications of MYC vs no change, deletion of 





As our group previously reported that b-catenin pathway is involved in immune 
evasion, I tested its relation with deletions in the NF-kB pathway to see if the 2 
mechanisms are interrelated or independent. I compared the CNAs of genes from the 
NF-kB pathway and CTNNB1 expression dichotomised into high (30%) and low (70%) 
using the software Xtile [213] by Dr Jérémie Nsengimana [76]. This analysis showed 
some overlap between the two immune evasion mechanisms but also some 
heterogeneity. More specifically, 15% of tumours had increased CTNNB1 expression 
alone, 32% had a deletion in at least one gene of the NF-kB pathway without CTNNB1 
overexpression, whilst 31% had both (i.e. increased CTNNB1 and a deletion in at least 
one gene). Figure 5.3 showed that tumours of the Low immune group were more likely 
to have NFKB1 deletions and high CTNNB1 overexpression, as well as more deaths. In 
prognostic terms, in the whole LMC dataset the effect of CTNNB1 upregulation was 
HR=2.2, P=5x10-5, 95%CI 1.5-3.1; the effect of any deletion in the NF-kB pathway was 
HR=2.03, P=2x10-4, 95%CI 1.4-3; and the effect of a combination of these two pathways 
was HR=3.4, P=5x10-5, 95% CI 2.2-5.5 (Figure 5.5, Table 5.10).  
 
 












0 2 4 6 8 10
analysis time (years)
B-catenin Low/NFKB score Low B-catenin High/NFKB score Low




Table 5.10: Melanoma specific survival analysis of combined Beta-catenin expression 
and NFKB CNA scores 
Combinations of the scores HR P 95% CI 
B-catenin Low/NFKB score Low - - - 
B-catenin High/NFKB score Low 2.03 0.019 1.12 3.67 
B-catenin Low/NFKB score High 2.02 0.005 1.24 3.29 
B-catenin High/NFKB score High 3.35 5x10-5 2.02 5.55 
 
5.4.2 Immunohistochemical staining 
 Antibody optimisation 
The concentrations of the antibodies were chosen based on visual examination of the 
intensity of staining. For the anti-MYC antibody optimised on healthy human tonsil 
tissue I used the concentration of 1:100 (Appendix A.3.1). The same concentration was 
used for anti-HLA-B antibody optimised on healthy human skin (Appendix A.3.2). A 
concentration of 1:250 was selected for the anti-NF-kB1 antibody optimised on healthy 
human sentinel lymph node biopsies. (Appendix A.3.3). 
 Scoring of the stained slides and statistical analysis 
The anti-MYC staining in the melanoma tumours was primarily observed in the nuclei 
and the staining was mostly homogenous, when assessing the staining by eye under 
light microscope. There was a trend to stronger staining for MYC protein in association 
with gene expression across the three staining groups 0, 1 and 2 but this did not reach 
statistical significance (P=0.14). There was a significant correlation when comparing 
high staining (scores 1 and 2 pooled) and absence of staining (0) (P=0.06) (Figure 5.6).  
The staining of HLA-B was predominantly observed on the cellular membrane (as 
expected given the HLAs function) and similarly to MYC the staining was mostly 
homogenous. The transcriptomic expression for HLA-B was incremental across the 
three ascending categories of membranous scores (P=0.006) (Figure 5.7). I observed 
similar results when I reduced the number of categories to 2 (negative and positive 






Figure 5.6: Example photograph of negative (top left) and positive (top right) nuclear 
staining of MYC (magnification 20x) in tumour cells 
The box and dot plots represent mRNA expression of MYC across the three 














































Figure 5.7: Example photograph of negative (top left) and positive (top right) 
membranous staining of HLA-B (magnification 20x) of tumour cells 
The box and dot plots represent gene expression of HLA-B across the three 











































The staining for NF-kB p105 in 29 tumours was observed in the tumour cell nuclei and 
in the cytoplasm, although the cytoplasmic staining was always seen as a pink blush, 
and it was problematic to assess whether it was target specific. NKFB1 gene expression 
did not vary significantly across the cytoplasmic staining scores of NF-kB p105 (P=0.4, 
P=0.1, Figure 5.8). The staining of the nuclei was clearer and more distinct, but the 
positive cells were so rare that looking only around the core would result in too many 
negative scores. Therefore, I counted the positive nuclei across the whole tumour 
(Figure 5.8). The NFKB1 expression was significantly higher in positively stained 
tumours (more than 5 positive nuclei) than in negatively stained (less than 5 nuclei 
stained) (P=0.04). The nuclear staining of NF-kB p105 in the tumour strongly correlated 












Figure 5.8 (following page): Example photograph of negative (top left) and positive 
(top right) nuclear staining of NF-kB p105 (magnification 20x) in both tumour 
cells and TILs 
The star on the right picture shows the positive staining of the TILs. The box and 
dot plots represent gene expression of NFKB1 across the three scoring categories 
(top) and two scoring categories (middle) of the membranous staining. The 


















































































Table 5.11: Cross tabulation of samples with nuclear postive and negative staining of 
NF-kB p105 of the tumour and TILs. Fisher’s exact P=3x10-5 
TILs nuclear 
staining 
Tumour cell nuclear staining 
Score 0 Score 1 Total 
Score 0 10 1 11 
Score 1 2 16 18 
Total 12 17 29 
 
The IHC scoring at the continuous scale using Nuance software could be analysed using 
3 types of metrics: a) percentage of haematoxylin staining (non-antibody specific 
nuclear staining), b) percentage of chromagen staining (overall antibody signal), and c) 
co-localised staining of haematoxylin and chromagen (antibody specific nuclear 
staining). Figure 5.9 below shows examples of such signals. 
 
Figure 5.9: Representative images of negative and positive co-localised signal for MYC 
(top panel) and negative and positive total chromagen signal for HLA-B (bottom 
panel)  
Blue colour indicates haematoxylin, pink is chromagen and yellow show co-







The correlation analyses showed that haematoxylin staining for MYC and HLA-B were 
positively correlated (R=0.6, P=0.002), which indicated consistency in staining (Figure 
5.10).  
 
Figure 5.10: Scatterplot representing the HLA-B scoring (percentage of positive pixels 
for haematoxylin) on the y-axis and MYC (percentage of positive pixels for 
haematoxylin) on the x-axis 
 
The correlation of HLA-B (chromagen) and MYC (haematoxylin + chromagen) on the 
continuous scale was negative (Spearman’s rank correlation: R=-0.6, P=0.02). However, 
this analysis was only the case where more than 1% of pixels were detected for MYC 
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Figure 5.11: Scatterplot representing the HLA-B scoring (percentage of positive pixels 
for chromagen) on the y-axis and MYC (percentage of positive pixels for both 
haematoxylin and chromagen) on the x-axis 
The vertical dashed line indicates MYC detection at less than 1%, which was 
ignored in deriving the best fit (red line). 
5.5 Summary 
In this chapter I showed that: 
• Tumours classified in the Low Immune Subgroup had more CNAs, many of which 
were deletions of genes from NF-kB and IFN-g signalling.  
• In the subset of genes tested, tumour gene expression (mRNA), as determined 
from the transcriptomes correlated with DNA CNAs: lower expression was 
associated with genomic deletion, whilst increased expression was associated 
with amplifications. 
• Majority of observed CNAs predicted poor survival such as amplification of MYC 
and deletions of NF-kB and IFN-g signalling genes. 
• The tumour gene expression levels correlated with protein levels assessed by IHC. 
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The aim of this chapter was to evaluate the observations made on the gene expression 
level using CNA data and protein scores obtained by using IHC. 
5.6.1 CNA 
The main question stated regarding the CNA data was whether the observation made 
on gene expression level in relation to immune responses can be also seen on the DNA 
level. Indeed, it was observed that there was a strong agreement for the results 
obtained from the transcriptomic and CNAs data. 
From the technical perspective, it is important to note that the CNA data was obtained 
from the DNA extracted from tumours that were thicker than average due to 
insufficient material for extraction of RNA and DNA from smaller tissue. Moreover, the 
approach I took to categorise the CNA data could be considered as arbitrary, because 
the categorisation of the continuous CNA data to define amplifications and deletions 
of a given gene can be challenging and there is no set threshold. There are existing 
methods to estimate the relative copy number within tumour data, such as GISTIC 
[214] or ABSOLUTE [215] algorithms. However, at the time I was analysing the CNA 
data none of them had been yet applied to these data. 
However, none of these limitations suggest a bias towards the observed results and 
the concordance between transcriptomic expression and CNA indicates a good 
robustness of the approaches used. 
I observed the variation of CNAs in key genes across the three immune subgroups. MYC 
was identified to be overexpressed in the Low Immune Subgroup on the gene 
expression level and the CNA data showed that the amplifications of MYC were more 
frequently present in that subgroup. Likewise, genes involved in NF-kB and IFN-g 
signalling were downregulated in the Low Immune Subgroup and I hypothesised that 
it might be due to deletions of these genes, which was confirmed by CNA data: many 
of these genes indeed were deleted much more frequently in the Low than in the High 
Immune Subgroup. As expected, the majority of observed DNA structural aberrations 
strongly predicted poor prognosis, and this observation confirm the importance of 
these results. The gene expression level was significantly correlated with CNAs for the 




correlation (for example CTNNB1) could be that gene expression is controlled by many 
other factors (such as promoter methylations, which was confirmed in TCGA data by 
Nsengimana et al. [76]) among which structural variation has only a minor role. 
Moreover, the gene expression might be suppressed or enhanced depending on the 
biological states of the cells irrespective of the DNA copy number.  
The landscape of CNA was already revealed in melanoma and the most frequently 
altered genes were identified [46][50][48]. For example MYC is known to be commonly 
amplified in melanoma [50] and as well as in other cancers [216]. Some of these studies 
were investigating the overall landscape of CNAs across the all melanoma sample types 
analysed together [50][48], and other was focused on categorised samples by driver 
mutations such as BRAF, NRAS and NF1 [46],. None of these studies however directed 
their questions towards effectiveness of the immune responses affected by these 
CNAs.  
The results from this chapter indicate that tumours which manifest low immune cell 
infiltration might have an immune evasion process induced by various mechanisms, 
including deletions of key immune genes (NFKB2, CHUK, IRAK2, MYD88, MAP3K7, JAK2, 
STAT1), amplifications of oncogenes (MYC), and up-regulation of b-catenin signalling. 
Moreover, the fact that these mechanisms were not mutually exclusive suggested that 
some of the tumours could be heterogenic, i.e. different tumour clones acquired 
diverse mechanism of immune evasion. 
These are impactful observations, because if indeed the aberrations induce 
impairment of immune responses to melanoma, they should be further investigated 
regarding immunotherapy resistance. For example mutations in JAK2 gene has already 
been reported to be involved in acquired and primary resistance to anti PD-1 therapy 
[217][218]. In summary, these results might suggest that a significant proportion of 
melanoma tumours in the Low Immune Subgroup may have an intrinsic resistance to 
immunotherapies. 
5.6.2 IHC 
The results from the transcriptomic data were also evaluated using the 
immunohistochemical staining. This approach enables to assess the protein level 




level assessment in FFPE samples, although with some limitations. Firstly, scoring of 
staining of melanoma tumours is challenging due to the strong pigmentation (melanin) 
within some of the tumours, which occasionally cannot be distinguished from the 
actual staining of the protein of interest. To mitigate this problem, we used purple 
instead of brown chromagen, nevertheless the problem still occurred for very 
pigmented tumours. For such tumours it was difficult to differentiate positive purple 
staining among very dark pigment, hence were excluded from the analyses. Secondly, 
staining can sometimes be irregular putatively as a reflection of tumour heterogeneity 
and this becomes a problem when a region surrounding one core is positive and 
another core negative. In this instance the sample was dropped, because it was not 
known which core was used for nucleic acid extraction. Moreover, assessing the 
staining for multiple proteins performed on separate slides for each protein is time 
consuming. There are methods available for simultaneous multi-antigen detection, 
but, usually they require usage of fluorochrome rather than chromagen [105][106] and 
are much more expensive than single-antigen detection. Finally, due to ethical issues 
tumour blocks were available only for samples from deceased patients, which 
restricted the statistical power and also may have potentially biased the results.  
Despite these caveats, I was able to demonstrate a positive association of IHC scores 
for the three proteins (MYC, HLA-B, and NF-kB p105) with measured gene expression 
in the tumours. However, in case if the gene expression did not correlate with IHC 
staining, the explanation could be that the protein of interest was posttranslationally 
modified, which could affect the epitope structure and the interaction with the 
antibody.  
Importantly staining was seen in the cellular components that were expected, for MYC 
and NF-kB p105 in the nucleus and HLA-B on the cellular membrane. There was a 
similar negative correlation between HLA-B and MYC on the protein level as on gene 
expression level in both the LMC dataset and patient-derived melanoma cell lines. 
However, the MYC-HLA-B correlation at protein level was negative only when MYC was 
detectable in the slides in more than 1% (Figure 6). Under this threshold, which is very 
low and could reflect the absence of MYC protein, HLA-B protein took a wide range of 
values, suggesting the existence of other regulators of HLA-B in the absence of MYC. 




posttranslational modifications of this protein as reported by Dellgren et al. [219]. 
Nevertheless, this result was remarkable given the challenge of MYC and HLA-B protein 
scoring on different slides from the same FFPE tumour block, which was very 
challenging. Ideally the experiment should be designed to performed dual (multi-
antigen) staining for both MYC and HLA-B with different colours of chromagen per 
antigen.  
Furthermore, IHC staining analysis showed that tumour nuclear localization of NF-kB 
p105 significantly positively correlated with TILs and with the gene expression of 
NFKB1, suggesting a reciprocal interaction of NF-kB signalling between tumour and 
immune cells. This fact and the observation that the deletions of the genes involved in 
the NF-kB signalling pathway were more frequent in the Low Immune Subgroup and 
were associated poor survival confirmed that this signalling pathway indeed might play 






Survival analysis of prognosis predictors in melanoma in 
relation to immune response 
6.1 Aims 
In Chapter 3, I reported the identification of three immune subgroups of primary 
melanomas. In this chapter I describe an investigation of the determinants of survival 
within the immune subgroups. The aims were: 
• To analyse the association between reported (smoking) or measured 
environmental factors (vitamin D levels) and melanoma specific survival (analysis 
adjusted for known prognosis predictors) in the whole dataset and in each of the 
three immune subgroups. 
To perform survival analyses taking under consideration total mutational load: 
• To test the association between a measure of mutational load and melanoma 
specific survival (analysis adjusted for known prognosis predictors). 
• To test this association within each of the immune subgroups. 
6.2 Background 
In Chapter 1, the known predictors of prognosis, such as AJCC stage, sex, age, mitotic 
rate, and site of melanoma were already described. As recently reviewed by Chen and 
Mellman et al. [87], effective cancer cell killing by immune cells is a multistep process 
which can be rendered ineffective at multiple points along the way. Chen and Mellman 
et al. described the potential effects of variation in host genetics, differences in the 
microbiome, environmental exposures, therapeutic agents and cancer cells themselves 
leading e.g. to inability to present tumour antigen/neoantigens, or suppression of 
immune responses by checkpoint molecule expression. I have already described 
evidence (Chapter 4 and 5) that tumour variation e.g. deletion of genes coding for the 
NF-kB signaling pathway or expression of oncogenic MYC might play a role in 




In this chapter I present an analysis of two environmental exposures, smoking and 
vitamin D levels for which the Leeds Melanoma Research Group has already identified 
a role in melanoma specific survival. Moreover, I present the initial analysis of LMC 
mutational load data (with the assumption that it might represent the neoantigen 
load). Overall, I report here an investigation of possible interaction effects on survival 
from these variables and immune responses.  
6.2.1 Environmental factors 
The Leeds Melanoma Research Group has previously explored the biological 
significance of microscopic ulceration and identified some evidence for a role for 
environmental exposures in melanoma progression. The group first performed an 
immunohistochemical study of ulcerated tumours and reported them to have higher 
vascularity and more macrophages [220]. Subsequent transcriptomic studies identified 
a “chronic wound healing” - chronic inflammatory gene expression phenotype [120]. 
The group then argued that if there was chronic inflammation in tumours, then 
ulceration might be more frequent in people with systemic inflammation [221]. 
Ulceration was shown to be more common in the obese patients, the vitamin D 
deficient, smokers and diabetics in univariable analysis but only smoking and vitamin 
D deficiency were associated independently with ulceration and poorer melanoma 
specific survival [221].  
I chose then to look at smoking and vitamin D levels as predictive of survival in the 
three immune subgroups. Since smoking and vitamin D levels (Chapter 3) did not vary 
across the three immune subgroups, I hypothesised that they might interact with these 
groups in terms of survival.  
The Leeds Melanoma Research Group has had a long-standing interest in the role of 
vitamin D in melanoma progression since participants in the Leeds Melanoma Cohort 
displayed an inverse relationship between vitamin D levels and tumour thickness [114]. 
Melanoma specific survival was also superior in those with higher levels of vitamin D 
independently of tumour thickness [221]. Four subsequent studies from three 
continents also reported an inverse relationship between vitamin D levels at diagnosis 
and Breslow thickness [222][223][224][225]. Vitamin D has been shown to inhibit 




C Reactive Protein (an inflammatory marker) [227] and that low levels are associated 
with autoimmunity and increased risk of infection [89]. These observations led to the 
hypothesis that vitamin D may be antiproliferative for melanoma cells but that it may 
also have a beneficial effect via reduction of systemic inflammation [228]. 
In my thesis I have used vitamin D levels in the survival analysis: I have not attempted 
to learn anything more about the role of vitamin D in melanoma progression. An in 
depth biological investigation of this environmental factor was a PhD project 
(simultaneous to my project) of Sathya Muralidhar, Marie Skłodowska-Curie PhD 
student.  
Cigarette smoking is a globally detrimental environmental factor and it is known to be 
the preventable cause of deaths from many different cancer types [229] and this factor, 
as well as deficiency of vitamin D was of interest to the Leeds Melanoma Research 
Group. The contribution of smoking and risk of melanoma development is uncertain 
and some studies even proposed a controversial protective effect of tobacco smoking 
on melanoma development [230][229][231]. As mentioned above, the Leeds 
Melanoma Research Group has reported that cigarette smoking was associated with 
poor melanoma specific survival and with ulceration in the LMC [221]. A later (2017) 
study performed by an independent research group confirmed that smoking was 
predicting poor outcome and additionally revealed that that it was associated with a 
greater likelihood of melanoma metastasis to sentinel lymph nodes [232]. This study 
and one more additionally reported that higher tumour thickness was associated with 
smoking [232][233]. 
These evidences indicate that a biological interaction between smoking and melanoma 
progression might occur, however the exact mechanisms behind this have not yet been 
elucidated.  
Some studies reported that cigarette smoking affects immune responses systemically: 
that it might induce systemic inflammation or cause immunosuppression [88]. A study 
analysing systemic inflammatory markers from participants suffering from prostate, 
lung, colorectal, and ovarian cancer, demonstrated that smokers had higher levels of 
some of these inflammatory markers than non-smokers [234]. Smoking associated 




exposed to inhaled chemicals from the cigarettes. In other types of cancer this 
phenomenon was not widely studied, yet smoking was described as a risk factor for 
various cancer types [88].  
The Bauer laboratory compared measures of the circulating immune cells between 
smokers and non-smokers and were able to identify associated methylation of some 
genes, which were occasionally followed by changes in their expression [236][237]. 
One of these genes was GRP15, which is known to be hypo-methylated in CD3+ T cells 
in smokers and this alteration in CpG sites was assumed to mediate enhanced gene 
expression of GPR15. However the causative effect of smoking on methylation of 
GPR15 was not evidenced [237]. GPR15 is non-the-less considered to be a biomarker 
of smoking being overexpressed in circulating immune cells in smokers in comparison 
to non-smokers [236][237] but its full biological function and significance is not yet 
understood. It was however proposed that the high expression of GPR15 might be 
involved in inflammatory states in the intestine and skin epithelial cells in smokers 
[238].  
In this chapter I report an investigation of the relationship between immune status, 
smoking and GPR15 expression in the LMC transcriptomic data set. 
6.2.2 Mutational load 
Adaptive immunity requires that tumour cells express antigenic peptides which might 
serve as neoantigens or self-antigens to which T cell tolerance is incomplete e.g. as a 
result of restricted tissue expression [239]. Neoantigens are peptides generated by the 
degradation of abnormal proteins, which are detected by the cell as intruders 
potentially harmful for the cell functions. Tumour antigens/neoantigens are presented 
via MHC class I to the immune cells (as described in Chapter 1). In order to trigger 
effective immune responses against melanoma the neoantigens must be broken down 
into smaller molecules that can be successfully presented to the effector immune cells 
present within the tumour microenvironment [87][239]. 
In principle it is expected that melanoma tumours having a high mutational load (and 
hence putatively more neoantigens) will have a more favourable survival, due to the 
greater likelihood of activation of adaptive anti-tumour immune responses. It is of note 




play an important role in anti-tumour immunity and do not require antigen 
presentation, such as innate immune responses. For example, if a tumour of a patient 
does not produce/present neoantigens but generates signals that activate e.g. NK cells, 
which effectively kill the tumour cells, the patient might still manifest relatively good 
survival.  
For primary melanoma, there has not yet been any reported association between 
mutational load and survival. However, many studies concentrating on 
immunotherapy treatment responses in metastatic melanoma have shown survival 
benefit for patients having higher mutational load [145][146][147] (as described in 
Chapter 3). As I defined in Chapter 3, I found no significant difference in mutational 
load across the three immune subgroups. Although, as discussed earlier, since the data 
were generated for candidate cancer genes rather than on the whole genome, these 
mutation data might not represent the true neoantigen load that triggers immune 
responses. Nevertheless, these data were used to test whether an association with 
survival in relation to the three immune subgroups could be observed.  
6.3 Methods 
6.3.3 Survival analysis 
The survival analyses were firstly performed for environmental together with clinico-
histopathological factors. The mutational load variable was afterwards analysed 
adjusting the factors significantly predicting prognosis in the first analysis. This order 
was reasoned by the fact that the data for mutational load was available only for 319 
of the 703 tumours, which would significantly reduce the power of the overall model if 
all variables were tested together. 
 Environmental factors 
Firstly, using a univariable Cox proportional hazard model, the association between the 
clinical and environmental variables (AJCC staging, age at diagnosis, sex (females vs 
males), site of melanoma (limbs vs the rest), smoking (ever vs never) and vitamin D 
levels at recruitment (season-adjusted) with MSS were tested in the whole 703 LMC 




whole survival model but repeated all analyses using 2 other variables describing 
smoking habits: duration of smoking and packs of cigarettes smoked per year.  
Subsequently, the significant clinical and environmental predictors from the 
univariable model were tested in a multivariable model adjusting the immune 
subgroups. 
Finally, a multivariable Cox proportional hazard analysis was conducted within each 
immune subgroup using the predictors that showed the strongest degree of 
independence from the previous analysis (Figure 6.1).  
 
Figure 6.1: Schematic work-flow of the survival analyses 
 
 Mutational load 
The derivation of the mutation count variable was explained in Chapter 2. Briefly, it 
represented the mutation count per megabase for a panel of 555 genes, which was 





Figure 6.2: Histogram representing the density of samples for the total mutation 
count per megabase for 555 gene panel 
The red lines show the points where the data were divided into three groups 
(high, low, intermediate).  
 
Association between the three groups of total mutational load in the whole data set 
(N=521) and survival was tested using a univariable Cox proportional hazard model. 
Subsequently a multivariable Cox proportional hazard model for mutational load was 
applied adjusting other prognostic factors. Finally taking the predictors with the 
strongest degree of independence from the multivariable analysis in the whole dataset 
I tested their association with survival within each of the three immune subgroups 
using a multivariable model. 
Taken together, the variables used for the survival analyses were: 
• Age at diagnosis (continuous, years) 
• Site of melanoma (%) - Rest (Head, Trunk, Rare) vs limbs, (see details in Chapter 
2) 
• Sex (females vs males) 
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• AJCC stage (%) (I vs II vs III trend) 
• Smoking (ever vs never) 
• Duration of smoking (years) 
• Reported packs of cigarettes smoked per year 
• Season-adjusted serum vitamin D at recruitment (continuous, nmol/L), 
• Categorised mutational load (high vs intermediate vs low). 
All these variables were described in detail in Chapter 2. 
6.3.4 Comparative analysis of the tumours by smoking status 
In order to explore the biological role of smoking, I then took an agnostic approach to 
analysis of the transcriptomic data. I hypothesised that if smoking was mediating an 
effect on host tumour interaction, then associated biological pathways would be 
identified in differential gene analyses comparing smokers with non-smokers. I also 
considered a candidate gene approach: I asked if the expression of genes coding for 
cytokines and their receptors, and inferred immune cell subgroups were associated 
with reported smoking. I listed the genes for 133 cytokines and their receptors from 
the Human Genome Organisation (HUGO) database (https://www.genenames.org). 
These and the immune cell scores were compared between smokers and never 
smokers using the Kruskal Wallis test and those with Benjamin-Hochberg FDR<0.05 
were considered significant. The analyses were repeated however with the restriction 
to the immune subgroup for which the smoking status predicted prognosis in the 
strongest manner. 
I sought to replicate a published finding that GPR15 expression is a marker of smoking 
in the blood [236][237] by testing the variation of this gene by smoking status in the 
tumours with the Kruskal Wallis test. To test whether GPR15 was associated with 
inflammatory states in the LMC tumour samples, as suggested in the literature [238] I 
tested the expression correlation with the list of genes coding for 133 cytokines and 
their receptors from the HUGO database (https://www.genenames.org) as above in 






6.4.1 Environmental factors 
In a univariable Cox proportional hazard model, AJCC staging, smoking (ever/never), 
duration of smoking, average packs of cigarettes smoked per year, site of melanoma, 
age at diagnosis, sex and tumour mitotic rate were significantly predictive of MSS while 
vitamin D levels was not statistically significant (Table 6.1).  
Table 6.1: Table representing results from univariable Cox proportional hazard model 
AJCC stage was categorized as stage I, II or stage III. Mitotic rate is the count of 
mitoses per mm2. Duration of smoking was measured in years. Sex was tested for 
males vs females. Site of melanoma was tested for rest vs limbs. Smoking was 
tested as ever vs never. HR means melanoma specific death hazards ratio. 
Predictor HR P 95% CI 
AJCC stage 2.46 1.2x10-16 1.99 3.05 
Age at diagnosis 1.03 2.4 x10-8 1.02 1.05 
Mitotic rate 1.03 2.2 x10-7 1.02 1.04 
Sex (males) 1.5 0.008 1.1 1.9 
Duration of smoking 1.02 3.4 x10-6 1.01 1.03 
Site (rest) 1.91 1.5 x10-5 1.41 2.59 
Packs per year 1.02 6.5 x10-5 1.01 1.03 
Smoking (ever) 1.63 0.001 1.21 2.20 
Vitamin D 0.99 0.089 0.99 1.00 
 
In the multivariable Cox model when testing the independence factors found 
significant in the univariable model, the AJCC, smoking (ever vs never), site of 
melanoma, age at diagnosis, and mitotic rate remained significant (Table 6.2). When 
the significant predictors of MSS were tested within each of the immune subgroups, 
using the multivariable model, different variables were found to be significant in each 
of the subgroups. Interestingly, smoking (ever vs never) remained the most striking 
predictor of prognosis in the High Immune Subgroup (Table 6.2). The hazard ratio was 





Table 6.2: Multivariable Cox proportional hazard model for the environmental and 
clinico-histopathological variables significantly predicting prognosis (including 
“smoking”: never/ever) in the univariable model, in the whole dataset and each 
immune subgroup 
AJCC stage was categorized as stage I, II or stage III. Site of melanoma was tested 
for rest vs limbs. Age at diagnosis was reported in years. Mitotic rate is the count 
of mitoses per mm2. HR means melanoma specific death hazard ratio. 
Predictor HR SE z P 95% CI 
OVERALL (N=666) 
AJCC stage 2.05 0.26 5.58 <10-7 1.59 2.64 
Smoking (ever) 1.45 0.25 2.14 0.03 1.03 2.04 
Site (rest) 1.64 0.32 2.51 0.01 1.11 2.41 
Age at diagnosis 1.03 0.01 4.26 <10-4 1.02 1.05 
Sex (males) 0.97 0.17 -0.14 0.89 0.69 1.38 
Mitotic rate 1.02 0.01 2.67 0.01 1.00 1.03 
Inter. cluster vs Low 0.76 0.14 -1.52 0.13 0.53 1.08 
High cluster vs Low 0.63 0.16 -1.86 0.06 0.39 1.03 
LOW IMMUNE (N=202) 
AJCC stage 2.01 0.37 3.82 <10-3 1.40 2.87 
Smoking (ever) 0.92 0.23 -0.34 0.73 0.56 1.51 
Site (rest) 1.98 0.56 2.42 0.02 1.14 3.43 
Age at diagnosis 1.03 0.01 3.1 0.002 1.01 1.06 
Mitotic rate 1.01 0.01 1.11 0.27 0.99 1.03 
INTERMEDIATE (N=207) 
AJCC stage 1.75 0.39 2.51 0.01 1.13 2.72 
Smoking (ever) 1.78 0.51 1.99 0.05 1.01 3.13 
Site (rest) 1.36 0.41 1.02 0.31 0.75 2.46 
Age at diagnosis 1.03 0.01 2.32 0.02 1.00 1.06 
Mitotic rate 1.04 0.01 3.55 <10-3 1.02 1.06 
HIGH IMMUNE (N=122) 
AJCC stage 3.99 1.47 3.74 <10-3 1.93 8.23 
Smoking (ever) 4.59 2.35 2.97 0.003 1.68 12.53 
Site (rest) 2.52 1.31 1.78 0.08 0.91 6.99 
Age at diagnosis 1.05 0.02 2.24 0.03 1.01 1.10 





The Kaplan Meier plot in Figure 6.3 is a graphical representation of the smoking effect 
in the whole LMC cohort. Ever smoking was associated with a significantly worsened 
survival. 
 
Figure 6.3: Kaplan Meier plot for ever vs never smoking in the whole dataset 
P from multivariable analysis adjusting for prognostic factors. 
 
In Figure 6.4 to Figure 6.6, Kaplan Meier plots show the different survival profiles 
associated with smoking in Low, Intermediate and High Immune Subgroups 
respectively. It can be seen that the effect of having ever smoked was the strongest in 
participants with tumours assigned to the High Immune Subgroup. There is a clear 
trend with the increasing strength of immune responses: no smoking effect (P=0.73) in 
low immune tumours, moderate effect (HR=1.8, P=0.05) in intermediate immune 






























































































Figure 6.4: Kaplan Meier plot for ever vs never smoking in the Low Immune Subgroup 
P from multivariable analysis adjusting for prognostic factors. 
 
Figure 6.5: Kaplan Meier plot for ever vs never smoking in the Intermediate Immune 
Subgroup 























































































































































































Figure 6.6: Kaplan Meier plot for ever vs never smoking in the High Immune Subgroup 
P from multivariable analysis adjusting for prognostic factors. 
 
I replicated the above observation using two more variables describing reported habits 
of smoking: duration of smoking and average packs smoked per year. All these 
variables were strong hazard factors for melanoma death in the High Immune 
Subgroup (HR=1.04, P=<0.001; HR=1.03, P=0.01, respectively) and less so in the 
Intermediate Immune Subgroup (HR=1.01, P=0.19; HR=1.02, P=0.09, respectively), 
with the weakest effect seen for average cigarette packs smoked per year in the Low 
Immune Subgroup (HR=0.01, P=0.23; HR=1.01, P=0.02, respectively). The difference in 
strengths of these HRs within one immune subgroup reflects the different units they 
correspond to: for example the effect of smoking for one year is not the same as 
smoking one pack per year.  
AJCC stage and age at diagnosis strongly predicted MSS in each of the immune 
subgroups (Table 6.2, Table 6.3, Table 6.4). Site of melanoma was the strongest 
predictor of MSS in the Low Immune Subgroup (Table 6.2, Table 6.3, Table 6.4). Mitotic 
rate had the strongest effect in the Intermediate Immune Subgroup (Table 6.2, Table 






























































































Table 6.3: Multivariable Cox proportional hazard model for the environmental and 
clinico-histopathological variables significantly predicting prognosis (including 
the “duration of smoking” variable) in the univariable model, in the whole 
dataset and each immune subgroup 
AJCC stage was categorized as stage I, II or stage III. Site of melanoma was tested 
for rest vs limbs. Age at diagnosis was reported in years. Mitotic rate is the count 
of mitoses per mm2. HR means melanoma specific death hazard ratio. 
Predictor HR SE z P 95% CI 
OVERALL (N=527) 
AJCC stage 2.03 0.26 5.49 <10-3 1.58 2.61 
Duration of smoking 1.02 0.01 2.9 0.004 1.00 1.03 
Site (rest) 1.65 0.32 2.56 0.01 1.12 2.43 
Age at diagnosis 1.03 0.01 4.04 <10-3 1.02 1.05 
Sex (males) 0.91 0.17 -0.49 0.62 0.64 1.30 
Mitotic rate 1.02 0.01 2.88 0.004 1.01 1.03 
Inter. cluster vs Low 0.81 0.15 -1.14 0.26 0.56 1.17 
High cluster vs Low 0.65 0.16 -1.75 0.08 0.40 1.05 
LOW IMMUNE (N=200) 
AJCC stage 1.95 0.36 3.64 <10-3 1.36 2.79 
Duration of smoking 1.01 0.01 1.2 0.23 0.99 1.02 
Site (rest) 1.78 0.49 2.07 0.04 1.03 3.06 
Age at diagnosis 1.03 0.01 2.79 0.005 1.01 1.05 
Mitotic rate 1.01 0.01 1.13 0.26 0.99 1.03 
INTERMEDIATE (N=207) 
AJCC stage 1.74 0.38 2.5 0.01 1.13 2.68 
Duration of smoking 1.01 0.01 1.3 0.19 0.99 1.03 
Site (rest) 1.43 0.43 1.19 0.23 0.79 2.60 
Age at diagnosis 1.03 0.01 2.25 0.03 1.00 1.06 
Mitotic rate 1.04 0.01 3.61 <10-3 1.02 1.06 
HIGH IMMUNE (N=120) 
AJCC stage 3.14 1.13 3.19 0.001 1.55 6.34 
Duration of smoking 1.04 0.01 3.14 0.002 1.01 1.06 
Site (rest) 1.97 1.04 1.29 0.20 0.70 5.53 
Age at diagnosis 1.04 0.02 1.9 0.06 1.00 1.09 




Table 6.4: Multivariable Cox proportional hazard model for the environmental and 
clinico-histopathological variables significantly predicting prognosis (including 
the “packs cigarettes per year” variable) in the univariable model, in the whole 
dataset and each immune subgroup 
AJCC stage was categorized as stage I, II or stage III. Site of melanoma was tested 
for rest vs limbs. Age at diagnosis was reported in years. Mitotic rate is the count 
of mitoses per mm2. HR means melanoma specific death hazards ratio. 
Predictor HR SE z P 95% CI 
OVERALL (N=507) 
AJCC stage 2.13 0.28 5.75 <10-3 1.65 2.76 
Packs per year 1.02 0.00 3.48 0.001 1.01 1.03 
Site (rest) 1.65 0.32 2.58 0.01 1.13 2.40 
Age at diagnosis 1.03 0.01 3.24 0.001 1.01 1.04 
Sex (males) 0.97 0.18 -0.14 0.89 0.68 1.40 
Mitotic rate 1.01 0.01 2.11 0.04 1.00 1.03 
Inter. cluster vs Low 0.79 0.15 -1.24 0.21 0.55 1.14 
High cluster vs Low 0.57 0.15 -2.16 0.03 0.35 0.95 
LOW IMMUNE (N=190) 
AJCC stage 1.98 0.36 3.75 <10-3 1.38 2.82 
Packs per year 1.01 0.01 2.38 0.02 1.00 1.03 
Site (rest) 1.98 0.56 2.43 0.02 1.14 3.44 
Age at diagnosis 1.02 0.01 2.13 0.03 1.00 1.05 
Mitotic rate 1.00 0.01 0.34 0.73 0.98 1.02 
INTERMEDIATE (N=202) 
AJCC stage 1.89 0.44 2.72 0.01 1.19 2.98 
Packs per year 1.02 0.01 1.71 0.09 1.00 1.04 
Site (rest) 1.44 0.42 1.23 0.22 0.81 2.57 
Age at diagnosis 1.03 0.01 2.05 0.04 1.00 1.05 
Mitotic rate 1.03 0.01 3.22 0.001 1.01 1.06 
HIGH IMMUNE (N=116) 
AJCC stage 4.28 1.74 3.58 <10-3 1.93 9.51 
Packs per year 1.03 0.01 2.49 0.01 1.01 1.05 
Site (rest) 1.50 0.76 0.8 0.43 0.55 4.07 
Age at diagnosis 1.04 0.02 1.63 0.10 0.99 1.08 





Smoking is known to be associated with deprivation [240]. The deprivation index in the 
LMC cohort was recorded as a Townsend score, based on the residence area (post 
code). Therefore, I took advantage of the information included in LMC and tested if the 
smoking effect (ever vs never) on survival was confounded by deprivation status. 
The results showed that the hazard ratio and the P value for the detrimental effect of 
smoking on MSS was the same before and after adjustment for Townsend score: 
HR=1.6 P=0.001, indicating that the smoking effect was unlikely to be confounded by 
deprivation. 
Taken together, reported smoking was shown to be associated with worse outcome 
independently to other known melanoma specific survival predictors and socio-
economic status, with the strongest effect being observed in the High Immune 
Subgroup.  
6.4.2 Comparative analysis of the tumours by smoking status 
 Agnostic analysis of the transcriptomic data 
I tested whole transcriptome differences in the tumours excised from smokers 
compared with non-smokers. No gene was significantly differentially expressed by 
tumours removed from participants who smoked and those who did not, after multiple 
testing correction (Benjamini-Hochberg FDR<0.05) in the whole dataset (see the top 20 
genes in Appendix A.4.1) and in the High Immune Subgroup (top 20 genes in Appendix 
A.4.2). 
 Clinico-histopathological factors and immune cell scores  
Subsequently, in order to understand the biological differences in the tumours 
between smokers and never smokers I tested whether the clinico-histopathological 
characteristics differed between these two groups. In the whole dataset, smoking was 
associated with thicker tumours (Breslow Thickness) (P=0.008), and with a higher 
mitotic rate at a borderline significant level (P=0.09) (Table 6.5). However, smoking 
status did not differ with ulceration status as previously reported in LMC [221], but this 
is likely to reflect weaker statistical power compared for the previous study which was 
based on more than 2000 patients [221]. When the analysis was restricted to the High 




Table 6.5: Variation of clinico-histopathological features of the tumours between 
ever and never smokers in the whole dataset 
Characteristic Ever smokers Never Smokers P-value (N) 
Number of participants (658) 334 324  - 
Ulcerated (%) 35.1 35.2 0.2 (658) 
Breslow thickness (median, 
mm) 
2.4 2.1 0.008 (648) 
Mitotic rate (median, 
count/mm2) 
4 3 0.09 (559) 
TILs (%) (as determined by 
clinic dermatopathologists) 
     Brisk 
     Non-brisk 
     Unclassified 
















TILs (%) – (single observer, S 
O’S) 
     Brisk 
     Non-brisk 
















Table 6.6: Variation of clinico-histopathological features of the tumours between 
ever and never smokers in the High Immune Subgroup  
Characteristic Ever smokers Never Smokers P-value (N) 
Number of participants (152) 74 78   
Ulcerated (%) 34 26 0.27 (152) 
Breslow thickness (median, 
mm) 
2.2 1.95 0.51 (149) 
Mitotic rate (median, 
count/mm2) 
3.5 2 0.08 (129) 
TILs (%) (clinic 
dermatopathologists) 
     Brisk 
     Non-brisk 
     Unclassified 













TILs (%) – (single observer, S 
O’S) 
     Brisk 
     Non-brisk 












As there was an interaction effect on survival between immune subgroups and 
smoking, I further asked if there were differences in immune cell scores by smoking. I 
tested the differential expression of 27 immune cell scores between ever and never 
smokers in the whole dataset and in the High Immune Subgroup. However, this analysis 
did not show any significant results even before adjusting for multiple testing (Table 
6.7). The score for plasmacytoid dendritic cells was only close to being significant 






Table 6.7: Differences in immune cell scores between ever and never smokers in the 
whole dataset and the High Immune Subgroup  
Negative Z score indicates higher score in ever smokers. 
 Whole data High Immune Subgroup 
Cell Type Z score P value Z score P value 
Activated B cells -0.74 0.46 0.36 0.72 
Central memory CD4 -0.78 0.44 -0.31 0.76 
Central memory CD8 -0.51 0.61 -0.72 0.47 
Cytotoxic cells -0.94 0.35 1.52 0.13 
DC -0.04 0.97 -0.87 0.38 
Effector memory CD8 -0.80 0.42 0.54 0.59 
Eosinophil -0.48 0.63 -0.13 0.89 
iDC -1.21 0.23 -0.28 0.78 
Immature B cells -1.28 0.20 -0.01 0.99 
Macrophages -0.61 0.54 0.52 0.6 
Mast cells -0.89 0.37 -1.04 0.3 
MDSC -1.28 0.20 -0.22 0.82 
Memory B cells -1.52 0.13 -0.87 0.39 
Monocytes -1.66 0.10 -0.62 0.53 
Neutrophils -0.09 0.93 0.61 0.54 
NK -0.94 0.35 0.52 0.61 
NK56 bright -0.46 0.65 1.6 0.11 
NK56 dim 1.02 0.31 0.04 0.97 
NKT -0.01 1.00 0.9 0.37 
pDC -1.09 0.28 -1.8 0.07 
T cells -0.60 0.55 -0.37 0.71 
TFH -0.17 0.86 1.23 0.22 
TGD -1.01 0.31 0.63 0.53 
Th1 -0.70 0.48 0.28 0.78 
Th17 0.90 0.37 0.78 0.43 
Th2 -0.87 0.38 -0.98 0.33 







Since GPR15 is known as a marker of smoking in circulating immune cells [236][237], I 
tested whether its tumour expression was associated with smoking status in the LMC. 
Surprisingly, the data showed that GPR15 expression was not significantly higher in the 
tumours of ever compared to never smokers in the whole dataset of 703 tumours 
(P=0.12), but GPR15 expression was significantly higher in tumours of ever smokers 
compared to never smokers of the High Immune Subgroup, even though the statistical 
power was lower in this subset (P=0.02) (Table 6.8). Using still smoker vs non-smoker 
as an alternative definition of the smoking variable, GPR15 expression was slightly 
higher in tumours of still smokers in both the whole dataset (P=0.01) and the High 
Immune Subgroup (P=0.002) (Table 6.9).  
Table 6.8: Association of GPR15 gene expression between ever and never smoking in 
the whole dataset and the High Immune Subgroup 
GPR15 
Ever (mean of 
log2 gene 
expression) 





Whole dataset 8.0 7.9 1.07 0.12 
High Immune 8.5 8.1 1.32 0.02 
 
Table 6.9: Association of GPR15 gene expression between non and still smokers in 
the whole dataset and the High Immune Subgroup 
GPR15 
Non-smokers  
(mean of log2 
gene expression) 
Still smokers  




Whole dataset 7.9 8.3 1.32 0.01 
High Immune 8.1 9.0 1.87 0.002 
 
Moreover, when I tested the expression of GRP15 across the three immune subgroups 
restricting the analysis only to “ever smokers” or “never smokers”, I observed that 







Figure 6.7: Expression (log2 scale) of GPR15 across the three immune subgroups 
restricted to never (top) and ever smokers (bottom) 
 Analysis of GPR15 expression in peripheral blood transcriptomes 
As our group have also generated gene expression data from peripheral blood from 
melanoma patients in an independent patient cohort, Dr John Davies (Senior 
statistician in the group) tested the whole transcriptome differences between non-
smokers and still smokers. Importantly the most significantly differentially expressed 
gene after multiple correction was GPR15 (P=1.5x10-5, data not shown), which 
corroborated the existing literature, suggesting that GPR15 is higher in peripheral 












































 GPR15 and cytokines 
Following the literature suggestions that GPR15 might be involved in inflammatory 
conditions and the above results that GPR15 correlated with smoking status 
particularly in the High Immune Subgroup I further tested the correlation between 
GPR15 tumour expression and the expression genes coding for cytokines and their 
receptors. 
The top positively correlating gene with GPR15 was Chemokine (C-X-C motif) ligand 3 -
CXCL3 (R=0.27, P=0.001). Among the other strong positively correlating genes (coding 
for cytokines and their receptors) with GPR15 in the High Immune Subgroup were: 
Interleukin 6 - IL6 (R=0.14, P=0.09), Interleukin 6 Receptor - IL6R (R=0.19, P=0.016), and 
Interleukin 6 Signal Transducer: - IL6ST (R=16, P=0.01) genes. It is of note that the 
correlations with GPR15 expression values were weak overall and the results were not 
corrected for multiple testing. The 0.05 alpha threshold would be 0.0004 after multiple 
testing correction (Bonferroni, 133 tests) and none of the correlations reaches this 
level. However, it is of interest that 12 genes reached significance (unadjusted 0.05 
level, Table 7) when no more than 7 were expected by chance. 
Table 6.10: Cytokines and their receptors most strongly correlated with GRP15 in the 
High Immune Subgroup, Spearman’s rank correlation  
Gene name P-value R 
CXCL3 0.001 0.27 
IL18R1 0.003 0.24 
IL7R 0.01 0.22 
CCL21 0.01 0.21 
IL6ST 0.01 0.20 
CCL19 0.02 0.19 
IL15 0.02 0.19 
IL6R 0.02 0.19 
IL32 0.04 0.17 
CXCL12 0.03 0.17 
CXCR6 0.05 0.16 
CCR4 0.05 0.16 
IL11RA 0.07 0.15 
IL6 0.09 0.14 
CCR2 0.08 0.14 
IL9 0.08 0.14 





A similar analysis conducted in TCGA dataset (metastatic tumours) confirmed that the 
expression of IL6ST and IL6R were positively correlated with GPR15 in the High Immune 
Subgroup (R=0.4, P=0.0003; R=0.3, P=0.01, respectively), while IL6 (R=-0.2, P=0.9) and 
CXCL3 (R=-0.2, P=0.1) were not. 
In the whole LMC dataset, none of these three genes was correlated with GPR15: IL6 
(R=0.04, P=0.3), IL6R (R=0.05, P=0.2), IL6ST (R=-0.03, P=0.5). In the whole TCGA dataset 
IL6R (R=0.13, P=0.02) and IL6ST (R=0.2, P=0.0004) were positively correlated with 
GPR15, but less so than in the High immune Subgroup. To add a layer of complexity, 
IL6 (R=0.2, P=0.0004) was positively correlated with GPR15 in the whole TCGA dataset, 
although it was not in the High Immune Subgroup.  
Summarising, the correlation between IL6R and IL6ST with GPR15 were consistent in 
the LMC and TCGA High Immune Subgroup. 
 GPR15 and ulceration 
To further explore the relationship between GPR15 and inflammation, I tested whether 
the expression of GPR15, CXCL3, IL6, IL6R, and IL6ST varied with ulceration status since 
the Leeds Melanoma Group has reported that tumour ulceration was associated with 
transcriptomic evidence of wound healing inflammation in a subset of this cohort (200 
tumours) [120]. While GPR15, CXCL3, IL6R, and IL6ST expression did not significantly 
vary between ulcerated and non-ulcerated tumours (P=0.5, 0.9, 0.8, 1.0, respectively), 
IL6 itself was significantly more expressed in ulcerated than in non-ulcerated tumours 
(P=1.2x10-5) (Figure 6.8), consistently with the earlier report  [120]. 
Taken together these data suggest that GPR15 might be associated with inflammatory 
IL6 signalling in the High Immune Subgroup as the results from the LMC were consistent 
with TCGA. Moreover, GPR15 correlated positively with CXCL3, however only in the 
LMC which could potentially be the result of biological differences between primary 







Figure 6.8: Expression of GPR15 (top) and IL6 (bottom) between non-ulcerated and 
ulcerated tumours 
 
6.4.3 Mutational load 
The survival analysis of the three immune subgroups by mutational load in the whole 
dataset showed that a high mutational load predicted the most favourable prognosis 
(HR=0.6, P=0.06) and no difference was seen between low and intermediate 
mutational loads (HR=1.3, P=0.3) (Figure 6.9). Similar results were observed in the Low 
Immune Subgroup (Figure 6.10), while in the Intermediate Subgroup none of the 
mutational load groups predicted prognosis (Figure 6.11. In the High Immune 
Subgroup, the results showed that high mutational load predicted even better 
prognosis compared to other subgroups (in fact all 21 patients who were classified in 












































Mutational load HR P 95% CI 
Low  - - - - 
Intermediate 1.3 0.3 0.79 2.1 
High 0.6 0.06 0.3 1.02 
Figure 6.9: Kaplan Meier plot for three mutational load groups in the 
whole dataset (N=301) 
Table represents the results from a univariable Cox proportional 
hazard model. 
 
Mutational load HR P 95% CI 
Low  - - - - 
Intermediate 1.0 1.0 0.5 2.0 
High 0.4 0.03 0.2 1.8 
Figure 6.10: Kaplan Meier plot for three mutational load groups in the 
Low Immune Subgroup (N=117)  





















































































































































































Mutational load HR P 95% CI 
Low  - - - - 
Intermediate 0.8 0.6 0.3 1.9 
High 0.6 0.3 0.2 1.7 
Figure 6.11: Kaplan Meier plot for three mutational load groups in the 
Intermediate Immune Subgroup (N=107) 
Table represents the results from a univariable Cox proportional 
hazard model. 
 
Mutational load HR P 95% CI 
Low  - - - - 
Intermediate 3.7 0.02 1.2 11.08 
High - - - - 
Figure 6.12: Kaplan Meier plot for three mutational load groups in the 
High Immune Subgroup (N=77) 
















































































































































































In the whole dataset, when mutational load survival analysis was adjusted for known 
melanoma prognosis predictors it remained significantly protective of melanoma 
death (trend test, HR=0.65, P=0.02), (Table 6.11). In the stratified adjusted analysis, the 
mutational load significantly predicted prognosis in the Low and High Immune 
Subgroups (HR=0.5, P=0.01; HR=0.4, P=0.05, respectively) and the HRs were 
comparable. Importantly smoking (ever vs never) still predicted prognosis significantly 
in the High and Intermediate Immune Subgroups (HR=5.8, P=0.03; HR=5.1, P<10-3) in 
these analyses including mutation load, but was not significant in the Low Immune 
Subgroup (HR=1.0, P=0.1) (Table 6.11). 
Table 6.11: Multivariable Cox proportional hazards model for the variables 
significantly predicting prognosis in the univariable model including smoking 
(never/ever) and mutational load in the whole dataset and within immune 
subgroups 
AJCC stage was categorized as stage I, II or stage III. Site of melanoma was tested 
for rest vs limbs. Age at diagnosis was reported in years. Mitotic rate is the count 
of mitoses per mm2. Mutational load was categorised as high, intermediate or 
low. HR means melanoma specific death hazards ratio. 
Predictor HR SE z P 95% CI 
OVERALL (N=240) 
AJCC stage 1.66 0.35 2.39 0.02 1.10 2.52 
Smoking (ever) 1.94 0.54 2.35 0.02 1.12 3.36 
Site (rest) 1.26 0.39 0.74 0.46 0.69 2.30 
Age at diagnosis 1.05 0.01 3.44 0.00 1.02 1.07 
Mitotic rate 1.02 0.01 1.86 0.06 1.00 1.03 
Inter. cluster vs Low 1.06 0.33 0.17 0.86 0.57 1.94 
High cluster vs Low 0.64 0.23 -1.25 0.21 0.31 1.30 
Mutational load 0.65 0.12 -2.42 0.02 0.46 0.92 
LOW IMMUNE (N=90) 
AJCC stage 1.49 0.46 1.28 0.20 0.81 2.73 
Smoking (ever) 0.99 0.38 -0.03 0.98 0.46 2.12 
Age at diagnosis  1.05 0.02 2.64 0.01 1.01 1.09 
Mitotic rate 1.01 0.01 0.74 0.46 0.99 1.03 




Predictor HR SE z P 95% CI 
INTERMEDIATE (N=82) 
AJCC stage 1.59 0.66 1.10 0.27 0.70 3.60 
Smoking (ever) 5.12 2.85 2.93 0.00 1.72 15.24 
Age at diagnosis 1.04 0.02 1.64 0.10 0.99 1.09 
Mitotic rate 1.06 0.01 3.98 0.00 1.03 1.09 
Mutational load 0.74 0.24 -0.92 0.36 0.39 1.41 
HIGH IMMUNE(N=68) 
AJCC stage 1.89 1.00 1.21 0.23 0.67 5.31 
Smoking (ever) 5.76 4.56 2.21 0.03 1.22 27.16 
Age at diagnosis 1.08 0.04 2.11 0.04 1.01 1.17 
Mitotic rate 1.09 0.09 1.14 0.25 0.94 1.27 
Mutational load 0.44 0.18 -1.99 0.05 0.20 0.99 
 
6.5 Summary 
• Vitamin D did not predict prognosis in the whole data, nor in immune subgroups. 
• Smoking strongly predicted death from melanoma in an immune dependent 
manner: the strongest in the High Immune Subgroup (in the analyses including 
and excluding the mutational load variable). 
• GPR15 was associated with smoking status and correlated with expression of 
genes in the IL6 signalling pathway in the High Immune Subgroup, with replication 
in metastatic tumours (TCGA dataset).  
• GPR15 was equally expressed in non-ulcerated and ulcerated tumours while IL6 
was more highly expressed in ulcerated tumours. 
• High mutational load predicted the most favourable prognosis, particularly in the 
High Immune Subgroup in the univariable analysis but the effect was comparable 






6.6.1 Effect of clinico-histopathological and environmental factors on 
prognosis in different immunological contexts 
 Clinico-histopathological factors 
AJCC stage was one of the strongest independent survival predictors in primary 
melanoma in the whole dataset and it remained consistently significant in stratified 
analysis by the immune subgroups. This observation indicated that irrespective of the 
level of immune response within melanoma AJCC stage is still a strong prognostic 
marker. Higher mitotic rate was borderline significant for melanoma death overall and 
subgroup analysis suggested that the strongest association was within the 
intermediate immune subgroup.  
Site of melanoma significantly predicted prognosis mainly in the Low Immune 
Subgroup, however this effect was driven by the fact that the rare (sun protected) sites 
were mostly classified into this group, and as mentioned in Chapter 1 these are the 
tumours that have the worse prognosis for the melanoma patients [14][15][17][18] 
possibly due to low C>T mutation rates [19], or late diagnosis [16].  
 Smoking 
The environmental exposures were analysed: vitamin D levels and smoking, however 
only smoking showed to be an important, very strong predictor of MSS in an immune 
dependent manner. The effect of cigarette smoking was the strongest in the High 
Immune Subgroup even though this was the smallest subset and the analysis had 
therefore the lowest statistical power. Higher cancer specific death associated with 
smoking was reported in breast cancer [241], head and neck [242], ovarian [243], 
prostate [244], and colorectal cancer [245]. However, none of these studies has tested 
the dependency on the immune responses.  
The absence of differentially expressed genes in tumours in relation to cigarette 
smoking in the agnostic analysis, despite a significant association with melanoma death 
was surprising. If overall survival was used it might have been hypothesised that the 




used accurate measures of cause of death and therefore we were confident that the 
increased hazard of death in smokers was related to melanoma itself. If I had more 
time during my PhD I would repeat the survival analyses testing the overall survival in 
order to explore whether the smoking effect was also related to non-melanoma 
specific death, although the number of non-melanoma death is limited. 
Given the well reported association of smoking with markers of systemic inflammation 
e.g. C reactive protein levels [246], we explored the association of smoking with 
immune cell scores but no significant associations were seen either for immune cells 
or for genes coding for immune checkpoint molecules. It is commonly accepted that 
smoking might induce either pro- or anti-inflammatory systemic states [247][248] 
implying complex effects on host/tumour interaction. 
There are a number of hypotheses which might explain the lack of detectable immune 
differences in the tumours of smokers vs non-smokers. The first hypothesis is that 
smoking may impair tumour cell killing functionally even when immune cells are 
present in the tumour, by downregulating the functions of adaptive and innate 
immune cells [88]. The second hypothesis is that inference of immune cell 
subpopulation from transcriptomic data might be insensitive to subtle changes in 
immune function. Or this changes were not related to the gene expression level but for 
example to protein modifications (so called non-genetic modifications). Third, the 
immune cells inferred within melanomas could be a reflection a chronic inflammatory 
state (from smoking or other causes) rather than specific anti-melanoma inflammation 
[88][248]. That is that the inferred T cells might not be targeted to tumour cells: rather 
that they are present within tumour cells as they may be present in other tissues in 
smokers. 
Furthermore, some studies showed that smoking might affect patient microbiome in 
the gut, which in turn might affect systemic immune responses [249]. Interestingly, 
recently researchers studying responses to immunotherapy in melanoma patients have 
shown that microbiome might indicate the outcome of this therapy. One study 
reported that higher diversity and relative abundance of bacteria of the 
Ruminococcaceae family [250] were associated with better responses to 
immunotherapy. Of note, another study analysing changes in microbiome of side-




Ruminococcus albus (Ruminococcaceae family) in these animals was decreased [251]. 
Another study reported that microbial diversity increases after smoking cessation in 
human samples [252]. In conclusion, these reports suggest that smoking might have an 
impact on anti-tumour immune response and immunotherapy outcomes by affecting 
patients’ microbiome, followed by changes in systemic responses. 
Cigarettes are composed of 4.500 compounds five of which are cancerogenic [253]. 
The major compound of cigarettes is nicotine, but it is not clear whether it acts as 
carcinogen, however it has been proposed to cause immunosuppression 
[253][254][255]. It is of note, that e-cigarettes, a relatively new method of “safe” 
smoking electronic nicotine delivery system (ENDS), might also be harmful and affect 
immune responses. It has been recently shown that the e-cigarette liquid induces 
inflammatory states of alveolar macrophages in vitro [256]. On the other hand, e-
cigarette vaping was reported to induce downregulation of immune genes in nasal 
epithelial cells [257]. 
Taken together, it is clear from the literature review that smoking does affect the 
systemic or tissue-specific immune responses as it might also be for e-cigarettes, 
however in melanoma it remains to be elucidated. In our study, cigarette smoking 
reduced patients survival, more so in those with strong immune infiltration, indicating 
that smoking impairs immune cell function rather than limit their numbers. 
In summary the results obtained from the survival analyses stress the importance of 
smoking cessation, for both classical cigarettes and e-cigarettes for melanoma patients 
and those at risk of developing melanoma. Additionally, because the strongest risk was 
seen in the High Immune Subgroup it also reinforces the view that smoking might 
generate a “false positive” immune responses within the tumour, which do not kill the 
tumour. Therefore, smoking habits of the patients should be taken under consideration 
in immunotherapy clinical trials.  
 GPR15 
The observation of GPR15 over-expression in smokers corroborated the literature, 
which suggested this gene as smoking biomarker. However, it was not proven that 
smoking directly increases GPR15 expression. It is rather proposed that smoking might 




chemokine receptor and with as yet unidentified natural ligand [238] and it is known 
to be expressed in immune cells, colon mucosa, but also in skin and bladder [238]. The 
knowledge about biological functions of GPR15 within each tissue type is limited, 
however it is proposed that it might be involved in their chronic inflammation, due to 
attraction of homing T cells into skin and colon [238][258]. 
In this chapter, I reported a positive correlation between GPR15 and genes involved in 
IL6 signalling in the High Immune Subgroup, from 2 datasets (the LMC and TCGA). IL6 
signalling is perceived as being involved in chronic and systemic inflammation 
[259][260]. Furthermore, IL6 was shown to regulate almost all hallmarks of cancer in 
various cancer types, including inhibition of apoptosis, promotion of survival, 
proliferation, angiogenesis, invasiveness and metastasis [261]. However, the exact role 
of IL6 signalling in melanoma is still not fully understood [262]. The Leeds Melanoma 
Research Group has reported evidence of its involvement in microscopic ulceration of 
primary melanoma, a marker of a chronically inflamed tumour, associated with 
systemic inflammation [220][221]. GPR15 did not significantly vary between ulcerated 
and non-ulcerated tumours, however IL6 itself was more highly expressed in ulcerated 
tumours. It would be interesting to follow up the correlation of GPR15 with the 
cytokines in more details, however the time did not allow me to do so.  
Summarising, the GPR15 expression in the melanoma tumours was significantly 
associated with smoking status and borderline with IL6 signalling in the High Immune 
Subgroup, which could support the hypothesis that the presence of the immune cells 
within melanoma tumour of the smokers was a non-melanoma specific (chronic) 
inflammation phenomenon. Clearly this is an important issue which encourages for 
further investigation, which should include IHC staining for GPR15 to define the origin 
of its transcript signal.  
6.6.2 Mutational load and prognosis 
The survival analyses including the mutational load variable had reduced sample size 
than the analyses excluding this variable, and therefore reduced statistical power. 
The high mutational load was associated with better outcome for melanoma patients 
overall and in the High and Low Immune Subgroups, but not in the Intermediate 




survival predictors. The high mutational load was associated with the most favourable 
outcome, but the poor outcome was related to intermediate mutational load, which is 
counterintuitive and challenging to understand. It may be explained by small sample 
size and calls follow up. In Chapter 3 it was shown that the mutational load did not vary 
across the three immune subgroups, which could be a true observation, or simply a 
result from the limitations of our dataset: the mutational data used for these analyses 
were not ideal as discussed in Chapter 3, since they covered a small number of genes. 
Nevertheless, assuming that the data truly reflected the unmeasured whole genome 
mutational load and that the mutational load could reflect the neoantigen load, it could 
be suggested that in LMC primary tumours the immune responses were not driven by 
it. All the results taken together suggested that melanoma cells need to have an 
effective antigen presentation machinery (as it is the case in the tumours from the High 
Immune Subgroup) in order to present the neoantigens to the immune system and only 
then the survival will improve (no death was observed among 21 High Immune patients 
with high mutation load up to 10 years after diagnosis). This observation was not 
surprising, as the literature proposes that either having downregulation and/or absent 
neoantigens are known immune evasive mechanisms in cancer [87] and that high 
mutational load was associated with better immunotherapy responses in melanoma  
[145][146][147] and other cancers [263], however lack of association between 
mutational lad and level of T cell infiltration across TCGA tumours was shown [264]. 
Therefore, even on a limited scale (i.e. based on a candidate gene panel), mutation 
data have the potential to be informative for the efficient use of immunotherapies. It 
would be interesting to conduct a comparative analysis of this economical approach 





Final Discussion  
7.1 Methodology 
7.1.1 LMC 
The Leeds Melanoma Cohort data set contains a collection of rich clinical, 
histopathological, exposure/environmental, and transcriptomic data from primary 
cutaneous melanoma tumours.  
The transcriptomic data were the basis of the analyses in this thesis (703 samples), 
which were replicated in independent datasets (TCGA and patient derived melanoma 
cell lines), validated by immunohistochemical staining (IHC) and further expanded to 
analysis of copy number alterations (CNAs) and mutational data, albeit for consequent 
reduced sample sizes.  
The development of checkpoint therapies and their positive impact on patient survival 
has reduced the focus on understanding the biological processes underlying the 
immune responses to the primary tumours [87], hence studies focusing on primary 
untreated melanoma, are in need. Therefore, the LMC is considered as a unique 
collection of the data, which allows us to address this research question. 
The LMC is one of the biggest population ascertained cohorts worldwide and this 
unique collection of data allowed me to perform agnostic genetic and survival analyses 
with statistical power.  
 Limitations of the data originating from the LMC 
LMC patients were predominantly treatment naive, in that only 16 of the 703 patients 
have been known to have received checkpoint therapies, as the period of recruitment 
(2000-2012) preceded frequent usage. However, as time passes more of them will 
receive such treatment at late relapse. The Leeds Melanoma Research Group is 
therefore in the process of seeking national data from Systemic Anti-Cancer Therapy 
(SACT) dataset to update the treatment information. I have reduced the chance of 




and by repeating the survival of the three immune subgroups and the results were 
unchanged. 
The transcriptomic and genomic LMC data were generated from FFPE tumour blocks. 
The storage of the tumours in formalin means that the tumour samples remain intact 
with the original and intratumoural shapes, allowing histopathological examination 
beyond the original clinical examination. The fixation process however affects the 
protein and particularly genetic material structures. DNA and RNA extracted from FFPE 
samples are usually degraded, and their strands are shortened [265] or may form 
crosslinks with proteins [266][267]. These changes might impact on the quantity of the 
extracted genetic material, introducing noise into the final data and/or meaning that 
some of the genes or their transcripts might not be detected by the probes or 
sequencing. Researchers have established procedures of extracting DNA and RNA from 
FFPE samples to reach higher efficiency and developed methods of gene expression 
analysis in order to overcome these problems and these were used by Leeds Melanoma 
Research Group. For example, the gene expression was measured using the Whole-
Genome DASL HT12v4 assay (Illumina®), which was particularly intended for the FFPE 
samples, by designing short probes (50bases) to enable the detection of degraded RNA. 
Note that this platform is not on the market any longer. Tumour samples might also be 
stored fresh and frozen in liquid nitrogen and this method affects the genetic material 
to a lesser degree than formalin fixation, however as mentioned above storage of 
samples as FFPE is preferred due to the preservation of the tumour structures, which 
are important for histopathological and immunohistochemical assessments. The 
studies benefitting from fresh frozen samples derive their samples from tumours which 
are large enough at excision for the pathologist to be satisfied to sacrifice a small 
proportion for research. Therefore, the sample sets built using this approach are 
inevitably biased towards thicker tumours. The TCGA data set was therefore 
predominantly composed of metastases and, even so, required the pooling of samples 
from international research centres. I have listed the use of formalin fixed tumours 
here as a weakness because of degradation of RNA but the Leeds Melanoma Research 
Group regard the design as a strength as the sample set is derived from population 
ascertained participants with primary disease and although there is some bias towards 




Importantly, because this is a population-based cohort, the design allows extrapolation 
to findings to the general population of melanoma patients, not just for those for 
whom a metastatic biopsy can be obtained. 
Heterogeneity of tumours is a well-documented feature of all cancers. The Leeds 
Melanoma Research Group chose to derive RNA from small tissue micro array (TMA) 
needles as when tumour sampling began, the quantity of RNA required was 
considerably larger than is now required. Using a 0.6mm diameter core allowed the 
generation of sufficient RNA without damaging the tumour block which the patient 
might require in the future for clinical testing. The group consistently sampled a region 
of the invasive tumour with the least stroma and inflammation order to make the 
samples comparable within the cohort. However, the gene expression data were 
usually analysed only from one cored region and these bulk tumour data could not 
therefore delineate the distinct tumour gene expression patterns, for example in case 
of heterogeneous tumours.  
This sampling method does not allow the distinction of the origin of the gene 
expression signal from the distinct components of the tumour microenvironment, such 
as fibroblasts, immune cells, blood vessels etc. However, it was the intent to sample 
the tumour in its microenvironment and indeed my project was dependent on this 
approach. The use of laser microdessection [268][269], can be adopted if the intent is 
to study specific cell populations or single cells from the tissue on the glass slide 
however it is very expensive and not logistically feasible for a large number of samples. 
Another method to address the heterogeneity issue could be single cell RNA 
sequencing from different parts of the tumour, however for this a fresh tissue (just 
after excision) is needed. Non-the-less single cell analyses are being carried out 
increasingly and these will complement the approach described in my thesis. 
The use of a TMA needle to sample the blocks generates relatively generous quantities 
of RNA but requires histopathological expertise in sampling. The haematoxylin and 
eosin stained slides were reviewed by Prof. Julia Newton-Bishop and Dr Jonathan Laye 
and were marked using a microfine felt tip pen. The intent was to sample the deepest 
part of the tumour but at a depth where a core would remain predominantly within 
tumour. In fact ,using the package Estimate [270], Nsengimana et al. reported [76] that 




techniques [46][117] and can therefore be judged as successful. In some tumours 
tongues of epidermis can be found even deep within the tumour. Moreover, some of 
tumour samples were relatively thin and the needle used for the core extraction could 
reach the keratin components and then the gene expression could be diluted by the 
gene signals from the “healthy” skin surrounding the tumour. Some of the results 
confirmed this concern, such as the “keratin” TCGA class in LMC (Chapter 3; and MYC 
dominant group (Chapter 4). However it is an inherent issue for transcriptomic studies 
devised to investigate host-tumour interaction as keratin tumour classes were 
reported by TCGA consortium (keratin group was predominantly (74%) comprised of 
primary tumours in TCGA) [46] and by Cirenajwis et al. (“normal-like” group was 
comprised of 62% of primary tumours and 31% of metastases of which 23% were local 
metastases) [136].  
Finally, the samples for which transcriptomic data could be combined with IHC, CNA or 
mutational data were available, were on average thicker (as generating sufficient RNA 
and DNA for all approaches requires bigger tumours) and the sample size was therefore 
smaller. This could be considered as biased/selected data, not representing the LMC as 
a whole.  
In summary, although some of the data originating from LMC could be potentially 
biased this dataset was nevertheless more representative of the population 
ascertained cohort compared to TCGA data, which was selected and from different 
centres and populations.  
7.1.2  Bioinformatic analyses to infer immune microenvironment of 
melanoma tumours 
Immunotherapies, especially checkpoint blockades showed a great success in 
melanoma treatment and this achievement is also emerging for other cancers 
[271][272]. For melanoma only a proportion (~50%) of patients benefit from these 
therapies [95] and on average similar response rates are observed in other cancers 
[272]. Therefore, understanding of the interaction of the tumour and immune 
microenvironment is critical to improving the impact of these therapies. 
Immunotherapies principally act by unleashing/increasing anti-tumour immune 




of the immune cells within the microenvironment. The lack of immune responses 
within the tumour is likely to be mediated by primary or acquired resistance 
mechanisms, such as immune evasion (discussed later on) or immune editing [273]. 
Another explanation of ineffective immunotherapies might be insufficiency of usage of 
the anti-checkpoint molecules antibodies (anti-PD1, anti-PD-L1, anti-CTLA4) blocking 
the immune responses, as these are not the only existing checkpoint molecules. 
The studies to recognise the patients’ response to immunotherapies are designed to 
understand different tumour types on the molecular level, the host immune responses 
and their interactions. 
Immunological research has traditionally used the reductive experiments such as in 
vitro examination of the functioning of the immune cells. By contrast, the bioinformatic 
approaches enable the study of more complex interactions on a greater scale (while 
requiring validation by in vitro and in vivo). This is what I have attempted to explore 
during this PhD work. 
I have used the inferred immune cell scores derived from relatively small areas of the 
tumours and categorised the tumours based on these scores, examining the whole 
transcriptome and clinico-histopathological characteristics resulting in the 
identification of three different immune microenvironments.  
Bioinformatic characterisation of the tumour immune microenvironment using gene 
expression data is rather challenging. At the beginning of my PhD project,  few 
bioinformatic methods to infer immune cell scores were available, but over time new 
approached emerged and many of them are based only on RNA-seq data [274]. In my 
thesis I have explored CIBERSORT and developed a method based on Angelova et al.’s 
Immunome, because these methods were available at the time of my initial analyses, 
were the most suitable for the microarray data and allowed inference of large numbers 
of different immune cell scores. 
Although CIBERSORT is an attractive algorithm for deconvolution of the immune cells 
from bulk tumour data, I observed that it had some limitations. For example, it failed 
to estimate the immune cell proportions from the tumours that manifested 
weak/moderate immune signals and more than a half of the samples could not be 




Application of the Angelova et al.’s Immunome for the characterisation of the immune 
cell scores within the LMC tumours, leaves uncertainties as to the origin of the 
measured gene expression signals (it was not clear from the literature or my 
examination of transcriptomes derived from melanoma cell lines) whether the 
expression of some genes originated from the melanoma or immune cells and specific 
adjustments were necessary. I found that almost half of the “Immunome” genes were 
highly expressed by the melanocytes and melanoma cell lines.  
Nonetheless, the successful use of Angelova et al.’ Immunome to colon cancer was 
reported [1]. In the LMC the immune cell scores were created after application of the 
gene filtrations steps (based upon gene expression by melanoma/melanocyte cell lines 
and excluding negatively correlating genes per cell type specific-score) and the results 
related to these scores were replicated in the fresh frozen NGS TCGA data. 
Clustering of tumour samples is commonly performed based on gene expression data 
[132]. In studies designed to find global tumour subtypes within a given dataset 
information on a large numbers of genes are used [46][136]. However, to address 
specific questions, only the genes of interest might be utilised for clustering. For 
example, Dr Jérémie Nsengimana applied the Bindea et al.’s Immunome (immune 
genes) to cluster LMC tumours and identified 6 immunologically and histologically 
different subgroups [76]. In my work I reasoned that using the 27 immune cell scores 
instead of hundreds of genes could reduce the dimensionality for clustering and result 
in more stable clusters, which would be less affected by the variation caused by 
histological or technical differences. Indeed, three immunologically different stable 
clusters (with distinct survival) were obtained, which were replicated in metastatic 
tumours from TCGA. The clustering analysis of the immune cell scores revealed that 
the majority of the immune cell scores were strongly correlated. Overall it was 
observed that the immune genes were highly correlated with each other and high 
expression of these cells was associated with good survival. This fact could mask 
putative subtle differences of the immune cell scores, which were highly related to 
each other at least on the gene expression level.  
My findings are in some ways similar to those reported in a recent publication, in which 
Pan-Cancer clustering of TCGA tumours was performed based on 6 immune signatures: 




Immunologically quiet, and TGF-beta dominant [275]. Although a direct comparison 
between Thorsson’s clustering and mine is slightly problematic as Thorsson et al. 
developed clusters based on 6 immune signatures, which were dissimilar from the 27 
immune cell scores I generated in the LMC. Moreover, the Thorsson’s signatures were 
not adjusted to cancer genes before the generation of immune signatures as it was 
performed in the LMC by removal of “melanoma” genes from the list of genes used to 
create the immune cell scores. The Pan-Cancer research group showed that melanoma 
samples were mainly dominant in: Wound healing, IFN-gamma dominant, 
Inflammatory, and Lymphocyte depleted clusters [275]. The number of immune 
clusters to which melanoma samples were assigned was comparable to the number of 
clusters obtained in LMC (four vs three), but the immune clusters were slightly 
dissimilar phenotypically from the ones identified in LMC. However, the Thorsson’s 
Inflammatory cluster could be compared to the LMC High Immune Subgroup, and both 
of these immune clusters were associated with good survival. The Thorsson’s 
Lymphocyte depleted cluster could be compared to the LMC Low Immune Subgroup, 
for which the survival was poor both in LMC and Pan-Cancer. The Thorsson’s Wound 
healing, IFN-gamma clusters were not identified in the LMC. However, the survival for 
these clusters could be compared to the LMC Intermediate Immune Subgroup, for 
which it was moderate in comparison to the rest of the immune subgroups.  
Additionally, another similarity that was observed between the Pan-Cancer and mine 
analysis was for example, higher expression of CTNNB1 associated with “Lymphocyte 
Depleted” cluster associated with the worse survival in the Thorsson et al.’s study [275] 
and alike observation was made in the LMC. 
Summarising, the three immune subgroups displayed a biologically informative 
subgrouping of the tumours, which was productively investigated from the 
transcriptomic, genomic and environmental perspective. These groups allowed us to 
discover new, and confirm already known, immunosuppressive pathways in 
melanoma. Moreover, the impact of smoking could only be discovered in this immune 
dependent manner, facilitated by having sufficient information to test the survival of 




7.2 Host immune responses  
Understanding the immune responses to melanoma and to cancer generally has 
become one of the main focuses in cancer research as discussed above. 
Currently the understanding of host-tumour interaction is focused on studies 
investigating the primary and acquired resistance to immunotherapies.  However, as 
mentioned above, it is important to uncover the initial/basic mechanisms of immune 
evasion/editing in the primary tumours. It is crucial to study the primary tumours as 
the understanding at the level of metastatic disease might be too late for the patient 
to be cured. Understanding the immune responses to early stage primary melanomas 
might result in discovery of prognostic biomarkers, identification of more effective 
adjuvant therapies and lifestyle factors which affect the overall immune response. 
The anti-cancer immune responses can be disrupted in each step of the path leading 
to cancer killing: from the release of the cancer antigens through priming, activation 
and trafficking of the T cells into the tumour, to the final cancer killing phase (described 
by Chen and Mellman [87]).  
Firstly, the release of cancer antigens/neoantigens is one of the initial mechanisms for 
tumours to be recognised by the immune system. Higher neoantigen load was 
proposed to have an impact on responses to immunotherapies and patients’ survival 
in various cancers, particularly in melanoma [145][146][147]. Alexandrov et al. 
described several mutational signatures and one of them was “signature 7” (rich in C>T 
mutations, the UV exposure signature), which was particularly highly enriched in 
melanoma. This signature was further shown to predict better survival and high 
immune cell scores in the TCGA dataset [148]. All the evidence suggests that 
neoantigen load/signature might trigger the immune responses. However, the whole 
machinery of neoantigen presentation is essential for effective antigen presentation. 
Loss of any major component of this process might impact on immunogenicity of the 
cancer cell (as discussed next). In this thesis, it was shown that in primary melanoma 
high mutational load was associated with better outcome. However, there was no 
overt relationship between the level of immune infiltration and the neoantigen load. 
Similar observation was made by Spranger et al. when analysing the TCGA data for 




difference of mutational load between inflamed and non-inflamed tumours [264]. One 
possible explanation for this could be incomplete data on the mutational/neoantigen 
load for the LMC, since it was represented by only a 555 gene panel.  Another 
explanation could be that it is not the load itself but quality of the presented antigens 
which is the most important factor [150][151]. 
Next, in order to present the neoantigens to the immune cells, tumours  are required 
to have the active antigen processing and presentation machinery. The down-
regulation of HLA class I signalling and losses in B2M were shown to be inversely 
correlated with two gene cytolytic score (GMZA, PRF1)  in various cancers, including 
melanoma [276] and to be involved in affecting the immunotherapy responses [277].  
The gene expression of antigen processing and presentation via HLA class I and II were 
significantly lower in the Low Immune Subgroup, which was not surprising. However, 
in this work the direct inverse relationship with HLA class I genes and the oncogene 
MYC was proposed as a novel finding. It suggested that this oncogene is not only 
involved in tumour progression by stimulating proliferation, but also by contributing to 
immune evasion. The negative association of MYC and HLA-B was already proposed in 
1994 by observation of melanoma cell lines [187]. However up to now it was not shown 
in human melanoma samples.  
A recent study by Jerby-Arnon et al. (November 2018) analysing single cell RNA 
sequencing from treated and non-treated patients by checkpoint blockade, reported 
that non responding tumours manifested up-regulation of MYC targets and down-
regulation of HLA class I molecules [278], which is partially consistent with the results 
from this thesis.  
Other mechanisms of immune evasion related to tumour intrinsic oncogenic pathways, 
including MYC were reported in various cancers [279]. For example, MYC was reported 
to up-regulate PD-L1 and CD47 molecules on human leukaemia and lymphoma cells 
[280], and to down-regulate HLA class II in human B cells tumours [188]. If I had 
additional time during my PhD, I would perform an experiment to prove this 
observation by knocking down, or overexpressing MYC in melanoma cell lines, and 
testing the expression of HLA-B and antigen processing and presentation genes using 




Moreover another oncogenic pathway such as loss of PTEN (a tumour suppressor gene) 
was demonstrated to impact on the reduction of T cell infiltration and T cell killing in 
melanoma mouse models and human samples treated by anti-PD1 therapy [281]. The 
work of this thesis did not uncover specifically PTEN involvement in immune responses 
on the gene expression level, however if I had more time I would test the CNA of this 
gene across the three immune subgroups. 
Summarising all the evidence of MYC functioning as a tumour immune suppressor, 
suggests that patients who do not respond to immunotherapy could be given MYC 
inhibitors to sensitize non responding tumours. MYC has already been considered as 
drug target as it is well known oncogene, but translation research has been difficult to 
target MYC directly in solid tumours [282]. The MYC induced tumours might require 
other targeting approaches such as for example an oncotic viral activity, which was 
reported to be permissive to tumours driven by MYC [283].  Alternatively, one study 
based on xenograft melanoma mice models, has suggested antisense oligonucleotides 
as viable treatment option in human patients after observing tumour shrinkage and 
expanded lifetime in mice [284].  
Even though tumours that manifest generation of neoantigens and have an effective 
antigen processing and presentation machinery need to provide a suitable niche for 
the effective infiltration of the immune cells into the tumour microenvironment. One 
of the results from this work, which could potentially explain the regulation of this 
process in melanoma was the observation of the down-regulation and losses of the 
components of tumour NF-kB signalling associated with lower immune infiltration and 
worse melanoma specific survival. These results could be considered as an immune 
evasion mechanism acquired by the tumour. Abnormal NF-kB signalling and NFKB1 
gene expression was particularly found to have carcinogenic functions and promote 
tumour progression as well as to act as tumour suppressor [190][191]. However, the 
deletions, and down-regulation of genes belonging to this pathway were not shown to 
be involved in immune evasion in melanoma and other solid cancers according to my 
literature search. However, one study described that loss of NFKB1 was causal for 
gastric cancer development specifically with aberrant inflammation within the tumour 
[196]. Moreover tumour NF-kB signalling was reported to be associated with T cell 




Additionally, a hyper-activation of NF-kB signalling within the tumour 
microenvironment was shown to contribute to reprograming of chemokine 
microenvironment to enhance recruitment of cytotoxic T cells into colorectal tumours 
[195]. 
In the LMC, the immunohistochemical staining analysis showed that tumour nuclear 
localization of NF-kB significantly correlated with lymphocytic infiltration, suggesting a 
reciprocal NF-kB-driven phenotype generated between the tumour and its 
surrounding microenvironment as described in the two studies mentioned above 
[285][195].  These results and the inferior survival for the patients with losses of the 
NF-kB pathway might highlight a potential warning for the implementation of targeted 
therapeutic inhibition of the NF-kB pathway in melanoma (Beleyer et al. [286][287]), 
because it could have adverse immune effects if in fact tumour NF-kB activated 
pathways are actively attracting T-cells to the melanoma tumour microenvironment.  
NF-kB signalling is a complicated process, particularly in cancer. Understanding its 
functioning in melanoma using only gene expression data is challenging, since it can 
only explain the level of association not causation. However, the CNA data could 
partially delineate the causative effect of the deleted genes. The observation 
concerning losses of NF-kB pathway genes could be further validated by performing a 
knock out e.g. for NFKB1 from the human tumour cells and test how does this affect 
the gene expression of downstream targets of NF-kB signalling. Most importantly it 
could be tested whether these cells were indeed less immunogenic by conducting 
immune cell killing experiments.  
b-catenin signalling is a pathway already shown to affect the immune cells trafficking 
(mainly dendritic cells) into the tumours [75] – the middle stage of the melanoma killing 
path. This pathway was revealed to be upregulated in a great proportion of primary 
melanoma tumours in LMC [76], and to regulate immune responses in other cancers 
[288] and this thesis reports analyses supporting these results. b-catenin is known to 
regulate MYC, however the reciprocal regulation was also proposed [149]. Moreover, 
it was recently reported by Prof. David Fisher from Harvard University (oral 
presentation at the 15th International Congress of the Society for Melanoma Research 




G9A/EHMT2 (Euchromatic Histone Lysine Methyltransferase 2) might be involved in 
cancerogenic processes in melanoma and other cancers. Moreover, G9A was shown to 
increase the WNT/b-catenin pathway, which subsequently contributed to decreasing 
the immune responses (data not published). His research group proposed that G9A 
suppresses DKK1 a repressor of WNT/b-catenin pathway in melanoma mouse models 
and in vitro. In our collaborative analyses we have confirmed some of these results by 
using the LMC data. We performed differential gene expression between G9A high and 
low copy number changes and observed that among top pathways associated with G9A 
high tumours was WNT signalling and among the genes were MYC and DKK1. 
Moreover, we observed that high G9A copy number was significantly higher in the CIC 
4 (Low Immune/b-catenin high) from Nsengimana et al.’s consensus immune clusters. 
Once the tumour is infiltrated and recognised by the immune cells it may evolve and 
affect the immune cells so that they become inefficient in their killing functions 
(mechanism described as “immune suppression”). One of the most recognised immune 
suppressive mechanisms in cancer including melanoma is persistent activation of 
regulatory immune cells within the tumour microenvironment, such as Tregs 
[289][81][290] and MDSCs [291][292]. Moreover, up regulation of checkpoint 
molecules such as PD-L1, PD1 and IDO by the tumour or immune cells within the 
tumour microenvironment, are considered to be involved in suppressing the activation 
of T cells [87]. However, some studies including the one from the Leeds Melanoma 
Research Group, reported that checkpoint molecules and regulatory immune cells 
correlate with the overall immune cells abundance and improved survival, and this 
observation is considered as homeostatic feedback [189][76][293]. Overall, the 
immune homeostatic feedback is important in terms of prevention of the development 
of excessive inflammation i.e. by checks and balances. The results of this thesis 
corroborated these observations, as all the immune cell scores were highly correlated 
and the immune checkpoint molecules were significantly upregulated in the High 
Immune Subgroup.  
Another mechanism affecting responsiveness of the immune system in different 
phases of the melanoma killing path is impaired interferon gamma signalling 
[294][295]. The disruption of this signalling might result in down-regulation of antigen 




attract anti-tumour immune cells [218][296]. I observed that the genes involved in 
interferon signalling were downregulated in the Low Immune Subgroup and JAK2 
deletions were frequently observed in this subgroup. Mutations/deletions of JAK2 have 
recently been reported to be involved in primary and acquired resistance to anti PD-1 
therapy in melanoma metastatic tumours [217][218]. The results from this thesis 
indicate an early onset of these aberrations in melanoma progression, which might 
further impact on patients’ responsiveness to immunotherapies. 
Summarising the overview acquired from all the results from transcriptomic, and CNA 
data together allowed me to conclude that immune evasive pathways were not 
mutually exclusive, and moreover their co-existence was shown to worsen the 
patient’s survival. It could be concluded that the tumours in which many immune 
evasive pathways were observed could imply higher tumour heterogeneity, and 
different immune evasive mechanisms being active. Moreover, these observations 
suggest that a great proportion of melanoma tumours in the Low Immune Subgroup 
could have an intrinsic resistance to immunotherapies. 
Finally, environmental factors might influence systemic immune responses, which 
might have a further effect on recognition or killing of the tumour by the immune cells. 
One of the well-studied determinant of inflammatory/suppressor effect on systemic 
immunity is cigarette smoking [247][248].  
In this thesis, it was shown that cigarette smoking decreased the protective effects of 
immune cells within the tumours in the High Immune Subgroup. Importantly, these 
results were consistent when using three different variables describing habits of 
smoking and it was shown that it was not cofounded by deprivation status. It was also 
observed that GPR15 expression, a known biomarker for smoking in the circulating 
blood [237], was significantly associated with smoking in the LMC tumours. 
Furthermore, GPR15 was suggested to be associated with chronic inflammatory 
pathologies [258]  and in LMC and TCGA it was observed that GPR15 suggestively 
correlated IL6 signalling, an inflammatory pathway. However this observation would 
need a further validation on the protein level and testing for whether it was related to 




The literature is rich in describing the studies regarding cancer specific survival and 
cigarette smoking. For example smoking was shown to shorten survival for breast 
[241], head and neck [242], ovarian [243], prostate [244], and colorectal cancer [245] 
patients. Previously in the LMC it was demonstrated that smoking was associated with 
worse outcome [221]. However, none of these studies showed the interaction between 
smoking and the immune responses. Hence our results might be considered as novel 
and clinically relevant, stressing the importance of smoking cessation and 
incorporation into the studies analysing immunotherapy responses. Moreover, since it 
is not clear whether the survival effect of smoking in melanoma patients was due to 
different cigarette compounds, or mostly nicotine, it is important to stress that e-
cigarettes might be potentially as harmful as cigarettes due to nicotine. As a result of 
relatively short existence of e-cigarette (vaping) there is not much evidence that the 
nicotine delivery system affects the immune responses systemically.  However the 
system were shown to affect immune responses in vitro [256] and in the human nasal 
tissue [257].  
 
Summarising, the strength of this study was the ability to discover new and confirm 
already reported immune evasive mechanisms in primary melanoma using gene 
expression, copy number and protein level data. Furthermore, I made the novel 
observation that the survival associated with a well-known environmental factor such 
as smoking interacted with immune responses measured at the gene expression level. 
All the novel results from this thesis might be further investigated in relation to 






A.1 Creation of the immune cell scores 
A.1.1 Percentage calculation of the remained genes per immune cell score 
after the first filtration step 
Cell type Before 
(number of genes) 
After 
(number of genes) 
% of genes 
remained 
Removed 
mDC 21 0 0.0 x 
pDC 18 1 5.6 
 
Effector_memory_CD4 14 1 7.1 x 
Activated_CD8 24 2 8.3 x 
Activated_CD4 35 3 8.6 x 
Monocytes 25 5 20.0 
 
Memory_B_cells 14 5 35.7 
 
NK56_bright 8 3 37.5 
 
MDSC 85 37 43.5 
 
Th2 25 11 44.0 
 
NK56_dim 17 8 47.1 
 
Central_memory_CD4 21 10 47.6 
 
iDC 21 11 52.4 
 
Eosinophils 15 8 53.3 
 
Central_memory_CD8 18 10 55.6 
 
Effector_memory_CD8 42 25 59.5 
 
TFH 10 6 60.0 
 
Immature_B_cells 24 15 62.5 
 
Neutrophils 16 10 62.5 
 
NK 17 11 64.7 
 
Cytotoxic_cell 9 6 66.7 
 
NKT 12 8 66.7 
 
TGD 43 30 69.8 
 
TH17 26 19 73.1 
 
Mast_cells 42 31 73.8 
 
Treg 26 20 76.9 
 
DC 34 27 79.4 
 
T_cells 86 69 80.2 
 
Macrophages 22 18 81.8 
 
Th1 37 31 83.8 
 













































































A.1.3 Final list of genes per immune cell scores after filtration process 
Probe Gene Cell_type 
ilmn_1777998 ARHGAP25 Activated_B_cells 
ilmn_2068274 CLEC9A Activated_B_cells 
ilmn_1770673 AKNA Activated_B_cells 
ilmn_1688959 CD27 Activated_B_cells 
ilmn_1780397 TRAF3IP3 Activated_B_cells 
ilmn_1786176 CD37 Activated_B_cells 
ilmn_2233783 CD38 Activated_B_cells 
ilmn_1695025 CD2 Activated_B_cells 
ilmn_1748473 GIMAP4 Activated_B_cells 
ilmn_1687052 PAX5 Activated_B_cells 
ilmn_1665943 MAP4K1 Activated_B_cells 
ilmn_1677505 CCL21 Activated_B_cells 
ilmn_1726597 FAM65B Activated_B_cells 
ilmn_1665647 CD180 Activated_B_cells 
ilmn_1768016 TNFRSF17 Activated_B_cells 
ilmn_1782729 CLECL1 Activated_B_cells 
ilmn_2327860 MAL Central_memory_CD4 
ilmn_1689160 DPEP2 Central_memory_CD4 
ilmn_1656287 SPOCK2 Central_memory_CD4 
ilmn_1681301 AIM2 Central_memory_CD4 
ilmn_1741143 TXK Central_memory_CD4 
ilmn_1791226 NXN Central_memory_CD4 
ilmn_1788481 ADAM19 Central_memory_CD4 
ilmn_1730986 MALT1 Central_memory_CD4 
ilmn_1789955 PNRC1 Central_memory_CD4 
ilmn_1752520 SLFN11 Central_memory_CD8 
ilmn_1716736 CD80 Central_memory_CD8 
ilmn_1770768 SLAMF1 Central_memory_CD8 
ilmn_2120210 RCAN2 Central_memory_CD8 
ilmn_2395981 PYHIN1 Central_memory_CD8 
ilmn_3235514 GPR183 Central_memory_CD8 
ilmn_1693552 CD300A Central_memory_CD8 
ilmn_1656011 RGS1 Central_memory_CD8 
ilmn_2222443 KLRK1 Central_memory_CD8 
ilmn_2079655 KLRB1 Cytotoxic_cells 
ilmn_1716983 LILRA2 Cytotoxic_cells 
ilmn_1652825 IL10RA Cytotoxic_cells 
ilmn_2196078 SLAMF6 Cytotoxic_cells 
ilmn_2326953 LAT2 Cytotoxic_cells 
ilmn_1724422 SELL Cytotoxic_cells 




Probe Gene Cell_type 
ilmn_2176063 FCGR1A DC 
ilmn_1655987 STAB1 DC 
ilmn_1751095 CD300E DC 
ilmn_1714602 CD86 DC 
ilmn_1652381 SIGLEC5 DC 
ilmn_1670490 PDPN DC 
ilmn_2307903 VCAM1 DC 
ilmn_1783593 CCL13 DC 
ilmn_1726666 GPX3 DC 
ilmn_1752658 NGFR DC 
ilmn_1691339 CLEC1A DC 
ilmn_1759787 THBD DC 
ilmn_1794038 FAM49A DC 
ilmn_1719547 INHBA DC 
ilmn_1785902 C1QC DC 
ilmn_1727689 TNFAIP2 DC 
ilmn_1795754 CLIC2 DC 
ilmn_1682259 CLEC4C DC 
ilmn_1677693 GPR109B DC 
ilmn_1678841 UBD DC 
ilmn_1725320 SIGLEC1 DC 
ilmn_1680144 HLA-DQA2 DC 
ilmn_2376458 CSF2RA DC 
ilmn_2218856 CCL3L1 DC 
ilmn_1684850 PRKAR2B DC 
ilmn_1787529 C3AR1 Effector_memory_CD8 
ilmn_1722981 TLR5 Effector_memory_CD8 
ilmn_2101278 RGS18 Effector_memory_CD8 
ilmn_1715885 PTPN22 Effector_memory_CD8 
ilmn_2409720 SLA2 Effector_memory_CD8 
ilmn_1673030 CMKLR1 Effector_memory_CD8 
ilmn_2097410 DAPP1 Effector_memory_CD8 
ilmn_1664828 APOBEC3H Effector_memory_CD8 
ilmn_1684349 IL2RB Effector_memory_CD8 
ilmn_1724181 IL15 Effector_memory_CD8 
ilmn_2368318 FGR Effector_memory_CD8 
ilmn_2405684 BIRC3 Effector_memory_CD8 
ilmn_2074762 FCRL6 Effector_memory_CD8 
ilmn_1702534 CD244 Effector_memory_CD8 
ilmn_1701237 SH2D1B Effector_memory_CD8 
ilmn_1784141 JAKMIP1 Effector_memory_CD8 
ilmn_1666902 GPR114 Effector_memory_CD8 




Probe Gene Cell_type 
ilmn_1731233 GZMH Effector_memory_CD8 
ilmn_1778977 TYROBP Effector_memory_CD8 
ilmn_2112580 FCGR3A Effector_memory_CD8 
ilmn_2331121 FCGR2C Effector_memory_CD8 
ilmn_2386453 KLRD1 Effector_memory_CD8 
ilmn_1730628 RNASE2 Eosinophil 
ilmn_2113126 RNASE3 Eosinophil 
ilmn_1653766 CCL24 Eosinophil 
ilmn_1715823 FBXO16 Eosinophil 
ilmn_1772631 EPX Eosinophil 
ilmn_1700428 HLA-DOB Immature_B_cells 
ilmn_1697309 NCF1 Immature_B_cells 
ilmn_1792075 CD22 Immature_B_cells 
ilmn_1815168 HVCN1 Immature_B_cells 
ilmn_1664063 FAM129C Immature_B_cells 
ilmn_2333774 TAGAP Immature_B_cells 
ilmn_2106725 NCF1B Immature_B_cells 
ilmn_1699599 FCRL3 Immature_B_cells 
ilmn_2105223 FCRL5 Immature_B_cells 
ilmn_1661646 BANK1 Immature_B_cells 
ilmn_2226183 FCRL1 Immature_B_cells 
ilmn_1784774 P2RY10 Immature_B_cells 
ilmn_3247998 STAP1 Immature_B_cells 
ilmn_1676003 PNOC Immature_B_cells 
ilmn_1791329 FCRL2 Immature_B_cells 
ilmn_1773963 GNA15 MDSC 
ilmn_1681067 PIK3R5 MDSC 
ilmn_1701947 GPR34 MDSC 
ilmn_2394161 ST8SIA4 MDSC 
ilmn_1701914 CD274 MDSC 
ilmn_1744212 INPP5D MDSC 
ilmn_1662451 FCER2 MDSC 
ilmn_2396444 CD14 MDSC 
ilmn_1795183 RNASE1 MDSC 
ilmn_1689518 PECAM1 MDSC 
ilmn_2133316 GIMAP7 MDSC 
ilmn_1686405 KDR MDSC 
ilmn_1760189 NAIP MDSC 
ilmn_1754894 C1orf162 MDSC 
ilmn_3242540 CD163L1 MDSC 
ilmn_2345898 SLA MDSC 
ilmn_2383611 PTPRE MDSC 




Probe Gene Cell_type 
ilmn_1752307 FLT1 MDSC 
ilmn_1755643 MGAT4A MDSC 
ilmn_2366330 FERMT3 MDSC 
ilmn_1734855 SELPLG MDSC 
ilmn_1676575 IKZF1 MDSC 
ilmn_1695851 PARVG MDSC 
ilmn_1688231 TREM1 Macrophages 
ilmn_1690783 TREML1 Macrophages 
ilmn_2365091 FCAR Macrophages 
ilmn_2357419 LILRA5 Macrophages 
ilmn_2379599 CD163 Macrophages 
ilmn_1713686 IL34 Macrophages 
ilmn_1734748 LILRA1 Macrophages 
ilmn_3192001 CCL14 Macrophages 
ilmn_1709613 IGF1 Macrophages 
ilmn_2371280 CSF3R Macrophages 
ilmn_1792473 AIF1 Macrophages 
ilmn_2331087 MS4A7 Macrophages 
ilmn_1782741 CD300LB Macrophages 
ilmn_1715991 SDPR Mast_cells 
ilmn_2054297 PTGS2 Mast_cells 
ilmn_1785732 TNFAIP6 Mast_cells 
ilmn_1763344 ADCYAP1 Mast_cells 
ilmn_2339835 PTGS1 Mast_cells 
ilmn_2208413 ARHGAP15 Mast_cells 
ilmn_1663519 SLC24A3 Mast_cells 
ilmn_1808226 RGS16 Mast_cells 
ilmn_2299095 SIGLEC6 Mast_cells 
ilmn_1723944 TARP Mast_cells 
ilmn_3243061 SIGLEC14 Mast_cells 
ilmn_1680424 CTSG Mast_cells 
ilmn_1783956 ATP8B4 Mast_cells 
ilmn_1770772 CMA1 Mast_cells 
ilmn_1700081 FST Mast_cells 
ilmn_1815690 TIE1 Mast_cells 
ilmn_1806721 MS4A2 Mast_cells 
ilmn_1766551 CPA3 Mast_cells 
ilmn_1792323 HDC Mast_cells 
ilmn_1735712 KRT1 Mast_cells 
ilmn_1731777 NTRK1 Mast_cells 
ilmn_2310896 NLRP3 Mast_cells 
ilmn_2377746 RUNX2 Memory_B_cells 




Probe Gene Cell_type 
ilmn_1738517 FCRL4 Memory_B_cells 
ilmn_1679798 TLR9 Memory_B_cells 
ilmn_2066151 TEK Monocytes 
ilmn_1723035 OLR1 Monocytes 
ilmn_1668063 FCN1 Monocytes 
ilmn_2112357 CD300LF Monocytes 
ilmn_1651826 BASP1 Monocytes 
ilmn_1658926 NOTCH3 NK 
ilmn_2339294 LILRB5 NK 
ilmn_1781824 FASLG NK 
ilmn_2409384 SIGLEC7 NK 
ilmn_1770433 PIK3CG NK 
ilmn_1729915 PILRA NK 
ilmn_1795236 SIGLEC9 NK 
ilmn_1658399 KLRG1 NK 
ilmn_1796247 CRTAM NK 
ilmn_1688373 LST1 NK 
ilmn_1803945 HCP5 NK56_bright 
ilmn_1798270 C11orf75 NK56_bright 
ilmn_2178226 KRT86 NK56_bright 
ilmn_2352090 GPRC5C NK56_dim 
ilmn_1776640 MPL NK56_dim 
ilmn_1805404 GRIN1 NK56_dim 
ilmn_1705814 KRT80 NK56_dim 
ilmn_1698952 TNFRSF11A NKT 
ilmn_1667232 KIR2DL3 NKT 
ilmn_2190842 KIR3DL2 NKT 
ilmn_1786810 KIR2DL1 NKT 
ilmn_1752647 KLRC1 NKT 
ilmn_1750761 NCR1 NKT 
ilmn_1790692 GNLY NKT 
ilmn_2131828 KIR3DL1 NKT 
ilmn_1802096 ABTB1 Neutrophils 
ilmn_2363392 TNFSF14 Neutrophils 
ilmn_1678939 VNN2 Neutrophils 
ilmn_1669317 GPR77 Neutrophils 
ilmn_2092118 FPR1 Neutrophils 
ilmn_1740875 FPR2 Neutrophils 
ilmn_1688580 CAMP Neutrophils 
ilmn_3243190 EMR4P Neutrophils 
ilmn_1698367 CD84 TFH 
ilmn_1715131 CCR7 TFH 




Probe Gene Cell_type 
ilmn_1806725 PDCD1 TFH 
ilmn_2399363 CLEC4A TGD 
ilmn_1701248 TREM2 TGD 
ilmn_1711332 TFEC TGD 
ilmn_2415303 CLEC10A TGD 
ilmn_2203271 FPR3 TGD 
ilmn_1693009 FGL2 TGD 
ilmn_1731503 MARCO TGD 
ilmn_2359800 MS4A6A TGD 
ilmn_2203926 MRC1 TGD 
ilmn_1701195 PLA2G7 TGD 
ilmn_1738992 MNDA TGD 
ilmn_1761778 TNFSF8 TGD 
ilmn_1676372 CD209 TGD 
ilmn_1686623 CSF1R TGD 
ilmn_1791771 HCK TGD 
ilmn_1782070 NPL TGD 
ilmn_2085862 SLC15A3 TGD 
ilmn_1731240 FGF7 TGD 
ilmn_1795762 PLEK TGD 
ilmn_1810275 SLC7A7 TGD 
ilmn_1750961 TM6SF1 TGD 
ilmn_2123743 FCER1G TGD 
ilmn_1670302 HK3 TGD 
ilmn_1702231 C1orf54 TGD 
ilmn_1747622 CD33 TGD 
ilmn_1780533 RNASE6 TGD 
ilmn_1667224 SLAMF8 TGD 
ilmn_2382403 FCGR2B TGD 
ilmn_2342835 P2RY14 T_cells 
ilmn_1790350 TPRG1 T_cells 
ilmn_2370336 MS4A4A T_cells 
ilmn_1717197 CD3G T_cells 
ilmn_2086143 CCR4 T_cells 
ilmn_2355953 LILRB4 T_cells 
ilmn_1719433 CD1D T_cells 
ilmn_1668822 BATF T_cells 
ilmn_1772674 IL21 T_cells 
ilmn_1721762 IL18RAP T_cells 
ilmn_1740633 PRF1 T_cells 
ilmn_1674640 CXCR6 T_cells 
ilmn_1749362 CD28 T_cells 




Probe Gene Cell_type 
ilmn_1696463 SPI1 T_cells 
ilmn_1781700 IL18R1 T_cells 
ilmn_2389211 LAIR1 T_cells 
ilmn_1723520 CD1A T_cells 
ilmn_1719756 ZAP70 T_cells 
ilmn_1769782 LAX1 T_cells 
ilmn_1728106 TNF T_cells 
ilmn_1736311 POU2F2 T_cells 
ilmn_1739667 JAK3 T_cells 
ilmn_2207291 IFNG T_cells 
ilmn_1749591 ITGAL T_cells 
ilmn_2377669 CD247 T_cells 
ilmn_2109416 NAPSB T_cells 
ilmn_1651316 CD69 T_cells 
ilmn_1722411 HRH2 T_cells 
ilmn_1775501 IL1B T_cells 
ilmn_1798204 IL21R T_cells 
ilmn_1739421 CCR8 T_cells 
ilmn_1726230 CD1B T_cells 
ilmn_1683774 IL2RA T_cells 
ilmn_2059744 IL7 T_cells 
ilmn_2160476 CCL22 T_cells 
ilmn_1785202 STAT4 T_cells 
ilmn_1699908 IL12RB1 T_cells 
ilmn_1725519 CCL11 T_cells 
ilmn_2098126 CCL5 T_cells 
ilmn_2384188 NFATC1 T_cells 
ilmn_1666594 IRF8 T_cells 
ilmn_2337928 CXCR5 T_cells 
ilmn_2312340 LILRB2 T_cells 
ilmn_1671509 CCL3 T_cells 
ilmn_1681132 IL12B T_cells 
ilmn_1766363 FLT3 T_cells 
ilmn_2406132 LILRB3 T_cells 
ilmn_1699160 ITK T_cells 
ilmn_2377109 LCK T_cells 
ilmn_1778143 GRAP2 T_cells 
ilmn_1683456 CCL7 T_cells 
ilmn_2099528 BTLA T_cells 
ilmn_2335754 CD1E T_cells 
ilmn_1786303 LILRA3 T_cells 
ilmn_2353732 CD8A T_cells 




Probe Gene Cell_type 
ilmn_1654210 CD1C T_cells 
ilmn_2073307 IL10 T_cells 
ilmn_2316974 LILRB1 T_cells 
ilmn_1739794 CD3E T_cells 
ilmn_1683178 JAK2 T_cells 
ilmn_2325837 CD3D T_cells 
ilmn_1702385 LILRA4 T_cells 
ilmn_2061043 CD48 Th1 
ilmn_2175912 ITGB2 Th1 
ilmn_1792538 CD7 Th1 
ilmn_1746565 CD6 Th1 
ilmn_1677793 P2RX5 Th1 
ilmn_1653498 IGSF6 Th1 
ilmn_2359907 CD68 Th1 
ilmn_2376205 LTB Th1 
ilmn_1671353 IL12A Th1 
ilmn_1777519 ITGB7 Th1 
ilmn_2342066 METRNL Th1 
ilmn_2340217 PTPRC Th1 
ilmn_1802653 EBI3 Th1 
ilmn_1693826 HAVCR2 Th1 
ilmn_1813379 TNFRSF9 Th1 
ilmn_1673363 CD97 Th1 
ilmn_2415786 CD96 Th1 
ilmn_1730176 ITGAX Th1 
ilmn_2145033 CCR5 Th1 
ilmn_1708348 ADAM8 Th1 
ilmn_1795464 LTA Th1 
ilmn_1692714 TBX21 Th1 
ilmn_1662843 CD53 Th1 
ilmn_1685009 ITGAM Th1 
ilmn_2342579 IL7R Th1 
ilmn_2334210 ITGB4 Th1 
ilmn_1684943 TRAT1 Th1 
ilmn_2208903 CD52 Th1 
ilmn_1743570 CEACAM3 Th17 
ilmn_1715603 IL23A Th17 
ilmn_1769925 C2CD4A Th17 
ilmn_1749744 SH2D6 Th17 
ilmn_1774983 IL17A Th17 
ilmn_2227195 CCDC65 Th17 
ilmn_2043079 ILDR1 Th17 




Probe Gene Cell_type 
ilmn_1788109 IL17C Th17 
ilmn_1761766 GPR25 Th17 
ilmn_1655549 SIGLEC10 Th2 
ilmn_2338348 UBASH3A Th2 
ilmn_2170813 LAMP3 Th2 
ilmn_1675677 TMPRSS3 Th2 
ilmn_2406656 GATA3 Th2 
ilmn_1751400 SKAP1 Th2 
ilmn_2376431 CCR2 Th2 
ilmn_2125017 TIGIT Treg 
ilmn_1769129 CCL19 Treg 
ilmn_1788531 SIT1 Treg 
ilmn_1739393 SELE Treg 
ilmn_1698218 TRAF1 Treg 
ilmn_1677827 TLR7 Treg 
ilmn_1796642 NCF2 Treg 
ilmn_2313672 IL1RL1 Treg 
ilmn_1723004 CD72 Treg 
ilmn_1715417 SELP Treg 
ilmn_2414762 TLR10 Treg 
ilmn_1749006 RCSD1 Treg 
ilmn_2341229 CD34 Treg 
ilmn_2129668 TGFB1 Treg 
ilmn_1763487 CTLA4 Treg 
ilmn_1772387 TLR2 Treg 
ilmn_1705047 TLR8 Treg 
ilmn_1793730 TM7SF4 iDC 
ilmn_1750678 TIMD4 iDC 
ilmn_1797236 TGM2 iDC 
ilmn_1795715 DPYD iDC 
ilmn_1796409 C1QB iDC 
ilmn_1724066 PLCB2 iDC 
ilmn_1656057 PLAU iDC 





A.2 Enriched pathways 
A.2.1 Top enriched pathways in the Low Immune Subgroup  
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of numbers of genes contained in pathways to total genes in the 
Reactome FI network; “Number of protein in GeneSet” is the number of proteins within a given pathway; and “Protein from network” indicates 









Network P-value FDR Nodes 
The citric acid 




0.0148 161 66 1.11E-16 5.27E-14 ATP5C1, UQCRC1, UQCRC2, ECSIT, DLD, ATP5A1, SLC16A1, 
UQCRB, UQCRH, UQCRQ, NDUFC1, NDUFB9, NDUFB7, NDUFB3, 
NDUFB2, NDUFA8, NDUFA7, NDUFA4, NDUFA1, SUCLA2, BSG, 
ATP5S, ATP5J, ATP5H, ATP5O, ATP5E, ATP5D, NDUFAF2, 
NDUFAF1, COX7B, COX7C, COX8A, COX5B, COX5A, COX6C, 
NDUFAB1, TACO1, COX6A1, SDHC, COX6B1, NDUFB11, COX11, 
CYC1, PDHA1, CYCS, UQCRFS1, NDUFS5, NDUFS4, NDUFS2, 
NDUFS1, LRPPRC, IDH3A, PDK2, PDHX, COX7A2L, SUCLG1, 
TRAP1, DLAT, PDP2, NDUFA13, NDUFA11, NDUFA10, ATP5G3, 
ATP5G2, ATP5G1, ATP5F1 
Mitochondrial 
translation(R) 
0.0085 92 58 1.11E-16 5.27E-14 MRPL19, MRPL16, MRPL14, MRPL15, MRPL12, MRPL13, 
MRPL10, MRPL11, MRPL27, MRPL28, MRPL23, MRPL24, 
MRPL21, MRPL30, MRPL36, MRPL34, MRPL35, MRPL32, 
MRPL33, MRPL42, MRPL40, MRPL48, MRPL45, MRPL46, 













Network P-value FDR Nodes 
MRPL9, GADD45GIP1, MRPS17, MRPS15, MRPS28, MRPS26, 
MRPS27, MRPS24, MRPS23, MRPS2, MRPS21, MRPS7, MRPS5, 
MRPS9, MRPS35, MRPS36, MRPS33, MRPS34, MRPS30, 
MRPS18B, MRPS18A, GFM2, MRRF, TUFM, DAP3, TSFM, MTIF2 
Ribosome(K) 0.0142 154 59 1.32E-14 4.17E-12 MRPL19, MRPL16, MRPL14, MRPL15, MRPL12, MRPL13, 
MRPL10, MRPL11, MRPL27, MRPL28, MRPL23, MRPL24, 
MRPL21, MRPL30, RPLP1, RPLP0, MRPL36, MRPL34, MRPL35, 
MRPL32, MRPL33, MRPL4, MRPL3, MRPL2, MRPL1, MRPL9, 
RPL23A, MRPS17, MRPS15, MRPS2, MRPS21, MRPS7, MRPS5, 
MRPS9, RPL26L1, RPL4, RPL32, RPL34, RPL8, RPL6, RPL7, RPL36, 
RPL39, RPL22, RPL29, RPL12, RPS2, RPL10A, RPS7, RPS5, RPL7A, 





0.0455 494 121 9.03E-14 2.14E-11 CSNK2A1, CSNK2A2, NR2F6, ZNF45, MED20, PMS2, ATAD2, 
CENPJ, STK11, CDC25C, MSH2, SMYD2, MNAT1, EXO1, RABGGTB, 
BIRC5, E2F1, E2F7, NDUFA4, TRIM28, CSNK2B, KCTD15, 
SUPT4H1, WWTR1, COX7B, BRCA1, COX7C, HNF4A, COX8A, KIT, 
YAP1, PCNA, COX5B, COX5A, TCEB2, TCEB1, NPM1, COX6C, 
RPA3, TACO1, COX6A1, COX6B1, CCNB1, COX11, TFAP2A, 
SUPT5H, CYCS, YWHAE, CHD4, TRIAP1, YWHAQ, YWHAG, TGIF1, 
TAF9, AURKB, AURKA, TGS1, SSRP1, ERCC3, ERCC2, TAF4, TAF2, 
GLS, MYC, PIP4K2B, MED1, NEDD4L, PRDX5, PRELID1, PLK2, GPI, 
PHF20, ING2, TEAD1, TEAD4, GTF2H2, GTF2H4, LRPPRC, YEATS4, 
USP7, SUPT16H, GTF2F1, GTF2F2, FANCI, CDK8, CDK5, RHEB, 













Network P-value FDR Nodes 
POLR2E, POLR2F, RBBP7, POLR2I, TP53RK, KAT5, CHEK1, 
COX7A2L, RRAGB, RRAGD, DNA2, TPX2, RPTOR, PRMT5, PRMT1, 
SGK1, NR6A1, CDK5R1, KCTD1, TBL1XR1, SMAD2, KDM5B, THRA, 
HSPD1, ERBB2, BAX 
rRNA 
processing(R) 
0.0165 179 62 2.15E-13 4.08E-11 RPLP1, RPLP0, TRMT112, NSUN4, BYSL, TSR1, ISG20L2, 
HSD17B10, NOP56, NOP58, RPL23A, NOL11, UTP14A, EXOSC7, 
EXOSC5, EXOSC4, PES1, EXOSC8, BOP1, DKC1, RPP21, RPP25, 
DDX49, UTP15, UTP18, RPL4, RPL32, RPL34, RPL8, RPL6, RRP9, 
RPL7, RPL36, RPL39, RPL22, RPL29, GAR1, PNO1, RIOK2, RPL12, 
RPS2, WDR18, WDR12, RPL10A, RPS7, RPS5, NHP2, WDR3, 
RPL7A, NOB1, RPL37A, RPL36A, RPL35A, PWP2, RPS15, RPS13, 
RPS21, NOL9, EMG1, RPS3A, SENP3, SKIV2L2 
Parkinson's 
disease(K) 
0.0131 142 53 7.80E-13 1.23E-10 ATP5C1, UQCRC1, UQCRC2, GPR37, ATP5A1, UQCRB, UQCRH, 
UQCRQ, NDUFC1, SLC25A5, SLC25A4, NDUFB9, NDUFB7, 
NDUFB3, NDUFB2, NDUFA8, NDUFA7, NDUFA4, NDUFA1, ATP5J, 
ATP5H, ATP5O, ATP5E, ATP5D, COX7B, COX7C, COX8A, COX5B, 
COX5A, COX6C, NDUFAB1, COX6A1, SDHC, COX6B1, NDUFB11, 
CYC1, CYCS, UQCRFS1, NDUFS5, NDUFS4, NDUFS2, NDUFS1, 
COX7A2L, VDAC2, VDAC1, NDUFA13, NDUFA11, NDUFA10, 
ATP5G3, ATP5G2, ATP5G1, ATP5F1, SNCA 
Mitotic 
Prometaphase(R) 
0.0091 99 43 1.00E-12 1.36E-10 CSNK2A1, CSNK2A2, CDCA5, NCAPG, CDCA8, CENPA, CENPF, 
APITD1, CENPI, CENPL, CENPM, CENPN, CENPO, CENPQ, NDC80, 
BIRC5, CSNK2B, KIF2C, MAD2L1, ERCC6L, BUB1B, CCNB2, CCNB1, 













Network P-value FDR Nodes 
HDAC8, ZW10, ZWINT, AHCTF1, XPO1, RANBP2, KIF18A, CKAP5, 
ITGB3BP, BUB1, CLASP1, CLASP2 
Mitotic Metaphase 
and Anaphase(R) 
0.0151 164 57 1.76E-12 2.08E-10 PSMD8, PSMD4, PSMD2, PSMD3, PSME3, CDCA5, CDCA8, 
CENPA, PSMB7, PSMB4, PSMB5, CENPF, APITD1, CENPI, CENPL, 
CENPM, CENPN, CENPO, CENPQ, ANAPC5, NDC80, BIRC5, CDC16, 
KIF2C, MAD2L1, ERCC6L, BUB1B, BANF1, PSMD10, PSMD12, 
PSMD11, PSMD14, PSMD13, UBE2C, NUP133, AURKB, SEH1L, 
SKA1, ANAPC11, RAD21, PLK1, NUF2, ESPL1, HDAC8, PPP2R1A, 
ZW10, ZWINT, AHCTF1, XPO1, RANBP2, PTTG1, KIF18A, CKAP5, 
ITGB3BP, BUB1, CLASP1, CLASP2 
Oxidative 
phosphorylation(K) 
0.0122 133 50 2.69E-12 2.78E-10 ATP5C1, UQCRC1, UQCRC2, ATP5A1, UQCRB, UQCRH, UQCRQ, 
NDUFC1, NDUFB9, NDUFB7, NDUFB3, NDUFB2, NDUFA8, 
NDUFA7, NDUFA4, NDUFA1, ATP6V1E2, ATP5J, ATP5H, ATP5O, 
ATP5E, ATP5D, ATP6V1C1, COX7B, COX7C, COX8A, COX5B, 
COX5A, COX6C, NDUFAB1, COX6A1, SDHC, COX6B1, NDUFB11, 
COX11, CYC1, UQCRFS1, NDUFS5, NDUFS4, NDUFS2, NDUFS1, 
COX7A2L, NDUFA13, NDUFA11, NDUFA10, ATP6V1D, ATP5G3, 
ATP5G2, ATP5G1, ATP5F1 
Alzheimer's 
disease(K) 
0.0157 171 58 2.92E-12 2.78E-10 ATP5C1, UQCRC1, UQCRC2, EIF2AK3, GRIN2C, ATP5A1, UQCRB, 
UQCRH, NAE1, UQCRQ, NDUFC1, NDUFB9, NDUFB7, NDUFB3, 
NDUFB2, HSD17B10, NDUFA8, NDUFA7, NDUFA4, NDUFA1, 
ATP5J, ATP5H, ATP5O, APH1B, ATP5E, ATP5D, COX7B, COX7C, 
COX8A, COX5B, COX5A, COX6C, NDUFAB1, COX6A1, SDHC, 
COX6B1, NDUFB11, CYC1, CYCS, GSK3B, UQCRFS1, NDUFS5, 













Network P-value FDR Nodes 
CDK5R1, NDUFA13, NDUFA11, NDUFA10, ATP5G3, ATP5G2, 
ATP5G1, ATP5F1, SNCA 
Huntington's 
disease(K) 
0.0178 193 62 4.81E-12 4.14E-10 ATP5C1, UQCRC1, UQCRC2, PPARGC1A, ATP5A1, UQCRB, 
UQCRH, UQCRQ, NDUFC1, SLC25A5, SLC25A4, NDUFB9, NDUFB7, 
NDUFB3, NDUFB2, NDUFA8, NDUFA7, NDUFA4, NDUFA1, ATP5J, 
ATP5H, ATP5O, ATP5E, ATP5D, RCOR1, COX7B, COX7C, COX8A, 
COX5B, COX5A, COX6C, NDUFAB1, COX6A1, SDHC, COX6B1, 
NDUFB11, CYC1, CYCS, UQCRFS1, NDUFS5, NDUFS4, NDUFS2, 
NDUFS1, TAF4, CREB3L4, CLTC, POLR2C, POLR2D, POLR2E, 
POLR2F, POLR2I, COX7A2L, VDAC2, VDAC1, NDUFA13, NDUFA11, 
NDUFA10, ATP5G3, ATP5G2, ATP5G1, ATP5F1, BAX 
Cell Cycle 
Checkpoints(R) 
0.0151 164 52 3.95E-10 3.12E-08 PSMD8, PSMD4, PSMD2, PSMD3, GTSE1, PSME3, PSMB7, 
PSMB4, PSMB5, CDC25C, CDC25A, ANAPC5, PKMYT1, MCM10, 
EXO1, HERC2, BRCC3, CDC16, BRCA1, RPA3, MAD2L1, BUB1B, 
UBE2V2, PSMD10, PSMD12, PSMD11, PSMD14, PSMD13, CCNB2, 
CCNB1, UBE2C, YWHAE, YWHAQ, YWHAG, RNF8, ANAPC11, 
CDC7, CDC6, CDK2, RFC5, RFC3, RFC4, MCM3, MCM4, RBBP8, 




0.0103 112 41 5.25E-10 3.83E-08 RPLP1, RPLP0, EIF1AX, EIF4EBP1, EIF5B, EIF4B, RPL23A, EIF3M, 
EIF3K, EIF3I, EIF3H, EIF3F, EIF3D, PABPC1, RPL4, RPL32, RPL34, 
RPL8, RPL6, RPL7, RPL36, RPL39, RPL22, RPL29, RPL12, RPS2, 
RPL10A, RPS7, RPS5, EIF2B3, EIF2B2, RPL7A, RPL37A, RPL36A, 

















0.0139 151 48 1.71E-09 1.15E-07 AKT2, AKT3, UQCRC1, UQCRC2, EIF2AK3, PKLR, UQCRB, UQCRH, 
UQCRQ, PIK3CB, NDUFC1, NDUFB9, NDUFB7, NDUFB3, NDUFB2, 
NDUFA8, NDUFA7, NDUFA4, NDUFA1, PIK3R2, COX7B, COX7C, 
COX8A, COX5B, COX5A, COX6C, NDUFAB1, COX6A1, SDHC, 
COX6B1, NDUFB11, CYC1, CYCS, GSK3B, UQCRFS1, NDUFS5, 
NDUFS4, NDUFS2, NDUFS1, IRS2, MLXIP, COX7A2L, NDUFA13, 
NDUFA11, NDUFA10, ADIPOR1, ADIPOR2, BAX 
S Phase(R) 0.0113 123 42 2.40E-09 1.51E-07 PSMD8, PSMD4, PSMD2, PSMD3, PSME3, CDCA5, PSMB7, 
PSMB4, PSMB5, CDC25A, MNAT1, POLA1, PCNA, RPA3, PSMD10, 
PSMD12, PSMD11, PSMD14, PSMD13, POLD2, POLE4, POLE2, 
MYC, RAD21, CDC6, CDK4, CDK2, RFC5, RFC3, RFC4, MCM3, 




0.016 174 52 2.81E-09 1.66E-07 PSMD8, PSMD4, PSMD2, PSMD3, GTSE1, PSME3, DYNLL1, 
PSMB7, PSMB4, PSMB5, CENPF, CENPJ, NEK2, CDC25C, CDC25A, 
PKMYT1, TUBGCP5, TUBGCP4, MNAT1, HSP90AB1, FOXM1, 
E2F1, CETN2, DYNC1I2, DYNC1H1, PSMD10, PSMD12, PSMD11, 
PSMD14, PSMD13, CCNB2, CCNB1, YWHAE, YWHAG, CCNA2, 
AURKA, CEP70, CEP76, PLK4, PLK1, PHLDA1, FKBPL, HMMR, 
CDK2, CEP152, PPP2R1A, TPX2, XPO1, TUBG1, CKAP5, CLASP1, 
WEE1 
Cell cycle(K) 0.0114 124 40 2.59E-08 1.43E-06 CDC25C, CDC25A, ANAPC5, PKMYT1, E2F1, CDC16, PCNA, 
MAD2L1, BUB1B, CCNE2, CCNE1, CCNB3, CCNB2, CCNB1, 
YWHAE, GSK3B, YWHAQ, YWHAG, CCNA2, MYC, ANAPC13, 













Network P-value FDR Nodes 




0.012 130 40 8.81E-08 4.58E-06 PSMD8, PSMD4, PSMD2, PSMD3, PSME3, DHFR, PSMB7, PSMB4, 
PSMB5, CDC25A, MNAT1, MCM10, E2F1, POLA1, PCNA, RPA3, 
CCNE2, CCNE1, PSMD10, PSMD12, PSMD11, PSMD14, PSMD13, 
CCNB1, RRM2, POLE4, POLE2, MYC, CDC7, CDC6, CDK4, CDK2, 
TFDP2, MCM3, MCM4, SKP2, TOP2A, TYMS, CKS1B, WEE1 
Nucleotide 
Excision Repair(R) 
0.0094 102 34 1.34E-07 6.71E-06 ACTL6A, DDB1, RUVBL1, INO80C, MNAT1, CETN2, PCNA, RPA3, 
UBE2V2, PPIE, POLD2, ERCC3, ERCC1, ERCC2, ERCC8, GTF2H2, 
GTF2H4, USP7, CHD1L, COPS4, COPS5, COPS2, COPS8, RFC5, 








A.2.2 Top enriched pathways in the CTNNB1 dominant group in the whole dataset 
 “GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of numbers of genes contained in pathways to total genes in the 
Reactome FI network; “Number of protein in GeneSet” is the number of proteins within a given pathway; and “Protein from network” indicates 










Network P-value FDR Nodes 
Melanogenesis(K) 0.0093 101 3 3.36E-04 0.0221 GNAI2, CTNNB1, WNT2 
role of brca1 brca2 and atr in cancer 
susceptibility(B) 
0.0018 20 2 3.50E-04 0.0221 RAD1, ATR 
Generic Transcription Pathway(R) 0.0455 494 5 3.97E-04 0.0221 PPP2R5C, POLR2C, RAD1, TAF9B, 
ATR 
p53 pathway feedback loops 2(P) 0.0022 24 2 5.02E-04 0.0221 CTNNB1, ATR 
Tight junction(K) 0.0126 137 3 8.14E-04 0.026 GNAI2, PARD6A, CTNNB1 
Transcriptional regulation of 
pluripotent stem cells(R) 
0.0033 36 2 1.12E-03 0.026 FOXP1, POLR2C 
Hippo signaling pathway(K) 0.0142 154 3 1.14E-03 0.026 PARD6A, CTNNB1, WNT2 
ATR signaling pathway(N) 0.0034 37 2 1.18E-03 0.026 RAD1, ATR 
Fanconi anemia pathway(N) 0.0041 45 2 1.74E-03 0.0322 RAD1, ATR 
TGF-beta receptor signaling(N) 0.0043 47 2 1.89E-03 0.0322 PARD6A, CTNNB1 
Basal cell carcinoma(K) 0.0051 55 2 2.57E-03 0.0397 CTNNB1, WNT2 
Rap1 signaling pathway(K) 0.0195 212 3 2.83E-03 0.0397 GNAI2, PARD6A, CTNNB1 
CDC42 signaling events(N) 0.0064 70 2 4.12E-03 0.0492 PARD6A, CTNNB1 














Network P-value FDR Nodes 
HTLV-I infection(K) 0.0237 258 3 4.92E-03 0.0492 CTNNB1, WNT2, ATR 
Regulation of nuclear beta catenin 
signaling and target gene 
transcription(N) 
0.0074 80 2 5.34E-03 0.0492 MDFIC, CTNNB1 
Signaling events mediated by 
Hepatocyte Growth Factor Receptor 
(c-Met)(N) 
0.0074 80 2 5.34E-03 0.0492 PARD6A, CTNNB1 







A.2.3 Top enriched pathways in the MYC dominant group in the whole dataset 
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of numbers of genes contained in pathways to total genes in the 
Reactome FI network; “Number of protein in GeneSet” is the number of proteins within a given pathway; and “Protein from network” indicates 










Network P-value FDR Nodes 
Keratinization(R) 0.0099 108 18 1.11E-16 2.26E-14 SPRR2E, KRT80, KLK5, KLK8, 
EVPL, CASP14, SPRR2A, DSP, JUP, 
KRT1, SPINK5, KRT10, KRT5, 
KRT15, KRT14, PKP3, DSC1, DSC3 
Validated transcriptional targets of 
deltaNp63 isoforms(N) 
0.0041 45 4 1.09E-05 1.11E-03 SFN, TP63, KRT5, KRT14 
a6b1 and a6b4 Integrin signaling(N) 0.0032 35 3 1.70E-04 0.0115 COL17A1, EGFR, SFN 
Bladder cancer(K) 0.0038 41 3 2.69E-04 0.0131 EGFR, MYC, FGFR3 
p53 pathway(P) 0.004 44 3 3.31E-04 0.0131 SFN, TP63, SERPINB5 
Posttranslational regulation of 
adherens junction stability and 
dissassembly(N) 
0.0044 48 3 4.26E-04 0.0131 EGFR, DSP, JUP 
Validated transcriptional targets of 
TAp63 isoforms(N) 
0.0045 49 3 4.52E-04 0.0131 EVPL, TP63, SERPINB5 
Direct p53 effectors(N) 0.0121 132 4 6.72E-04 0.0168 EGFR, SFN, TP63, SERPINB5 
Central carbon metabolism in 
cancer(K) 














Network P-value FDR Nodes 
p73 transcription factor network(N) 0.0069 75 3 1.54E-03 0.0275 MYC, SFN, TP63 
Glucocorticoid receptor regulatory 
network(N) 
0.0072 78 3 1.72E-03 0.0275 SFN, KRT5, KRT14 
Regulation of nuclear beta catenin 
signaling and target gene 
transcription(N) 
0.0074 80 3 1.85E-03 0.0275 MYC, SFN, KRT1 
E-cadherin signaling in 
keratinocytes(N) 
0.0019 21 2 1.89E-03 0.0275 EGFR, JUP 
MicroRNAs in cancer(K) 0.0275 299 5 1.97E-03 0.0275 EGFR, MYC, TP63, SERPINB5, 
FGFR3 
p53 pathway feedback loops 2(P) 0.0022 24 2 2.46E-03 0.032 MYC, TP63 







A.2.4  Top enriched pathways in the High Immune Subgroup 
“GeneSet” is the pathway name, “Ratio of protein in Geneset” indicates ratios of numbers of genes contained in pathways to total genes in the 
Reactome FI network; “Number of protein in GeneSet” is the number of proteins within a given pathway; and “Protein from network” indicates 
















0.0063 68 42 1.11E-16 1.99E-14 JAK1, RNASEL, STAT1, STAT2, PSMB8, SOCS3, SOCS1, PTPN6, 
IFI35, RSAD2, IFI27, BST2, ISG15, ISG20, ADAR, IRF3, IRF1, IRF2, 
IRF7, IRF5, IRF9, SAMHD1, MX1, IFNAR2, IFITM3, IFITM1, 
IFITM2, IFIT1, IFIT3, IFIT2, HLA-B, HLA-C, HLA-A, HLA-F, HLA-E, 




0.0071 77 39 1.11E-16 1.99E-14 RFX5, PSME1, PSME2, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-
DRB1, HLA-DPA1, HLA-DMA, HLA-DMB, KIR3DL3, HLA-DPB1, 
HLA-DOA, KIR2DL5A, HLA-DRA, CIITA, IFI30, CTSS, CTSB, CD74, 
CD8B, KIR2DL4, TAPBP, CD4, HLA-DQA1, KIR2DS3, KIR2DS5, 
HLA-DQB1, TAP2, TAP1, B2M, HLA-B, HLA-C, HLA-A, HLA-F, 
















Network P-value FDR Nodes 
Influenza A(K) 0.0161 175 56 1.11E-16 1.99E-14 HLA-DRB5, HLA-DRB4, EIF2AK2, EIF2AK4, HLA-DRB3, HLA-
DRB1, IKBKB, IKBKE, JAK1, HLA-DPA1, RNASEL, HLA-DMA, HLA-
DMB, STAT1, STAT2, HLA-DPB1, HLA-DOA, SOCS3, TNFRSF10A, 
NFKB1, TNFRSF10D, CXCL10, HLA-DRA, MYD88, CIITA, PIK3CD, 
CCL2, ICAM1, TNFSF10, RSAD2, PIK3R1, IL18, IL33, IL6, ADAR, 
DDX58, IRF3, IRF7, IRF9, MX1, HLA-DQA1, IFIH1, IFNGR1, HLA-
DQB1, IFNAR2, MAP2K3, PML, TYK2, TLR4, TLR3, FAS, NFKBIA, 




0.0067 73 47 1.11E-16 1.99E-14 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK1, HLA-DPA1, 
PTAFR, STAT1, HLA-DPB1, PIAS1, SOCS3, SOCS1, HLA-DRA, 
CIITA, PTPN6, IFI30, ICAM1, TRIM26, TRIM21, TRIM22, IRF3, 
IRF1, IRF2, IRF7, IRF5, IRF9, HLA-DQA1, TRIM8, TRIM5, IFNGR1, 
HLA-DQB2, HLA-DQB1, PML, B2M, HLA-B, HLA-C, HLA-A, HLA-F, 
HLA-E, SP100, OASL, OAS1, OAS2, OAS3, GBP2, GBP1, CAMK2G 
Signaling by 
Interleukins(R) 
0.0423 460 99 1.11E-16 1.99E-14 PSME1, PSME2, PDGFB, IL22RA2, IL18BP, IKBKB, IKBKG, JAK1, 
DUSP5, RAPGEF1, PTAFR, STAT1, STAT3, PSMB8, PSMB9, 
F13A1, RORA, PIM1, MAP3K8, SOCS3, SOCS1, NFKB1, NFKB2, 
CXCL10, MYD88, RASGRF2, PIK3CD, KSR1, TNFRSF1B, IL2RG, 
CCL2, FYN, PTPN6, IL27RA, ICAM1, PIK3R1, CCR1, STAT5B, IL24, 
SYK, IL18, OSMR, IL32, IL33, KITLG, PDGFRB, PDGFRA, IL4R, 
RASGRP1, RASGRP4, RASGRP3, IRAK2, IL6, MMP2, IRAK3, 
MMP9, IL9R, PSMB10, PTK2B, CD4, JUNB, HIF1A, HMOX1, 
TIMP1, ZEB1, ALOX5, CSF2, CSF1, FGF1, IL13RA1, RASAL3, 
















Network P-value FDR Nodes 
IL1R2, TWIST1, LIF, GFRA1, TYK2, GFRA2, VAV1, RHOU, IL11RA, 




0.017 185 57 2.22E-16 3.31E-14 C3, HLA-DRB5, HLA-DRB4, EIF2AK2, EIF2AK4, HLA-DRB3, HLA-
DRB1, IKBKB, IKBKG, IKBKE, JAK1, HLA-DPA1, RNASEL, HLA-
DMA, HLA-DMB, STAT1, STAT2, HLA-DPB1, HLA-DOA, SOCS3, 
NFKB1, HLA-DRA, MYD88, CCL2, CD74, IL6, DDX58, IRF3, IRF7, 
IRF9, CFP, HLA-DQA1, IFIH1, IFNGR1, HLA-DQB1, IFNAR2, TAP2, 
TAP1, TRAF3, TRAF5, PML, IFIT1, HLA-B, HLA-C, HLA-A, HLA-F, 





















0.0244 265 67 7.88E-15 1.01E-12 PDGFB, IL22RA2, PDGFC, CRLF2, CXCL13, CXCL14, CXCL16, 
LEPR, TNFRSF8, TNFRSF4, TNFRSF11B, TNFRSF10A, 
TNFRSF10D, CXCL10, CXCL11, CXCL12, FLT4, TNFSF13B, 
TNFRSF1B, IL2RG, CCL8, CCL2, TNFRSF6B, TNFSF10, TNFSF11, 
CCR1, TNFSF13, CD40, TNFRSF13B, IL24, IL18, OSMR, CD70, 
KITLG, PDGFRB, PDGFRA, IL4R, IL6, IL9R, TNFSF4, IFNGR1, 
CCL18, CCL16, CCL25, CCL23, CSF2, CSF1, IL13RA1, IFNAR2, 
CX3CR1, IL15RA, IL1R1, IL1R2, LIF, CX3CL1, CXCR3, CD40LG, 




0.0098 107 39 9.58E-14 1.07E-11 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, IKBKB, IKBKG, 
JAK1, HLA-DPA1, HLA-DMA, HLA-DMB, STAT1, STAT3, HLA-
DPB1, RORA, HLA-DOA, NFKB1, HLA-DRA, IL2RG, IL27RA, 
STAT5B, PPP3CC, IL4R, IL6, CD4, PRKCQ, HIF1A, HLA-DQA1, 
NFATC2, IFNGR1, RARA, HLA-DQB1, AHR, LAT, IL1R1, RUNX1, 




0.0172 187 52 2.71E-13 2.68E-11 PREX1, LYN, IKBKB, IKBKG, STAT1, STAT2, STAT3, CXCL13, 
CXCL14, CXCL16, RAP1A, NFKB1, CXCL10, CXCL11, CXCL12, 
PIK3CD, ARRB2, ROCK1, ROCK2, CCL8, CCL2, PIK3R1, CCR1, 
STAT5B, GNGT2, RAC2, GNAI2, PAK1, RASGRP2, GRK5, GRK6, 
PTK2B, ADCY4, ADCY3, ADCY7, CCL18, CCL16, CCL25, CCL23, 
SOS1, CX3CR1, CX3CL1, VAV3, VAV1, WAS, CXCR3, CCL4L1, 





















0.0156 170 49 3.75E-13 3.34E-11 TXNIP, RBCK1, IKBKB, IKBKG, IKBKE, JAK1, RIPK3, RNASEL, 
STAT1, STAT2, NFKB1, MYD88, CCL2, CTSB, IL18, CYBA, 
CARD16, IL6, TNFAIP3, IRF3, IRF7, IRF9, ATG12, MEFV, GSDMD, 
TMEM173, CARD9, IFNAR2, ITPR1, PSTPIP1, TRAF3, TRAF5, 
RNF31, NOD1, NLRC4, NOD2, TYK2, TLR4, NLRP1, NFKBIA, 
CXCL2, CASP8, CASP5, CASP1, OAS1, OAS2, OAS3, GBP2, GBP1 
TNF signaling 
pathway(K) 
0.0101 110 38 9.68E-13 7.84E-11 IKBKB, CASP10, IKBKG, RIPK3, MAP3K8, MAP3K5, SOCS3, 
NFKB1, CXCL10, PIK3CD, TNFRSF1B, CCL2, ICAM1, PIK3R1, IL6, 
TNFAIP3, MMP9, CREB3L1, JUNB, CSF2, CSF1, MAP2K3, BCL3, 
MAP3K14, TRADD, TRAF3, TRAF5, CEBPB, NOD2, CFLAR, LIF, 




0.0087 95 35 1.32E-12 9.77E-11 LYN, IKBKB, IKBKG, TICAM2, LY96, NFKB1, NFKB2, CXCL12, 
MYD88, TNFSF13B, ICAM1, TNFSF11, BTK, CD40, SYK, RELB, 
CARD11, TNFAIP3, DDX58, PRKCQ, PLCG2, MAP3K14, LAT, 
TRADD, TRAF3, TRAF5, CFLAR, IL1R1, GADD45B, TLR4, CD40LG, 
CCL4L1, NFKBIA, CXCL2, BLNK 
Measles(K) 0.0125 136 42 2.17E-12 1.48E-10 EIF2AK2, EIF2AK4, IKBKE, JAK1, STAT1, STAT2, STAT3, 
TNFRSF10A, NFKB1, TNFRSF10D, MYD88, PIK3CD, IL2RG, FYN, 
TNFSF10, PIK3R1, STAT5B, CCND3, CCND2, IL6, TNFAIP3, ADAR, 
DDX58, IRF3, IRF7, IRF9, MX1, PRKCQ, CDKN1B, IFIH1, IFNGR1, 
TACR1, IFNAR2, CBLB, SH2D1A, TYK2, TLR4, FAS, NFKBIA, 
















Network P-value FDR Nodes 
Osteoclast 
differentiation(K) 
0.0121 132 41 3.34E-12 2.14E-10 IKBKB, IKBKG, JAK1, STAT1, STAT2, NCF4, TNFRSF11B, SOCS3, 
SOCS1, NFKB1, NFKB2, PIK3CD, LCP2, FYN, FCGR2A, TNFSF11, 
BTK, PIK3R1, PPP3CC, SYK, RELB, CYBA, OSCAR, SIRPB1, IRF9, 
JUNB, PLCG2, NFATC2, FOSL2, CYLD, IFNGR1, CSF1, IFNAR2, 
MAP3K14, IL1R1, TYK2, CAMK4, SIRPG, NFKBIA, BLNK, TGFBR2 
Viral 
myocarditis(K) 
0.0054 59 27 4.24E-12 2.50E-10 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, BID, HLA-DPB1, HLA-DOA, HLA-DRA, FYN, 
ICAM1, CD40, RAC2, LAMA2, HLA-DQA1, HLA-DQB1, SGCA, 
HLA-B, HLA-C, HLA-A, HLA-F, HLA-E, CD40LG, CASP8, MYH6 
Natural killer cell 
mediated 
cytotoxicity(K) 
0.0124 135 41 6.61E-12 3.70E-10 HCST, BID, KIR2DL5A, TNFRSF10A, TNFRSF10D, PIK3CD, LCP2, 
SH3BP2, FYN, GZMB, PTPN6, ICAM2, ICAM1, TNFSF10, PIK3R1, 
PPP3CC, RAC2, SYK, PAK1, MICB, KIR2DL4, PTK2B, PLCG2, 
KIR2DS3, KIR2DS5, NFATC2, IFNGR1, CSF2, IFNAR2, LAT, SOS1, 





0.0052 56 26 7.71E-12 3.82E-10 C2, C3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-
DPA1, PTAFR, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-
DRA, C1S, C1R, FCGR2A, ICAM1, MASP1, CFB, CFD, CFH, CFI, 
















Network P-value FDR Nodes 
Tuberculosis(K) 0.0165 179 48 7.80E-12 3.82E-10 RFX5, C3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, 
CASP10, JAK1, HLA-DPA1, HLA-DMA, HLA-DMB, BID, STAT1, 
HLA-DPB1, HLA-DOA, CORO1A, NFKB1, HLA-DRA, MYD88, 
CIITA, APAF1, KSR1, FCGR2A, CTSS, PPP3CC, SYK, IL18, CD74, 
IRAK2, VDR, IL6, HLA-DQA1, MRC2, IFNGR1, HLA-DQB1, 
CARD9, CLEC4E, CLEC7A, TRADD, LSP1, CR1, CEBPB, NOD2, 
TLR1, TLR4, TGFB3, CASP8, CAMK2G 
Th1 and Th2 cell 
differentiation(K) 
0.0085 92 33 1.15E-11 5.41E-10 RBPJ, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, IKBKB, 
IKBKG, JAK1, HLA-DPA1, HLA-DMA, HLA-DMB, STAT1, HLA-
DPB1, HLA-DOA, MAF, NFKB1, HLA-DRA, IL2RG, STAT5B, 
PPP3CC, IL4R, CD4, MAML1, PRKCQ, HLA-DQA1, NFATC2, 





A.2.5  Genes differentially expressed between CNNTB1 dominant and MYC 
dominant group in the Low Immune Subgroup 
probe gene detected05 z p_value 
ilmn_1663158 ZNF174 0.8375 -5.9197 3.23E-09 
ilmn_2084391 RAD18 0.7729167 -5.819325 5.91E-09 
ilmn_2335198 NCOA1 0.7020833 -5.648805 1.62E-08 
ilmn_2248863 ZBTB38 0.8708333 -5.635275 1.75E-08 
ilmn_1654112 PARD6A 0.8333333 -5.595262 2.20E-08 
ilmn_1688041 TMEM53 0.9166667 -5.36422 8.13E-08 
ilmn_1764297 ARF6 0.9083334 -5.350971 8.75E-08 
ilmn_1652309 TTC8 0.81875 -5.337494 9.42E-08 
ilmn_1794560 TMEM93 0.8416666 -5.2772 1.31E-07 
ilmn_3248941 C6orf225 0.8270833 -5.170131 2.34E-07 
ilmn_1699362 IK 0.8270833 -5.156789 2.51E-07 
ilmn_1809259 HRASLS2 0.4958333 -5.089804 3.58E-07 
ilmn_2356786 ADD1 0.875 -5.063047 4.13E-07 
ilmn_1765880 C16orf57 0.9458333 -5.063033 4.13E-07 
ilmn_1700419 HSPC171 0.8104166 -5.02957 4.92E-07 
ilmn_1660223 CREBL2 0.90625 -5.026237 5.00E-07 
ilmn_2155516 QTRTD1 0.8083333 -4.962656 6.95E-07 
ilmn_3237779 TMEM184C 0.8604167 -4.956006 7.20E-07 
ilmn_1741462 FAHD1 0.7916667 -4.9225 8.55E-07 
ilmn_1718265 ATG5 0.5541667 -4.922486 8.55E-07 
ilmn_1798053 SEPT14 0.6229166 -4.902463 9.46E-07 
ilmn_1807807 SKA2 0.9041666 -4.88233 1.05E-06 
ilmn_1715901 FBXL17 0.7791666 -4.878997 1.07E-06 
ilmn_1659082 ZCRB1 0.7958333 -4.868945 1.12E-06 
ilmn_2371470 C1orf124 0.75 -4.842653 1.28E-06 
ilmn_3234775 SLAIN2 0.8104166 -4.828843 1.37E-06 
ilmn_1746426 TOMM70A 0.8979167 -4.825456 1.40E-06 
ilmn_1812254 KIF5A 0.7854167 -4.822095 1.42E-06 
ilmn_1667201 WDR51B 0.6875 -4.822095 1.42E-06 
ilmn_1708580 PDZK1IP1 0.4229167 4.808724 1.52E-06 
ilmn_1665761 BCL11B 0.7333333 4.838964 1.30E-06 
ilmn_1722718 BMP2 0.4604167 4.848866 1.24E-06 
ilmn_1730223 RNF39 0.55 4.855559 1.20E-06 
ilmn_1770922 TMEM45A 0.86875 4.862252 1.16E-06 
ilmn_1795359 SPRR2A 0.4354167 4.865612 1.14E-06 
ilmn_1674386 PITX1 0.6604167 4.875638 1.09E-06 




probe gene detected05 z p_value 
ilmn_2094952 NUAK2 0.7354167 4.909115 9.15E-07 
ilmn_1752813 UGT1A6 0.3604167 4.919279 8.69E-07 
ilmn_2067656 CCND2 0.8729166 4.982777 6.27E-07 
ilmn_2110271 OLFM2 0.825 5.006159 5.55E-07 
ilmn_1798577 SLC6A11 0.55 5.009548 5.46E-07 
ilmn_1763491 CKMT1B 0.6145833 5.009987 5.44E-07 
ilmn_1750785 SYTL1 0.4 5.196902 2.03E-07 
ilmn_1768772 DEGS2 0.4583333 5.23041 1.69E-07 






A.3 Representative images of antibody optimisation 
A.3.1 Representation of antibody optimisation for MYC. Magnification 20X 
 












A.4 Top genes differentially expressed by smoking status (never/ever) 
in the whole dataset and in the High Immune Subgroup 
A.4.1 The top 20 genes differentially expressed by smoking status 
(never/ever) in the whole dataset. The negative z indicates that the 
gene is higher in ever smokers 
probe gene z P-value FDR 
ilmn_1772163 PRKY -4.16 0.00003 0.14 
ilmn_1693338 CYP1B1 -4.09 0.00004 0.14 
ilmn_1732039 DDX3Y -4.26 0.00002 0.15 
ilmn_1756506 CYorf15B -4.16 0.00003 0.15 
ilmn_1721218 KRT13 4.09 0.00004 0.16 
ilmn_2052433 CYorf14 -4.20 0.00003 0.16 
ilmn_1730670 FSTL3 -4.01 0.00006 0.17 
ilmn_1787831 ODF3L2 4.02 0.00006 0.17 
ilmn_1783142 RPS4Y1 -4.28 0.00002 0.18 
ilmn_1776195 TMSB4Y -3.94 0.00008 0.20 
ilmn_2090059 ZFY -3.92 0.00009 0.20 
ilmn_1734205 RASSF1 -4.49 0.00001 0.21 
ilmn_1678425 WFDC8 -3.85 0.00012 0.23 
ilmn_1685690 JARID1D -3.81 0.00014 0.24 
ilmn_1770266 ZNF354B -3.86 0.00011 0.24 
ilmn_1667750 SLC4A5 3.83 0.00013 0.24 
ilmn_2056795 USP9Y -3.80 0.00015 0.24 
ilmn_1741674 PPP1R9A 4.30 0.00002 0.25 
ilmn_1670821 CYorf15A -3.69 0.00022 0.28 
ilmn_2179083 LOXL4 3.71 0.00020 0.29 
 
A.4.2 The top 20 genes differentially expressed by smoking status 
(never/ever) in the High Immune Subgroup. The negative z indicates 
that the gene is higher in ever smokers 
probe gene z P-value FDR 
ilmn_2098126 CCL5 1.49 0.14 0.96 
ilmn_1722825 FLJ36701 1.49 0.14 0.96 
ilmn_2053679 ACADM 1.49 0.14 0.96 
ilmn_1707799 DGKK -1.51 0.13 0.96 




probe gene z P-value FDR 
ilmn_2062524 RBBP4 1.49 0.14 0.96 
ilmn_1740505 SGMS1 -1.48 0.14 0.96 
ilmn_1683475 TOMM40 1.51 0.13 0.96 
ilmn_1813344 C20orf7 1.48 0.14 0.96 
ilmn_1726786 TNRC6B 1.48 0.14 0.96 
ilmn_1722059 SAFB 1.51 0.13 0.96 
ilmn_1735959 CNOT4 -1.49 0.14 0.96 
ilmn_1789653 PBLD -1.51 0.13 0.96 
ilmn_2149815 CYP2F1 1.48 0.14 0.96 
ilmn_1748889 PCDHGA7 -1.49 0.14 0.96 
ilmn_1713301 DGCR2 -1.48 0.14 0.96 
ilmn_1656134 CNOT7 -1.51 0.13 0.96 
ilmn_3249351 SNORA35 -1.48 0.14 0.96 
ilmn_2173651 TBC1D3 -1.48 0.14 0.96 
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